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ABSTRACT 
 
Viruses boast a highly skilled mode of entry into the cells of all living organisms. This occurs due to 
the intelligent make-up of these biological systems. A drug delivery system was designed to mimic 
viruses ordinarily, hence taking advantage of cell entry ease that these viruses parade and 
ultimately, as a result, ensuring intracellular antiviral transmittal to targeted sites in the body. The 
Hepatitis B Virus (HBV) was used as a representative virus with representative antiviral drug being 
Lamivudine (LMV). An architecturally-configured nanoparticulate system (ACNS) was formed by a 
novel graft copolymerization of hydrophobic epsilon-Caprolactam (ECL) onto the backbone of 
hydrophilic Hyaluronic acid (HA) (HA-g-ECL). HA-g-ECL showed competence in forming amphiphilic 
micelles broadening areas of its application in drug delivery. A Box-Behnken experimental design 
strategy generated formulations thoroughly screened in terms of variables (copolymer, surfactant 
and solvent) affecting responses (size, drug entrapment efficiency and mean dissolution time). 
ACNS particles were created with sizes varying from 32.03nm to 132.95 nm holding a negative 
surface charge. LMV content ranged from 18.52 – 47.77 %. Sustained drug release with an initial 
burst release was attained. A single optimal formulation was computed by way of statistical variable 
response optimization. Commendable desirability percentages were achieved for measurement 
outcomes. A cryoprotectant screening evaluation determined 20 % mannitol to be optimal in 
maintaining ACNS size. Optimal ACNS was surface-modified with a viral-mimicry targeting ligand for 
liver concentration. Linoleic acid (LA) was graft copolymerized to chitosan synthesizing chitosan-
linolate (C-LA) employed as a coat (C-LA ACNS). Tests to assess response data deviation of C-LA 
ACNS from optimal ACNS were carried out with positive outcomes. Ex vivo internalization via 
fluorescent microscopy and imaging studies in liver HepG2 cells showed positive uptake in both 
optimal ACNS and C-LA ACNS with exemplary findings for C-LA ACNS due to an augmented 
intracellular receipt. In vivo appraisal proceeded in a rodent animal model dispensing C-LA ACNS 
intraportally. Ultrasound imaging confirmed echogenic C-LA ACNS robust in the hepatic area. Ultra 
Performance Liquid Chromatography was executed on blood plasma and hepatic tissue samples for 
LMV detection and quantification. C-LA ACNS proved an impressive hepato-targeting ability with 
LMV Cmax = 91.723 μg/mL in liver tissue against LMV Cmax = 8.947 μg/mL in blood plasma at 
equivalent time points. ACNS demonstrated significant liver targeting ability on the grounds that a 
fatty acid be incorporated into its structure. Evolution of this mechanism will lead to favorably high 
levels of antiviral drugs within sites in the body that are laden with viral disease and will assist in 
destruction of the virus. This system will prove particularly beneficial in the treatment of opportunistic 
infections associated with HIV/AIDS and HBV. 
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CHAPTER 1 
INTRODUCTION 
1.1. Background to this study 
 
Amongst all of the disease causing agents in humans, viruses are the most notorious, active 
and important. Viruses which are obligate parasites have DNA or RNA as their genetic material 
with mutation rates that are markedly different and quantifiable. Some show genetic stability and 
others show varying rates of mutation. Numerous new viruses have been reported worldwide 
causing major outbreaks eg. Human Herpesvirus-8 (HHV-8) in 1995, Avian Influenza A (H5N1) 
Virus in 1997, Nipah virus in 1999, Severe Acute Respiratory Syndrome (SARS) Virus in 2002 
and Chikungunya Virus (CHIKV) in 2005 [WHO Report, http://www.searo.who.int/entity/ 
emerging_diseases/documents/b0005.pdf, Accessed 21st April, 2015]. The perpetual viral 
emergence and re-emergence poses a serious public health concern. Viral latency and 
resistance, improper diagnosis, toxicity and immunosuppression caused by antivirals may be 
due to this. Thus, there is a struggle against viruses and foolproof antiviral therapies are lacking 
against them. To make matters worse, drugs are failing in human clinical trials (Saxena et al., 
2009).  
 
This study aims to utilize a pair of polymers that have not been previously conjoined and surface 
modified, and architecturally resembles the structural outline of viruses in general. The Hepatitis 
B Virus (HBV) will be used as a model virus with the model antiviral drug being lamivudine 
(LMV). A vast majority of individuals worldwide are chronically infected with HBV and it is 
considered one of the most lethal human pathogens. The virus consists of a partially double 
stranded circular DNA genome that is encapsulated within the viral capsid and envelope and it 
undergoes reverse transcription during its replication cycle (Xia et al., 2006). The main danger 
of patients suffering from a chronic HBV infection lies in the emergence of cirrhosis leading to 
morbidity and mortality from hepatocellular cancer or drawbacks arising from the cirrhosis such 
as portal hypertension and liver failure (Lebray et al., 2003). The principal aims that need to be 
addressed to attain a favourable therapeutic approach in a hepatitis B infection should include a 
reduction in the viral load to imperceptible levels, a decrease in the rate of progression of the 
disease and a reduced rate of evolution of drug-resistant HBV (Bartholomeusz et al., 2003). 
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Many significantly effective antiviral agents are active intrinsically but they are shown to be 
associated with unacceptable systemic toxicity. It may be possible to achieve the following when 
using novel controlled delivery systems: prolonged efficacy, optimum therapeutic responses and 
a reduced toxicity by, reproducibly and predictably transporting and promoting the release of the 
drug to the specific target environment. The site of infection such as the liver in this case clearly 
makes it useful to architecturally design therapeutic agents with their carriers targeted at the 
level of the organ. However, targeting agents at the cellular level is not very easy because the 
life cycle of the virus is limited to the inside of the host’s cells, with a reduced selective toxicity of 
antiviral agents. 
 
Compared to interferon-alpha (IFN), these agents selectively target the viral reverse 
transcriptase inhibitor to cause inhibition of the HBV genome replication and are considered to 
be superior with respect to the extent and time it takes to drop HBV DNA levels. Likewise, 
numerous challenges and drawbacks still remain with the use of oral anti-HBV agents. These 
are the high rate of relapse with short term therapy, the emergence of drug resistant genotypic 
mutations of HBV in long term therapy and drug resistance (Ghany and Liang, 2007; Li et al., 
2010; Liaw et al., 2004; Palumbo, 2008). An attempt to enhance efficacy and diminish viral 
resistance occurring has been the recently emerged concept of combination therapy. Still, only 
minimal data is available and no combination therapy proved to be beneficial as compared to 
monotherapy (Asselah et al., 2005; Nash and Alexander, 2008). 
 
Hepatocyte drug delivery with specificity to their receptors such as the asialoglycoprotein 
receptor (ASGP-R) has made possible the selectivity and targeting of drugs and foreign genes 
to these cells to combat dreaded diseases such as the HBV. Several attempts have been made 
to label carriers (polymers, human serum albumin, recombinant high density lipoproteins (HDL) 
with ASGP-R specific ligands (galactose, lactose, acetylgalactosamine, asialofetuin) to design 
specific carriers for drug and gene delivery to hepatocytes. Several notable studies have also 
been conducted concerning small interfering ribonucleic acids (siRNAs) as drug delivery 
treatments for HBV. 
With that said this study suggests a novel architecturally-configured nanosized system (ACNS) 
encompassing the union of polymers, encapsulating therapeutic molecules that will be effective 
in targeted intracellular therapeutic drug delivery, as an example, an antiviral to the liver, 
selectively targeting hepatocytes, and site-specifically delivering the therapeutic molecule to 
render the formidable HBV to imperceptible levels. 
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1.2. Rationale and motivation for this study 
 
Drawbacks arising from the conventional antiviral delivery systems include those of poor oral 
absorption or bioavailability, accumulation in tissues leading to toxicity and a very rapid 
elimination from the body. Other significant problems that may be encountered are severe and 
unwanted side effects, large interindividual variations in bioavailability as well as an impractical 
administration frequency (Meijer et al., 1992). A drug delivery system to propose targeted 
controlled delivery of LMV is necessitated in view of its harmful and toxic side-effects. The most 
significant warning and precaution constantly highlighted to patients using the oral form of the 
drug is the great risk of developing lactic acidosis and a severe form of hepatotoxicity that may 
include hepatomegaly and steatosis which could be fatal. In addition to this and according to the 
U.S. Food and Drug Administration (FDA) [http://www.accessdata.fda.gov/drugsatfda_docs/lab 
el/2013/021003s015,021004s015lbl.pdf, Accessed January 7th, 2014] there is evidence of 
exacerbation of the viral disease once treatment is halted. Arduous dosing frequencies could be 
the reason for discontinuation of treatment embracing a system capable of controlled and 
sustained delivery of the drug. There is also the risk of emergence of resistant HIV-1 and HBV 
infection when complete and required treatment doses are not attained. Formulating an 
intracellular targeted virus-like nanoparticulate system, as depicted in Figure 1.1, should prove 
to be operative and overcome a number of the challenges linked with conventional antiviral drug 
delivery systems. 
 
Targeted drug delivery comprises a therapeutic agent, a targeting moiety and a carrier system 
where the drug is incorporated by passive absorption or chemical conjugation. The choice of 
carrier is extremely important as it determines the fate of the drug (Park et al., 2010). The virus-
like nanoparticle system will be administered via intravenous injection for targeted drug delivery, 
owing to their small size (Park et al., 2010). When nanoparticles are injected into the 
bloodstream, they are rapidly cleared by the reticuloendothelial system (RES), thus leading to a 
decreased pharmacological action (Harush-Frenkel et al., 2007). Surface coating of the system 
with a substance that is able to alter the immune response and clearance may overcome this 
problem (Zahr et al., 2006). This can be achieved by simply employing a polymer in the outer 
make-up of the carrier system that possesses the function in avoidance of macrophage uptake 
and increasing the circulation to efficiently target diseased cells. The constituents in the 
formulation of the ACNS will only have an appearance of a viral entity in instances where the 
hydrophobic polymer mimics the envelope, the hydrophilic core with antiviral mimics its DNA 
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and the chemically adsorbed targeting ligand are ordered in the same manner of arrangement 
as the glycoprotein spikes posing the similar relevant functions in terms of entry into a cell. 
 
 
Figure 1.1: Schematic representation of a) a typical virus and b) the ACNS. 
 
The mechanism of intracellular uptake of the ACNS is depicted in Figure 1.2. On approach to a 
cell, the ACNS is endocytosed following the action of surface attachment of the targeting ligand. 
The drug which is still intact within the hydrophilic core, together with the carrier, end up in small 
vesicles (endosomes) within the cell. These endosomes mature and fuse with lysosomes. In a 
normal situation of uptake, during this process, there is a drop in pH within these vesicles and 
together with enzymatic degradation within the lysosomes, inactivation of the drug and its carrier 
occurs before it is released into the cytosol to allow for its therapeutic action (Breunig et al., 
2008). Therefore, at this point there should be endolysosomal escape of the drug-carrier system 
owing to the properties of the bulk hydrophobic polymer, followed by drug unpacking and 
degradation of the biodegradable delivery system to eliminate toxicity (Panyam et al., 2002). 
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Figure 1.2: Schematic representation of the uptake of the ACNS: a) cell attachment; b) 
endocytosis; c) ACNS within endosome; d) fusion; e) endolysosomal escape; f) free drug 
release and g) carrier degradation. 
 
1.3. Novelty of this study 
 
1. The design of a novel, nano-sized architecturally-configured system is achieved by virtue of 
copolymerization of a hydrophobic and hydrophilic polymer in an original manner, with a 
double emulsion solvent-evaporation method for the amphiphilic copolymer to be made into 
nanoparticles encapsulating an antiviral in the ACNS core. Targeting nano-appendages on 
the nanoparticle surface will be carried out by a method of chemical adsorption onto the 
newly copolymerized nanoparticles. 
2. The design of a nanosized system: The blood-brain barrier (BBB) acts to hinder the 
transmission of several important essential and therapeutic agents. Thus in the design of a 
system that is nanoscopic, encapsulating therapeutic molecules and genes that may be 
effective in diagnosis and therapy, delivery across the BBB will prove to be successful. 
3. The ACNS will be formulated to specifically target the formidable HBV. An inordinate 
advantage arises by the addition of targeting appendages, made from target-specific 
ligands, (Figure 1.1) adsorbed onto the surface of the polymer foundation to be directed to 
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infected hepatocytes harboring the virus and thus directing and delivering the therapeutic 
specifically to this site. 
 
1.4. Aim and objectives 
 
The aim of this study is to design a nanoparticulate system in order to gain targeted intracellular 
delivery and subsequently attain release of free drug into the cytosol specifically of hepatic cells. 
The above mentioned aim can be achieved by an outline of the following objectives: 
 
1. To select a suitable combination of a hydrophilic and hydrophobic polymers to formulate 
the nanoparticulate system for entry into cells. 
2. To utilize the method of double emulsion solvent-evaporation in the development of the 
nanosized drug-carrier complex. 
3. To elucidate the physicochemical parameters of the nanoparticulate system such as 
size, surface chemistry and morphological analysis including their shape and ionic 
charge, structure of the system and its adhesion to the cell surface. 
4. To execute in vitro studies in order to assess the drug release profile of the ACNS 
investigating whether it is capable of providing sustained drug release over time. 
5. To execute ex vivo studies utilizing a specific cell line in order to visualize uptake of the 
ACNS. 
6. To execute in vivo studies on an appropriate animal model to evaluate the bioavailability 
of the ACNS and thus its therapeutic efficacy. 
 
1.5. Overview of this dissertation 
 
Chapter One is an introductory chapter in which the infamous virus as a driving force for 
disease and its pathophysiology is discussed. The dreadful HBV is more specifically examined 
and challenges faced with conventional antiviral agents are also addressed. This chapter 
highlights the rationale behind the configuration of the ACNS and outlines the novelty, aim and 
objectives of the study. 
 
Chapter Two is a literature review that discusses aspects of intracellular targeting and 
therapeutic delivery. It also reviews drug delivery strategies against HBV previously attempted 
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by researchers as well as focusing on the more recent and novel approaches employed for HBV 
eradication. 
 
Chapter Three has its complete focal point on the synthesis and development of a novel 
amphiphilic graft copolymer that is to be the foundation of the ACNS for the study. The method 
by which the copolymer is fabricated is evaluated by conducting tests to measure its yield as 
well as proving the occurrence of graft copolymerization in addition to several tests being 
conducted to fully characterize the ACNS. 
 
Chapter Four aims to fully elucidate the trends seen with selected variables and their effect on 
response outcomes for the design and development of an optimal ACNS generated from an 
experimental model. The selected variables were amount of copolymer, amount of surfactant 
and volume of solvent. The responses for optimization were drug entrapment efficiency (DEE), 
size and mean dissolution time (MDT). 
 
Chapter Five encompasses the optimization of ACNS. The optimized formulation is fully 
characterized by testing size, DEE, MDT and assessing its predicted and observed 
measurements from the model. Structural variations in the make up of the copolymeric 
nanosystem are explored, thermal profiles using differential scanning calorimetry (DSC) and 
thermogravimetric analysis (TGA) are evaluated and all of these are contrasted against a 
coated optimized ACNS for targeted drug delivery to the hepatic region 
 
Chapter Six is an ex vivo component of the study and describes the ability of the ACNS to be 
internalized intracellularly by HepG2 cells. The imaging microscopy tests employed to visualize 
the uptake of un/coated ACNS were confocal fluorescence microscopy and a high speed fiber-
optic fluorescence live imaging system. 
 
Chapter Seven outlines the in vivo study that was undertaken to evaluate the efficacy of ACNS 
on a rat model. This was a pilot study. A first-time tried intraportal injection procedure was 
applied to ensure targeting of ACNS to the liver. Ultrasound imaging was used to detect ACNS 
on live rats. Rats were euthanized, blood samples were taken and livers were removed to 
assess drug release from ACNS. Livers were homogenized and treated for detection of drug. 
Ultra Performance Liquid Chromatography (UPLC) was utilized to quantify and detect the drug 
in biological samples. 
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Chapter Eight is a conclusion to the dissertation and provides an insight into future outlooks 
and recommendations in which the study can be enhanced. 
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CHAPTER 2 
A LITERATURE REVIEW ON HEPATO-TARGETING: AN OVERVIEW OF DRUG DELIVERY 
AND TREATMENT STRATEGIES FOR HEPATITIS B VIRUS INFECTION 
2.1. Introduction 
 
Hepatitis B Virus (HBV), a formidable DNA virus, is transmitted percutaneously, sexually and 
perinatally resulting in worldwide mortality from cirrhosis, liver failure and hepatocellular 
carcinoma. This virus replicates its genome through an RNA intermediate utilizing reverse 
transcription. Figure 2.1 is a schematic depicting the HBV virion. The virus, with a diameter of 
40-42 nm, consists of a partially double-stranded, circular DNA genome that is encapsulated 
within the viral capsid and envelope and it undergoes reverse transcription during its replication 
cycle (Chen et al., 2008). Even though perinatal HBV infection can lead to high levels of the 
virus replicating and lacking substantial injury to the liver in the earlier years of life, eventually 
the risk of cirrhosis and hepatocellular carcinoma (HCC) progression will be directly proportional 
to the HBV DNA level maintained over time consistently and persistently. Liver histologic and 
clinical improvements are associated with reduced HBV replication. Thus, interventions that 
decrease HBV replication are expected to put a halt on the progression of liver disease and 
display an improvement in the natural history of chronic HBV infection (Dienstag, 2008). 
 
Figure 2.1: The HBV virion (Modified from Chen et al., 2008). 
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A significant threat to patients suffering from a chronic HBV infection lies in the emergence of 
cirrhosis leading to morbidity and mortality from hepatocellular cancer or drawbacks arising from 
the cirrhosis such as portal hypertension and liver failure. Anti-HBV therapy, over the last few 
years, promised an enhanced effectiveness against HBV. Drugs such as interferon-α2B, 
pegylated interferon-α2A, lamivudine, adefovir, entecavir and telbivudine have all been 
recognized and acknowledged for their treatment and direct antiviral activity against chronic 
HBV (Ruiz-Sancho et al., 2007). The principal aims that need to be addressed to attain a 
favourable therapeutic approach in an HBV infection should include a reduction in the viral load 
to imperceptible levels, a decrease in the rate of progression of the disease and a reduced rate 
of evolution of drug-resisitant HBV (Bartholomeusz et al., 2003). The mechanics for targeted 
drug delivery are foremost in consideration for parenteral administration in addition to shielding 
therapeutics from degradation and untimely elimination. These mechanics are drug delivery 
vehicles consisting of soluble carriers eg. synthetic polymers, particulate carriers eg. micro- and 
nano- particles and target-specific recognition moieties eg. monoclonal antibodies. Dosage 
forms exist in sizes from the molecular level to macrodevices. Nanoparticles (usually less than 
200 nm) are solid colloidal particles utilized in parenteral drug delivery and targeting. 
Classes of drug targeting fall into two groups namely active and passive targeting. Active 
targeting utilizes certain interactions at the target site such as those of ligand-receptor and 
antigen-antibody binding, or in other cases, signals such as temperature or magnetic fields that 
can be applied externally. Passive targeting involves adjusting carrier systems’ physicochemical 
properties to that of the physiological and histological features of the target site. At the target 
site of action, in this case being the liver, a drug is transported by its carrier. For this seemingly 
straight-forward and simple approach to work, multiple fundamental requirements (nonspecific 
interactions, access to the target site, drug release and suitability) must be satisfied. 
 
2.2. Intracellular drug delivery and hepatitis B viral entry 
 
A broad range of drugs require an intracellular mode of delivery so as to exert their therapeutic 
action in any of the affected organelles found therein. Thus, the importance lies not only in 
delivery of the therapeutic agent to a specified tissue but also to the specified cellular 
compartment. Transporting a diverse range of biologically active molecules and agents into cells 
remains a general crucial problem in drug delivery. A biological membrane's lipophilic nature 
poses restriction to the direct entry of these compounds (Torchilin, 2006). As a result of the 
'curiosity' of certain cells, the ingestion of drug delivery systems/substances ensues. The 
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endocytosis process embraces a notion of membrane manipulation in which substances are 
encased and absorbed. Along with the above concept of cellular internalization of therapeutic 
agents and their carriers, exist reports that show that endocytosis is conjointly the putative 
uptake mechanism for the HBV particles. A study suggests entry of HBV into human 
hepatocytes occurs by attachment to the asialoglycoprotein-receptor (ASGP-R) molecules that 
are found on these liver cells. This manifests via the viral preS1-related envelope binding site for 
the ASGP-R receptor. Building on it, a study demonstrated that a bio-nanocapsule (BNC) 
containing a liposome with hepatitis B virus surface antigen (HBsAg) L protein embedded as a 
transmembrane protein and within it containing several drugs and genes were to be delivered 
with specificity to human hepatic cells in the same manner as and according to the HBV’s 
mechanism of infection of these cells in the early stage (Yamada et al., 2012). 
 
2.2.1. Endocytic uptake mechanisms 
 
Phagocytosis, pinocytosis and receptor-mediated endocytosis (depending on either the clathrin 
and/or caveolae-mediated processes) are three subtypes of endocytosis. Neutrophils, 
macrophages and dendritic cells form the RES and such cells can be grouped under the 
phagocytosis subtype, achieving the internalization of materials of up to 10 μm in diameter 
(Kohane, 2007). Sub-micron material and substances in solution are taken up by the pinocytosis 
mechanism and this internalization can be carried out by basically all cell types. Receptor-
mediated endocytosis via the caveolin- and clathrin-coated pits involves a triggered signal that 
is sent to the intracellular space. This occurs upon binding of ligands to the innumerable 
receptors found on the cellular membrane. The signal generates an assembly of biochemical 
pathways and may also cause the ingestion of the ligand with its appended drug loaded delivery 
device (Faraji and Wipf, 2009). The means of HBV recombinant capsid-like core particle uptake 
and its predetermined course intracellularly was explored once it had been bound to heparan 
sulfate proteoglycans (Cooper and Shaul, 2006). Results reflected internalization of these 
particles through clathrin-mediated endocytosis. Figure 2.2. depicts the steps involved in the 
intracellular delivery of therapeutic agents. 
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Figure 2.2: Basic steps involved in the intracellular delivery of therapeutic agents (TAs) 
(Modified from Faraji and Wipf, 2009). 
 
However, there is a problem with the endocytic pathway in terms of particles entering the cell. 
Molecules and particles that have entered the cell become entrapped in small vesicles within 
the cell, namely endosomes. These endosomes mature and fuse with lysosomes. In a normal 
situation of uptake, during this process, there is a drop in pH within these vesicles together with 
enzymatic degradation within the lysosomes owing to the action of the lysosomal enzymes 
found therein (Figure 2.3.).  
th
e 
TAs 
TAs 
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Figure 2.3: Entry processes involved, vesicular formation and breakdown of intracellular 
components (Modified from Li et al., 2012). 
 
Inactivation of the drug and its carrier occurs before it is released into the cytosol to allow for its 
therapeutic action. Therefore, only a small amount of unaffected substance appears in the 
cytoplasm of the cell causing the major problem of bioavailabilty. Thus far, attempts have been 
sought to bring assorted macromolecular drugs and drug-loaded carriers directly into the 
cytoplasm, protecting the therapeutic agents and DNA from the lysosomal degradation and 
ultimately enhancing the efficiency and therapeutic potential of the drug or DNA incorporation 
into the genome of the cell (Vasir and Labhasetwar, 2007). These attempts although collective 
and diversified have been only somewhat successful. A method of destabilizing the endosomal 
membrane can prove to substantially enhance the escape of the drug delivery system from the 
endosome. However, this destabilization can also be toxic to the cells and be discordant for 
some therapeutic agents. The means of escape as for PLGA nanoparticles which do not open 
the endolysosomes comprises a direct interaction of the nanoparticles with the endo-lysosomal 
membrane as a result of the surface charge reversal from anionic to cationic that occurs under 
acidic conditions within the vesicle (Stepensky, 2010). Translocation motif (TLM) is a cell 
permeable peptide found in the surface protein of human HBV. Intracellularly, their activation by 
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endosomal proteases sources their disclosure on the surface of the virus. This unveiling of the 
TLM is crucial in the mediation of viral particle translocation across the endosomal membrane 
and effectively into the cytosol (Lepère et al., 2007). 
 
2.2.2. Intracellular drug delivery aids 
 
2.2.2.1. Emulsifiers as facilitators of intracellular drug delivery 
Polyvinyl alcohol, an emulsifier in varying concentrations, has been shown to alter surface 
charges of drug loaded delivery devices and results have also shown its influence on 
intracellular uptake and cellular distribution/endolysosomal escape (Sahoo et al., 2002). 
Therefore, types of emulsifiers and corresponding concentrations may also modulate 
intracellular delivery and distribution. The potential of another polymer, polyethylene glycol 
(PEG), is marveling. PEG chains can be grafted onto the surface of polymeric nanoparticles or 
be covalently attached to a different polymer through the co-polymer synthesis process, to 
achieve surface modifications. It may also be surface adsorbed or entrapped into the matrix of 
the drug loaded delivery device. PEG modification prevents the aggregation of surface modified 
liposomes and greatly delays particle content leakage of the therapeutic load in comparison to 
unmodified nanoparticles. PEG protects a therapeutic load from carrier uptake by the RES, from 
metabolism and from excretion and has therefore been employed in promoting prolonged 
circulation. Functionalized PEG chains can have trans-activating transcriptional activator (TAT) 
peptide covalently attached to it. Inclusion of a TAT peptide in a PEG-nanoplex compared to 
TAT in poly(ethyleneimine) (PEI) particles without the PEG, clarified an enhanced transfection 
efficiency in vivo, suggesting that PEG is necessary for site-specific localization (Vasir and 
Labhasetwar, 2007). PEG conjugated to interferon-α (IFN-α), the main treatment for chronic 
HBV, have been shown to augment the pharmacokinetics of standard IFN (Asselah et al., 
2007). HBsAg clearance is also established with PEG IFN (Sonneveld and Janssen, 2011). 
 
2.2.2.2. pH-sensitive carriers in intracellular drug delivery 
The use of pH-sensitive carriers such as liposomes and cell penetrating molecules, mentioned 
later, are the most efficient and thus favored noninvasive methods. Liposomes with its pH 
sensitive components, coalesces with the endovacuolar membrane as a result of the action of 
the lowered endosomal pH. This promotes destabilization and content release into the cytosol 
(Torchilin, 2006). It should also be noted that certain diseased tissues, tumours, infections and 
inflammations illustrate an acidic environment in comparison to their surrounding non-diseased 
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tissues; therefore stable pH sensitive carriers at physiological pH 7.4 will dispense their contents 
within these acidic conditions and subsequently into the intracellular compartment (Lembo and 
Cavalli, 2010). pH-sensitive liposomes delivered the iminosugar N-butyldeoxynojirimycin (NB-
DNJ) into the endoplasmic reticulum of mammalian cells (Costin et al., 2002). Researchers 
stated that NB-DNJ had also exhibited efficiency in hindering the duplication of the HBV by their 
restraint within hepatic cells. An illustration of a pH-sensitive carrier for intracellular drug delivery 
is depicted in Figure 2.4. 
 
 
Figure 2.4: pH sensitive carriers for intracellular targeting (Modified from Koren and Torchilin, 
2012). 
 
2.2.2.3. Peptide based strategy for intracellular drug delivery 
To help internalizing the nanocarrier systems, cell penetrating peptides (CPPs) such as the TAT 
peptide, amongst the many, have been coupled to the surface of liposomes and this coupling 
led to their adept delivery intracellularly via a non-endocytic route. Molecules that are modified 
with CPPs are enhanced to traverse cell membranes and deliver their cargo into the cytosol or 
the nucleus. CPPs contain a little under 30 amino acids which for the most part are amphipathic 
maintaining a net positive charge. For instance, the CPP HBV TLM mentioned earlier has the 
amino acid sequence PLSSIFSRIGDP (Fonseca et al., 2009). Cargoes with molecular weights 
several times their own weight have been shown to be intracellularly delivered by CPPs. 
Several advantages over conventional modes exist since CPPs delivery mode is efficient for a 
variety of cell types and has a potential therapeutic function in terms of cellular delivery 
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(Torchilin, 2006). Synthetic recombinant CPPs and nucleocapsid subunits have been contrived 
to incommode the HBVs encasing as a result receding the viral yield. CPPs have also been 
considered for delivering antibodies intracellularly (Gupta et al., 2005) and a single-chain 
variable fragment antibody that works against the HBVs core protein has also been delivered 
intracellularly via a CPP (Xun et al., 2013). A schematic showing various strategies employed in 
intracellular delivery of therapeutics, including CPPs delivery mode, is depicted in Figure 2.5.  
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Figure 2.5: A schematic depicting the applications of CPPs as a mode of intracellular delivery of 
therapeutics (Modified from Koren and Torchilin, 2012). 
 
Ovalbumin was used as a model antigen that was integrated to the CPP TLM acquired by the 
HBV and this was applied as a vaccine (Bleifuss et al., 2006). The authors reported a prevailing 
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efficacy of TLM attached ovalbumin compared to ovalbumin alone concerning cellular and 
humoral immune system responses. Adequate transfection has also been observed both in vitro 
and in vivo with a lowered toxicity thus successful delivery to the cytosol makes the CPP 
approach useful for intracellular targeting (Mäe and Langel, 2006).  
Targeting residues conjugated to a peptide-based drug can be sufficient for its desired 
accumulation in the targeting organelle following its delivery to the cytoplasm. An example is the 
ER signal peptide that was conjugated to the antigenic peptide by a 1:1 drug: targeting residue 
ratio. This has been reported to have resulted into an enhanced localization in the endoplasmic 
reticulum of the target cells following its release from the nanoparticle or liposome-based drug 
delivery system (Stepensky, 2010). Viral vectors are efficient for gene delivery however, their 
use has shown to be limited following safety concerns. Furthermore, the alternative non viral 
vectors have problems with nuclear translocation and endolysosomal escape (Gupta, 2005). In 
addition, fusogenic peptides function with an end result being endolysosomal escape of the drug 
delivery system. An interaction with phospholipid membranes follows a resultant pore formation 
or the induction of membrane fusion and/or lysis (Lochmann et al., 2004). It has been noted that 
the incorporation of synthetic membrane-active peptides into a delivery system housing drugs 
such as oligodeoxynucleotides (ODNs), peptides, or plasmid DNA for its intracellular delivery 
has been possible due to its fusogenic property (Vasir and Labhasetwar, 2007). A study 
demonstrated a distinct inhibition of the HBV’s gene expression and replication by compounding 
an ODN specific to the polyadenylation signal for HBV, to a vehiculate system for DNA (Wu and 
Wu, 1992). This targeted the ASGP-R on hepatocytes.  
 
2.2.3. Nuclear Targeting 
 
In order to achieve the desired therapeutic and pharmacological effects at the intracellular level, 
an evolution of specialized drug delivery systems ought to have specificity and targeting ability 
in a sustained manner aimed at a cell organelle. Eukaryotic cells encase the nucleus, a 
significant subcellular structure and a place where DNA replication and transcription occur. 
Polymeric nanoparticles are interesting and intelligent tools to achieve successful and efficient 
delivery of DNA and/or drugs to the nucleus. One of the ways in which drug loaded delivery 
devices could be targeted to the nucleus itself is through the chemical coupling of ligands to 
their surface, a frequently seen and noted targeting mechanism. Organelle-specific localization 
signals such as the nuclear localization signal (NLS) could be critical in the development of a 
drug loaded device as a gene delivery system for nuclear targeting. A study concluded that to 
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promote an antiviral activity that is detectable by ODNs, a minimum NLS is needed to be 
conjugated to the polymer in use so as to be delivered in a more efficient way to the nucleus. 
Another study showed that hepatitis delta antigen (HDag), a hepatitis delta virus (HDV) 
encrypted protein, is conveyed through to the nucleus as a protein complex (Xia et al., 1992). 
Authors had identified an NLS within the HDag which ensured the nuclear transport, as well as 
remnants of the protein that did not incorporate the NLS but were still transferred to the nuclear 
region via a leucine zipper sequence that must be present on the HDag. A nuclear pore 
complex (NPC) which is present in the nuclear membrane allows all passive and active 
transport into and out of the nucleus. It comprises a pore-like, molecular sieve function where 
molecules that are smaller than 40-45k Da in size have the ability to diffuse freely. Larger 
proteins that need to pass through require NLS in order to be targeted to the nucleus 
specifically. Detection of nuclear targeting was brought about by gold nanoparticles and 
quantum dots usage. In addition to being easily synthesized in several size distributions, these 
two can be easily detected by transmission electron microscopy or fluorescence-based 
techniques and therefore have been used as a kind of model nanoparticle for nuclear direction. 
Researchers reported on the precore protein (P22) of the HBV and its transportation into a cells 
nucleus following discharge (Ou et al., 1989). This occurred by virtue of signal peptide cleavage 
and ensues a cytosolic process. A form of nuclear transport mechanism involves the endosome 
trafficking in a cell which causes a resultant early release of nanoparticles into the cytosol and 
the shielding of the nanoparticles from the consecutive degradation by cytoplasmic nucleases. 
Endosomes carry the nanoparticle away from the plasma membrane of the cell to perinuclear 
locations (Li et al., 2012). A prototype example of a maturation-dependent nuclear entry of HBV 
capsids is depicted in Figure 2.6. 
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Figure 2.6: Maturation-dependent nuclear entry of HBV capsids: a) Localization of hepatitis B 
capsids in HuH-7cells. Capsids (green, Left) and NPCs (red, Center) were stained by indirect 
immunofluorescence. Merged images are shown in the last column (Right). Recombinant 
capsids, devoid of viral polymerase (P-C) do not bind to cellular structures, immature capsids 
(ImmatC) show nuclear binding, whereas mature capsids (MatC) generate intranuclear capsids. 
Scale bar: 10 µm; and b) Views of nuclear envelope cross sections with adjacent cytoplasm (c) 
and nucleoplasm (n) from a Xenopus laevis oocyte that has been microinjected with ImmatC. 
Arrowheads point to capsids associated with the nuclear face of the NPC. Scale bar: 100 nm 
(Adapted from Köser et al., 2012). 
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2.3. Conventional anti-HBV therapies and drugs 
 
2.3.1. Cytokines and Nucleot(s)ide analogues 
 
Immune responses and inflammation involving the restore of tissue, the presenting of antigens, 
actuating cells and differentiation of bone marrow are all functions that engage small-scale 
superfluous proteins released from the cells of the body and immune system and partake in the 
accountability for developmental regularization. These are known as cytokines. As mentioned 
earlier, the IFN-α cytokine has displayed supportive findings toward HBV abatement. IFNs 
suppress HBV viral copying. IFN-α provides for the restitution of T-helper lymphocyte responses 
as a result of its antiviral activities and immunoregulatory processes, thus it remains the 
mainstay cytokine presently utilized in the intervention of chronic HBV. Solely, it allows for anti-
hepatitis B e antigen (HBeAg) seroconversion in 25 % of chronic HBV diseased cases 
(Tassopoulos et al., 1997; Larrubia et al., 2009). Researchers examined the impression that IFN 
left on patients with anti-HBeAg positive chronic HBV in terms of disease progression by 
pursuing reexamination after an average of 6 years (Brunetto et al., 2002). Conclusive results 
were a 2.5 fold decline in the progression of HBV. Perennial pursue of its effects were validated 
in other studies declaring that IFN treatment stimulates an enlarged survival rate, a diminished 
possible growth of HCC and consequently amelioration of liver histology. Future follow-ups 
showed a sustained clinical subsidence and HBsAG seroconversion (Janssen et al., 1999; van 
Zonneveld et al., 2004). A study pointed out that lambda-IFN has the potential to be useful for 
therapeutic purposes in the alleviation of chronic HBV or hepatitis C virus (HCV) (Robek et al., 
2005). Lambda-IFN is similar to IFN-α and IFN-β in its antiviral behaviour to inhibit HBV when it 
conveys its effects by means of a distinguishable receptor composite in a modified murine 
heaptocyte cell line. It also lowered HCV replication in Huh7 cells. Data in a study assessing the 
antiviral impact of IFN-α2a or IFN-α2b with attached PEG demonstrated close to 30 % and 3-5 % 
HbeAg seroconversion and HbsAg seroconversion rates respectively, and HBsAg was seen in 
around 7 % of patients after a 6 month follow-up (Zoulim, 2007). 
 
Nucleot(s)ide analogues can be perceived as prodrugs as their role as inhibitor of polymerase is 
generated by phosphorylation process of their nucleoside triphosphates or diphosphate (Zhou 
and Littler, 2006). Lamivudine (LMV) is a cytidine analogue that when compared to IFN-α, does 
not have a targeted immunoregulatory outcome but does show the response  restoration of T-
helper lymphocytes suited to HBV for the initial months of its therapy. The other nucleotide 
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analogues could also feature the same function (Ishikawa, 2012). LMV is a generally well-
endured antiviral and its treatment conduces a fall in HBV DNA level by 3 to 5 log10 copies/mL 
following 12 months of treatment equated to starting line measurements, an accompanied 
prompt removal of HBeAg and standardized/decreased levels of serum alanine 
aminotransferase (ALT). Protracted LMV therapy may result in a drop in the peril of developing 
liver cirrhosis and HCC (de Clercq et al., 2010). Patients in America harboring untreated chronic 
HBV exhibited well-disposed results on HBVs effects involving chemical processes in the body 
with reference to its histologic characteristics. HBeAg responses were generally kept up after 
LMV administration (Dienstag et al., 1999), however, it was shown in another examination that 
HBeAg responses were really not kept up after LMV administration surcease (Chan et al., 
2007). LMV therapy is suggested in people who do not show any seroconversion. The vast 
problem of drug resistance is seen immensely with LMV and its resistance moderates a higher 
HB viral load (Zoulim, 2007). 
One of the nucleotide analogues, Adefovir dipivoxil (ADV), proved its ability in decreasing the 
HBV DNA levels as well as showing an improved liver histology in serum. It is also an option for 
treatment of LMV-resistant patients with a case of chronic HBV (Hadziyannis and  
Papatheodoridis, 2004; Dai et al., 2007). Patients with chronic HBV were randomly assigned to 
receive specific dosages of ADV everyday for the duration of 48 weeks of a study (Marcellin et 
al., 2003). Results suggested a histologic liver progression, a receded amount of HBV DNA and 
ALT and a strengthened rate of HBeAg seroconversion. A study demonstrated that solid lipid 
nanoparticles (SLNs) are novel drug delivery systems for ADV for anti-HBV activity (Zhang et 
al., 2008). SLNs provide non-biotoxicity, drug targeting and sustained drug release as well as 
harbouring the incorporated compound in a protective fashion and it is also chemically 
degradable. A fluorescence marker (octadecylamine-fluorescein isothiocyanate) showed the 
uptake of SLN by HepG2.2.15 cells. Compared to the free ADV, a significant drop in levels of 
HBsAg, HBeAg and HBV DNA levels in vitro was observed. ADV was reviewed in its treatment 
of chronic HBV and propounded that it was also found to perpetuate its therapeutic efficiency 
after 3 years of its endured treatment (Hadziyannis and Papatheodoridis, 2004). 
Entecavir (ETV) is a powerful inhibitor of HBV replication and was permitted in 2005, for its use 
against active HBV and liver disease including affirmation of a continuous rise in serum ALT. It 
is also in concord with an amicable side effect profile and a lesser chance of drug resistance 
progression (Zoulim, 2007; Basu and Brown Jr., 2012). The long-term productiveness of ETV 
monotherapy in patients with perceptible HBV DNA levels was explored (Zoutendijk et al., 
2011). Conclusive findings suggested ETV could be extended after 48 weeks particularly 
23 
 
distinctly in patients with less of HBV DNA as it precipitates a virological reaction in most of 
these patients.  
Tenofovir disoproxil fumarate (TDF) has potent antiviral activity against HBV but has been 
investigated more in patients who are HIV positive and have been co-infected with HBV. Many 
examinations have implied that TDF notably reduced HBV viral load and is probable that it is 
more persuasive in therapy compared to ADV (Zoulim, 2007). ETV and TDF were reviewed in 
the clinical setting where it was shown that ETV produced an average of 86 % virologic 
responses in patients until 4 years of treatment and TDF produced an average of 82 % virologic 
responses until 1 year 9 months of treatment. There were laudatory reports on tolerability, 
commendable safety profiles and lesser occurrences of drug resistance for both ETV and TDF 
(Pol and Lampertico, 2012). Researchers proffered that 5 years of treatment with TDF was 
effectively impervious and may lead to the reversion of liver cirrhosis through endured abolition 
of HBV (Marcellin et al., 2013). 
The nucleot(s)ide telbivudine is known to be affiliated with the largest HBeAg seroconversion 
rates and  the property of immunomodulation. This makes it reciprocal in character to 
PEGylated IFN (Wang et al., 2013b). Serum HBsAg levels, after 36 months of telbivudine 
treatment, were evaluated in 162 cases that were positive for HBeAg and who upheld 
inconspicuous HBV DNA serum levels in a persistent manner. The speedy fall in serum HBsAg 
levels in the first 12 months of telbivudine therapy pinpoints patients who are more inclined to 
acquiring the compete removal of HBsAg  (Wursthorn et al., 2010). Table 2.1 summarizes the 
impression that cytokines and nucleot(s)ide analogues have on HBV. 
 
Table 2.1: Summary of anti-HBV cytokine and nucleot(s)ide analogue therapeutic agents as a 
treatment plan 
Therapeutic agent Effectiveness as anti-HBV therapy Reference 
IFN-αa/-PEGb/-lamdac Suppressed HBV viral copying, restored T-
helper lymphocyte responses/ 
immunoregulatory, allows for anti-HbeAgd 
seroconversion, prolonged decline in the 
progression of HBV, prolonged diminished 
growth of HCCe, sustained clinical 
subsidence and HBsAGf seroconversion, 
sudued HCVg replication 
Tassopoulos et al., 
1997; Janssen et al., 
1999; Brunetto et al., 
2002; van Zonneveld et 
al., 2004; Larrubia et 
al., 2009 
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Therapeutic agent Effectiveness as anti-HBV therapy Reference 
LMVh T-helper lymphocyte response restored, 
HBV DNA level decline, rapid HBeAg 
removal, decreased levels of serum ALTi, 
minimal risk of developing liver cirrhosis 
and HCC, improved liver histology, 
sustained HBeAg responses after 
treatment 
Dienstag et al., 1999; 
Chan et al., 2007; 
Zoulim, 2007; de 
Clercq et al., 2010; 
Ishikawa, 2012 
ADVj Decreased HBV DNA levels, improved 
serum liver histology, treatment in LMV-
resistance, decreased ALT, increased 
HBeAg seroconversion, decreased HBsAg 
and HBeAg levels, prolonged therapeutic 
efficacy 
Marcellin et al., 2003; 
Hadziyannis and 
Papatheodoridis, 2004; 
Dai et al., 2007; Zhang 
et al., 2008 
ETVk Potent HBV inhibition, minimal drug 
resistance progression, effective long-
term, precipitates virological responses, 
favorable side effect profile 
Zoulim, 2007; 
Zoutendijk et al., 2011; 
Basu and Brown Jr., 
2012 
TDFl Potent HBV inhibition, decreased HBV 
viral load, more persuasive therapy 
compared to ADV, sustained virologic 
responses, favorable safety profile, 
prolonged liver cirrhosis reversal 
Zoulim, 2007; Pol and 
Lampertico, 2012; 
Marcellin et al., 2013 
Telbivudine Highest HBeAg seroconversion rate, 
immunomodulation, rapid decrease in 
HBsAG levels, possible complete removal 
of HBsAg 
Wursthorn et al., 2010; 
Wang et al., 2013b 
aInterferon-α; bPegylated-Interferon; cLamda-Interferon; danti-Hepatitis B e antigen; 
eHepatocelullar carcinoma; fHepatitis B surface antigen; gHepatitis C virus; hLamivudine; 
iAlanine aminotransferase; jAdefovir dipivoxil; kEntecavir; lTenofovir disoproxil fumarate 
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2.3.2 Thiazolide anti-infectives 
 
Thiazolides have recently displayed promise as antiviral therapeutic agents that may amplify 
existing or forthcoming treatments against hepatitis. Nitazoxanide (NTZ) is a thiazolide anti-
infective that has activity against a range of viruses in cell culture models, anaerobic bacteria, 
protozoa and helminthes. NTZ antiviral exertion was first stumbled upon when patients with 
AIDS (co-infected with HBV or HCV) were being treated for cryptosporidial diarrhea as it was 
the first thiazolide that was primarily transpired for the treatment of the protozoan 
Cryptosporidium parvum. In studies of patients with chronic HBV, NTZ administration evoked 
the seroconversion of HBeAg and HBsAg with the overall abolishment of HBV DNA levels. In 
other studies of patients with chronic HCV, the administration of NTZ together with PEGylated 
IFN-α2a, with or without the addition of ribavirin, manifested efficiency and acceptable safety of 
the thiazolide (Korba et al., 2008a; Rossignol and Keeffe, 2008; Keeffe and Rossignol, 2009). 
Together with the metabolite of NTZ, Tizoxanide, and other thiazolides, reports have indicated 
the effective inhibition of both HBV and HCV replication in standard antiviral assays conducted. 
NTZ showed activity against both genotypes 1a and 1b HCV, the frequent LMV and ADV-
resistant HBV mutants as well as certain HCV mutants. It induced a reduction in the Hep2.2.15 
cell producing HBV proteins; however it did not have an effect on HBV RNA transcription (Korba 
et al., 2008b). Researchers performed a QSAR examination on a variety of thiazolides and they 
assessed its conclusion on HBV replication and activity (Stachulski et al., 2011). Briefly, the 
broad-spectrum NTZ presented efficacy against viruses amongst other things, the novel 2-
hydroxybenzoyl-N-(5-chlorothiazol-2-yl) amide displayed robust and selective HBV replication 
hindrance and in comparison to some analogous salicyloylanilides, favorable activity against 
HBV was shown with numerous 4′-and 5′-substituted thiazolides. It has been delineated that the 
action of removal with substitution of the nitro group found on NTZ with a group that is not 
reducible will allow for novel thiazolides to be formed that sustain a wide-spectrum of viral 
activity only, which would play a valuable role in HBV abatement (Rossignol, 2009).   
 
2.3.3 Small interfering ribonucleic acids 
 
Small interfering ribonucleic acids (siRNAs) with an efficient delivery system can overcome 
barriers, and cause the inhibition of gene expression of specific proteins. The mechanism by 
which this is achieved is known as RNA interference (RNAi). It is a natural procedure that 
protects the genome by targeting a particular messenger RNA (mRNA) for degradation and in 
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the event inhibiting protein synthesis and therefore, viral gene transcription, expression and 
ultimately replication. There are several notable studies that have been conducted concerning 
siRNA. Merely to achieve siRNA hepatocyte targeting, in one such study, a vehicle: siRNA 
Dynamic PolyConjugates was developed (Rozema et al., 2007). This technology involves a 
membrane-active polymer that confers its activity only until it reaches the endosome acidic 
environment and acquires the ability to drop off its siRNA cargo precisely to hepatocytes after a 
simple intravenous injection. Novel hepatotropic nontoxic lipid-based vector systems were 
generated to deliver chemically unmodified siRNAs to the liver (Carmona et al., 2008). 
Triggered PEGylated siRNA-nanoparticles were formulated. Due to the PEG coupling, the 
resulting pH sensitive oxime linkage causes the release of nucleic acids from the endosomes. 
Suppression of markers of HBV replication on account of triggered PEGylated siRNA-
nanoparticles go up to 3-fold relative to controls. Results from another study show that siRNA 
delivery follows a surface charge and size dependent manner (Wang et al., 2010). In another 
study, the aim was to optimally design siRNAs targeting the aberrant HBV and this was 
authenticated via quantitative structure-activity relationship (QSAR) analysis methods (Fu et al., 
2008). Cocktails of siRNAs could also be problem solving as combinations of siRNAs would 
cleave multiple sights on the mRNA target, making it difficult for restoration thereof (Chen et al., 
2008). Researchers demonstrated a study that showed the effects of an HBV specific 21-bp 
siRNA that is directed to the HBsAg region, a site where three prominent viral mRNAs project 
over one another, has on HBV replication in a cell culture system and a mouse model (Giladi et 
al., 2003). Results point out the marked inhibition of viral antigens, their transcripts and DNA 
and thus HBV replication as a whole. 
 
A study demonstrated an evaluation of synthetic siRNA combinations targeting various sites of 
HBV transcripts on its replication and antigen expression in vitro (Chen et al., 2005). Results 
showed that the siRNAs targeting the polymerase and pre-core region specifically inhibited virus 
replication and antigen expression in a dose-dependent manner. This was done efficiently 
compared to the use of single siRNAs at the same final concentration. In addition, no apoptotic 
change was observed in the cells after the combination siRNA treatment. A specialized delivery 
system known as a SNALP (stable nucleic-acid-lipid particle) contained chemically modified 
siRNA in its liposome form (Morrissey et al., 2002). These were administered intravenously into 
HBV replicating mice. HBV DNA reductions specifically lasted for days and weeks with this 
particular dosing. 3 mg/kg/day intravenous injections taken 3 times a day reduced serum HBV 
DNA >1.0 log10. A mouse model carrying replicating HBV was injected intravenously with 
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synthetic siRNA/apo A-I/1,2-dioleoyl-3-trimethylammonium-propane complexes (Kim et al., 
2007). The nanoparticles displayed liver specificity with low doses of less than or equal to 
2mg/kg still rendering effectiveness in only a single treatment with persistence of the therapeutic 
effect for 8 days. Observably, administration of these nanoparticles significantly diminished viral 
protein expression by receptor-mediated endocytosis. Researchers in another study coinjected 
a compounded N-acetylgalactosamine-melittin-like peptide with a siRNA compounded to 
cholesterol that is directed to coagulation factor 7 and validated the oppression of HBV's RNA, 
DNA and proteins with a lengthy effective continuity (Wooddell et al., 2013). Data proposed this 
system of RNAi-based therapeutics as procuring strong potential for chronic HBV infections. 
Another recent study added to the illustration of RNAi allaying HBV by proclaiming viral 
clearance of HBV from the liver of transgenic mice by recombinant adenoviruses expressing 
HBV-directed short hairpin RNAs (Uprichard et al., 2005). 
 
2.3.4 Heteroarylpyrimidines 
 
Heteroarylpyrimidines (HAPs) were identified as powerful inhibitors of the HBV capsid 
maturation step. The interaction site of the core protein-HAP and the exact point in the 
replication cycle where the HAP allows its principal function is unknown however the mode of 
action is the attachment to and degradation of the core protein. Cellbased HBV replication 
assays portrayed a greater potency of HAPs than LMV in the therapeutic treatment of HBV 
(Cuestas et al., 2010). Researchers tested the effect that an HAP [methyl 4-(2-chloro-4-
fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate] had on HBV capsid 
protein congregation (Stray et al., 2005). Results depict the HAP commanding the detachment 
of HBV capsids and consequently being capable of relaying diversified effects emanating from 
the incongruous assembling of HBV's capsid proteins. Therefore, actuating and decontrolling 
the assemblage of a virus could lead to prevailing antiviral-based treatments. A range of HAPs 
built on a crystallized arrangement of a capsid-HAP conjugate was formulated to attempt to 
better understand the HBV capsid assembly and replication in HepG2.2.15 cells in vitro (Bourne 
et al., 2008). The kinetics of assembly in vitro corresponded sufficiently with the prohibition of 
HBV in the cell culture. Results also alluded to contention between suitable and unsuitable 
assembly because of the interrelation of assembly kinetics and virus restriction. BAY 41-4109 is 
an HAP that was evaluated for its antiviral activity in transgenic rodents carrying HBV at 
variance of dosages (3-30 mg/kg, b.i.d/ t.i.d for 28 days). In relation to LMV, BAY 41-4109 was 
just as competent in lowering HBV DNA in a dose-dependent fashion. Results also suggested 
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lowered HBcAg in excised hepatic sections in disparity with LMV treated rodents indicating BAY 
41-4109 bears no resemblance in the mechanism of action of LMV as an antiviral. BAY 41-4109 
pharmacokinetics revealed swift absorption and a 30% bioavailability (Pan et al., 2008). BAY 
41-4109 was also studied for its causative effect on the intracellular EGFP-Core fusion proteins 
into HepG2 cells. It is conclusive that BAY 41-4109 is a powerful inhibitor of HBV having myriad 
effects on the arrangement of HBV's capsid to achieve this antiviral result (Haryanto et al., 
2007). Pyrazole and pyrimidine derivatives were also formulated to assess their antiviral 
exertion on HBV. Facts presented with controlled to high inhibitory activities (El-Sayed et al., 
2009). Table 2.2 reflects a compendiary of thiazolides, siRNAs and HAPs efficiency as HBV 
eradicators. 
 
Table 2.2: Summary of anti-HBV thiazolide, siRNA and HAP therapeutic agents as a treatment 
plan 
Therapeutic agent Effectiveness as anti-HBV therapy Reference 
Thiazolides Potent and selective HBV replication inhibition, 
HBeAg and HBsAg seroconversion, decreased 
HBV DNA levels, treatment in  LMV and ADV-
resistance, decreased Hep2.2.15 cell HBV 
proteins, no HBV RNA transcription effect 
Rossignol and Keeffe, 
2008; Korba et al., 
2008a; Korba et al., 
2008b; Keeffe and 
Rossignol, 2009; 
Rossignol, 2009; 
Stachulski,  2011 
siRNAs
a
 Gene expression inhibited, viral antigens 
inhibition, HBV transcripts inhibition, decreased 
serum HBV DNA and RNA
b
 levels, suppressed 
HBV replication markers, mRNA
c
 cleavage, 
polymerase and pre-core region targeting, 
effective continuance of treatment 
Carmona et al., 2008; 
Chen et al., 2008; 
Uprichard et al., 2005; 
Rozema et al., 2007 
HAPs
d
 Potent HBV capsid maturing inhibition, HBV core 
protein degradation, increased potency than 
LMV, potent antigens inhibition effect, 
misassembly of HBV's capsid proteins, dose-
dependent decrease in HBV DNA levels, 
decreased HBcAg
e
 
Stray et al., 2005; 
Bourne et al., 2008; Pan 
et al., 2008; Haryanto et 
al., 2007; El-Sayed et 
al., 2009; Cuestas et al., 
2010 
aSmall interfering ribonucleic acids; bRibonucleic acid; cMessenger RNA; dHeteroarylpyrimidines; 
eHepatitis B core antigen 
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2.4. Hepato targeting: A delve into attempts at earlier performed research studies 
 
Hepato or liver targeting does not necessarily reflect hepatocyte targeting as other cells in the 
liver such as the Kupffer cells, possess the ability to phagocytose. Therefore, carriers need to 
be modified chemically to achieve the ability of encompassing liver cell type specificity (Cuestas 
et al., 2010).   
The ASGP-R has been amongst the most distinguished and investigated of all receptors and 
was first corroborated by Ashwell and Morell (1974). The ASGP-R has provided for a location to 
accommodate cell-cell intercommunication that is membrane bound. It allows for targeting 
specificity of various therapeutic agents and has been the locus of incrimination for HBV uptake 
(Stockert, 1995). Figure 2.7 illustrates the ASGP-R mediated endocytosis (Lai et al., 2010). 
Several attempts have been made to label carriers (polymers, human serum albumin, and 
recombinant HDLs) with ASGP-R specific ligands (galactose, lactose, acetylgalactosamine, 
asialofetuin) to design specific carriers for drug and gene delivery to hepatocytes. 
Lysosome
Endosome
HEPATOCYTE
Ligand
ASGP-R
 
Figure 2.7: A schematic depicting the receptor-mediated endocytosis by the ASGP-R on 
hepatocytes (Modified from Lai et al., 2010). 
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Organ-specific targeted delivery has been achieved using linear aminopolysaccharide, chitosan, 
its derivatives and the likes. Studies have demonstrated liver targeting ability. Systems that 
target the liver employ passive trapping of the drug loaded delivery device by the RES or the 
active targeting established through recognition between hepatic receptor and ligand-bearing 
drug loaded delivery devices. In one such study, lactosaminated N-succinyl-chitosan was 
synthesized and its potential assessed as a liver specific drug carrier (Kato et al., 2001). It was 
found that this carrier accumulated in the liver and distributed throughout the liver as a result of 
interaction with the ASGP-R. 
 
Lactose conjugated to polyion complex micelles that consisted of PEG grafted to chitosan also 
indicated promising potential as liver specific nanocarriers to deliver the drug, diammonium 
glycyrrhizinate (Yang et al., 2009). Authors of one study modified the surface of chitosan 
nanoparticles by conjugating it with glycyrrhizin. The conjugation occurred through a process of 
oxidation of the glycyrrhizin with sodium periodate (Lin et al., 2008). In vitro studies showed 
localization of the glycyrrhizin conjugated chitosan nanoparticles in hepatocytes and the 
intracellular uptake amounted to 4.9 times than that in hepatic nonparenchymal cells. The 
nanoparticle dose as well as the incubation time were significant markers to the cellular uptake 
process. Liver targeting was achieved by a specific interaction between the glycyrrhizin and the 
hepatocytes, a ligand-receptor interaction. 
 
High density lipoproteins (HDL) present another assuring hepatic targeting carrier. They take up 
phospholipids and cholesterol from the body's peripheral tissues and delivers them to the liver 
hepatocytes via apolipoprotein (apo) A-l, the major lipoprotein component in HDL. Researchers 
of one study designed divalent and trivalent cluster glycosides attached to the antiviral 
nucleoside 9-(2-phosphonylmethoxyethyl) adenine (PMEA). This conjugation promoted ASGP-
R affinity (Biessen et al., 2000). Data from this work indicated more than 90 % of the therapeutic 
agent to be taken up by liver parenchyma cells thereby reducing its localization in other tissues 
significantly. Dextran conjugation is also seen favourable light. Synergistically, modification of 
dextran with galactose and mannose results in its selectivity for hepatocytes and Kupffer cells 
respectively (Cuestas et al., 2010). Liver-specific treatment and HCC targeting of doxorubicin is 
possible when the polymers used are functionalized with galactosamine (Seymour et al., 2002). 
Figure 2.8. depicts and follows the movement of a therapeutic drug loaded to liver hepatocyte. 
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Figure 2.8: Liver targeting by nanoparticle (NP) therapeutics: a) Nanosized particles of less 
than 200nm with specific functionalities aid in the evasion of premature Kupffer cell clearance; 
b) Nanosized particles extravasate into the space of Disse through sinusoidal fenestrations in 
basal lamina absence; c) A high local concentration of NP therapeutics diffusing across the 
loosely organized extracellular matrix in the space of Disse; d) Non-specific endocytic uptake; 
and e) Receptor-mediated uptake by the hepatocyte (Modified from Li et al., 2010). 
 
Various drug carriers often fail in delivering drugs to extravascular sites. A strategic plan would 
be to use low molecular weight prodrugs that have the ability to distribute themselves 
throughout the body but cleave intracellularly to the active form of the drug by an organ-specific 
enzyme. HepDirect prodrugs are a series of phosphate and phosphonate prodrugs that pursue 
a cytochrome P450-catalyzed oxidative cleavage reaction inside the hepatocytes. This certainly 
classifies a liver-targeting drug delivery approach. These prodrugs are cyclic 1, 3-propanyl 
esters that contain a ring substrate that presents sensitivity to oxidative cleavage by the 
cytochrome P450 with specificity to CYP3A4 (Erion et al., 2004).  
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Studies were also performed to test the potential of bile acids to deliver drugs distinctively to the 
liver since these bile acids are transported across the plasma membrane in the portal domain 
(Kramer et al., 1992). The liver-specific drug chlorambucil was used and covalently linked to 7 
alpha, 12 alpha, -dihydroxy-3 beta-(omega-aminoalkoxy)-5-beta-cholan-24-oic acid to form 
chlorambucil-bile acid conjugates and studies revealed success of bile acid molecules to 
behave as carriers for drug molecules and their specificity for the liver. Researchers designed a 
nanoparticle-based model delivery system that simulated nonviral gene delivery particles with 
respect to their surface properties in an attempt to identify design constraints to aid next 
generation gene delivery to the liver (Popielarski et al., 2005a; Popielarski et al., 2005b). Four 
nanoparticles were formulated from polystyrene beads viz. Gal-50 and Gal-140 which are 
galactosylated; and MeO-50 and MeO-140 which are methoxy terminated. The 50 and 140 
denotes the mean diameter of the nanoparticles in nanometers. Galactose is incorporated as a 
targeting ligand and provision of serum stability is attained with PEGylation of the nanoparticles. 
Results show that a slight anionic, galactose- PEGylated nanoparticle should size up to around 
50 nm and 140 nm in diameter in order to selectively target hepatocytes and Kupffer cells, 
respectively. Overall, these studies and findings support the concept that targeted delivery of 
antivirals to the liver increases the productiveness of these therapeutic agents in the treatment 
of viral liver infections and reducing their toxicity profiles in other bodily tissues and organs as a 
result of systemic exposure (Cuestas et al., 2010). 
 
2.5. Novel and recent advances in drug delivery developments for anti-HBV therapeutics 
 
2.5.1. Woodchuck Apolipoprotein A-1 
 
A significant protein component of high density lipoprotein is apolipoprotein A-1 and functions to 
passage cholesterol from the body's tissues to the liver where it is then excreted. Authors 
therefore studied woodchucks infected with the woodchuck hepatitis virus as a model to 
investigate chronic HBV and HCC in patients (Fioravanti et al., 2011). They proposed that the 
therapeutic effectiveness of the woodchuck animal model may be interpreted into a successful 
therapeutic plan for patients that are HBV diseased. Their study recounts the characterizing and 
cloning crafts of woodchuck Apo-A1 and the means of augmentation that allow it to be applied 
as a novel drug delivery strategy for HBV. 
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2.5.2. Bionanocapsules 
 
Bionanocapsules were linked with a lipoplex that contained HBsAg L protein entrenched as a 
transmembrane protein and was formulated and further complexed with PEI and DNA to 
produce stable complexes that was an efficient gene carrier for targeting to the human liver. The 
particles were delivered to the cells in the same manner of HBV infection in the primal phases 
(Somiya et al., 2012; Yamada et al., 2012). 
 
2.5.3. Bilosomes 
 
Researchers improving on an earlier study of bile salt stabilized vesicles (bilosomes) 
development have complexed the bilosomal system with cholera toxin B subunit. They loaded 
the system with HBsAg to elevate M-cell specificity and its transmucosal uptake. Conclusive 
results displayed significant anti-HBsAg IgG antibody titre response for this specific bilosomal 
system propounding assuring potential for target specific oral immunization against HBV 
(Shukla et al., 2008; Shukla et al., 2010). 
 
2.5.4. Recombinant Viral Vectors 
 
A novel vector established on an HBV mutant that has great ability to replicate and holds a 207-
bp deletion in the preS1/polymerase spacer region was constructed by researchers. They 
applied a new insertion approach that maintains the progression of the polymerase open 
reading frame and as a result recombinant HBV carrying protein/siRNA genes were attained 
and showed replication. They were confined with efficiency in hepatic cells. Hereon followed 
favourable wild type HBV (WT-HBV) antigen expression inhibition (Hong et al., 2013). Another 
study utilized a recombinant adenovirus vector for recombinant HBV delivery. The vector 
granted adept transduction of HepG2 cells generating WT-HBV in addition to transferred 
recombinant HBV yielding dominant viral replication. Viral clearance and successive HBV 
seroconversion was obtained due to the foreign-antigen-specific T-cell response that was 
prompted by the recombinant adenovirus/recombinant HBV immunotherapy. The study 
represented a profitable plan of action to do away with immune tolerance and thus ridding 
chronic HBV (Wang et al., 2014). 
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2.5.5. Polymeric Hydrogels 
 
Authors developed a novel scheme to lessen the amount of HBV vaccine doses by allowing it to 
be released from a bodily depot that would respond to oral stimuli. This was carried out by 
merging the HBV vaccine into a bioybrid hydrogel depot with a PEG foundation. In mice, the 
depot was receptive to the oral intake of novobiocin, the stimulus molecule. This led to proper 
immunization in the mice (Gübeli et al., 2013).  A diblock copolymeric hydrogel constituting 
(monomethoxy poly(ethylene glycol)-co-poly(lactic-co-glycolic acid) was also developed by 
authors. They used this to deliver both HBsAg and GM-CSF, an immune modulator and a 
haematopoietic growth factor. Their results displayed a valid and easy technique for actuating 
anti-hepatitis B surface antibodies in nonresponsive patients (Chou et al., 2010). 
 
2.5.6. Polymeric Microparticles 
 
PLGA and Dextran polymers were melded using a solvent evaporating method to formulate 
microspheres. Recombinant HBV vaccine was added into the copolymeric complex. In vivo 
investigations concluded PLGA/Dextran microspheres to be able to encourage an acceptable 
immune response (Moni et al., 2011). Another study that attempted to do away with repetitive 
injectable doses, designed once off HBsAg adsorbed microspheres composing poly(D,L)-
lactide-co-glycolide (PLGA) (L/G 50:50 and 75:25). It was developed to evaluate its ability for 
provoking the cell mediated immune response against HBsAg. Data exhibited the success of 
the PLGA microspheres as a vaccine in causing effective immune responses against HBV 
(Saini et al., 2011). 
 
2.5.7. Nanoparticles 
 
2.5.7.1. Inorganic Nanoparticles 
A study concerned with imaging in liver cancer placed emphasis on a proteoglycan known as 
Glypican-3 (GPC-3) which is involved with enabling cell growth that is found to be 
overexpressed in HCC. Superparamagnetic iron oxide novel multifunctional nanoparticles were 
developed. Particles were conjugated to streptavidin and Alexa Fluor 647. It was found with 
confocal fluorescence microscopy (CFM) that biotin-conjugated GPC-3 monoclonal antibody 
was confined only to the cellular surface of HepG2 cells expressing GPC-3. The GPC-3 
nanoparticle system proved that it can be utilized in imaging for HCC visualization as well as 
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capability to be used as a vehicle for delivery of therapeutics targeting tumors (Park et al., 
2011). Researchers also used magnetic nanoparticles' surface in another study to prepare 
multifunctional HCC targeting agents by blending bis-N-hydroxysuccinimide ester and OSu-
activated fluorescent dye Cy3. A mono-antennary and tri-antennary galactosyl ligands were 
each fixed onto the fluorescent magnetic nanoparticles and their uptake into HepG2 and HeLa 
cells were evaluated by CFM. Results show that this system is a good ligand transporter and its 
multivalent ligand assembly improves on the cell interaction with HepG2 receptors. The 
galactosyl Cy3 magnetic nanoparticles were also found to be non-cytotoxic (Lai et al., 2010). 
SiO2 nanoparticles were also used for attachment to HBV-like particles in order to transit 
immune response-regulating agents for targeted treatment (Dekhtyar et al., 2012). 
 
2.5.7.2. Polymeric Nanoparticles 
Poly(vinylbenzyl-O-β-D-galactopyranosyl-D-gluconamide) (PVLA) is known to be site 
specifically taken up into hepatocytes via ASGPR. Therefore, researchers synthesized a 
copolymer, poly(N-p-vinylbenzyl-[O-β-D-galactopyranosyl-(1→4)-D-gluconamide]-co-N-p-
vinylbenzyl-6-[2-(4-dimethylamino)benzaldehydehydrazono]nicotinate) (P(VLA-co-VNI)), and 
this was tagged with (99m)Tc for liver imaging. Results revealed promising potential for more of 
its application in the evaluation of liver cell function (Yang et al., 2011). Authors achieved site 
specificity to hepatocytes by synthesizing a galactosylated PEG-graft-PEI derivative via the 
modification of a biscarbamate cross-linked PEI by-product with PEG and lactobionic acid. The 
complex held a galactose moiety for hepatocyte targeting. It could also efficiently incorporate 
plasmid DNA into nanoparticles. Data displayed its successful targeting to the hepatocytes 
(Wang et al., 2013c). In a different study, nanoprecipitation and solvent evaporation techniques 
were used to prepare cationic poly(lactide) (PLA)-based nanoparticles together with PEI and 
chitosan as surface coating components. mPEG-PLA-PEI nanoparticles showed best ability to 
impede HBV surface antigen and thus allowing for transfection of siRNA (Wang et al., 2010). 
Researchers used a double-emulsification technique to prepare HBsAg passively adsorbed onto 
the surface of cationic PLGA nanoparticles to deliver IFN-α to site-specific hepatocytes. HbsAg 
coated (99m)Tc-labeled PLGA nanoparticles results presented notable liver recovery in contrast 
to normal PLGA nanoparticles (Giri et al., 2011). The particle size and hydrophobicity effects of 
porous PLA and PLGA nanoparticles were assessed on cell mediated and mucosal immune 
responses. The nanoparticles accommodated a set amount of HBsAg and administration 
occurred via pulmonary delivery. Data revealed that hydrophobic particles that were larger in 
size, greater than 500 nm, derived a potent increase in secretory IgA, IFN-γ and interleukin-2 
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levels as opposed to hydrophilic particles that were smaller than 500 nms. The larger sized 
hydrophobic particles also showed that they could be more easily taken up into rat alveolar 
macrophages. The study demonstrated the competence of the nanoparticles to induce 
augmented immune responses (Thomas et al., 2011). Authors also developed polymeric 
nanoparticles formulated for HBV gene silencing making use of the common biodegradable 
polymer PLGA again, but in this study, the cationic polymer chitosan is embodied into its matrix. 
The idea is to advance plasmid DNAs loading efficiency and cellular internalization. Conclusive 
data revealed better HBV silencing with the chitosan-PLGA system compared to plain plasmid 
DNA alone or simple PLGA nanoparticles. A successful plasmid DNA carrier system was 
formulated (Zeng et al., 2011). Micelles were developed in one study for incorporating 
Lamivudines (LMVs) prodrug, LMV stearate. LMV stearate was synthesized to increase LMVs 
lipophilicity being a very hydrophilic drug. Stearic acid-graft-chitosan oligosaccharide micelles 
were prepared and loaded with LMV stearate. Results showed that the micelles had constrained 
effects on HBVs antigen expression and DNA replication and this was more conspicuous when 
comparing with LMV or its prodrug alone (Li et al., 2010). Acyclovir was also complexed to 
chitosan-g-stearate through use of a succinate linker for anti HBV activity. The acyclovir-
chitosan-g-stearate was able to self assemble in aqueous solution constructing micelles. 
According to data there was a significant escalation in its inhibitory effect of HbsAg compared to 
plain acyclovir alone. An all round success of cellular internalization and anti HBV effects was 
observed with acyclovirs complexation to chitosan-g-stearate (Huang et al., 2011). Authors also 
revealed an assuring hepatic targeted siRNA delivery system for gene expression silencing 
formulated from N-acetylgalactosamine functionalized mixed micellar nanoparticles. The N-
acetylgalactosamine micellar nanoparticles were self aggregated in aqueous solution from N-
acetylgalactosamine functionalized PEG-b-poly(ε-caprolactone) and cationic poly(ε-
caprolactone)-b-poly(2-aminoethyl ethylene phosphate) (PCL-b-PPEEA). The targeting effect to 
the hepatocytes was displayed by noteworthy enhanced fluorescent siRNA found in primary 
hepatocytes implying positive anti HBV therapy in liver disease (Wang et al., 2013d). A drug 
carrier was synthesized from glycyrrhetinic acid-modified sulfated chitosan with glycyrrhetinic 
acid being the targeting ligand to HepG2 cells. The micelles formed from this complex revealed 
swift and eminent ability for in vivo liver targeting. Moreover, the formed micelles showed 
specificity for liver cancer cells in contrast to normal liver cells (Tian et al., 2012). 
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2.5.8. Lipids 
 
2.5.8.1. Ionizable Lipid Nanoparticles 
Researchers of a study found that apolipoprotein E, amongst its other roles, also had the ability 
to pose as an endogenous targeting ligand for ionizable lipid nanoparticles excluding cationic 
lipid nanoparticles. And the second means of targeting via an exogenous ligand was formed 
from an N-acetylgalactosamine cluster. Both target specific systems seemed profoundly 
adequate in carrying ionizable lipid nanoparticles to the hepatic environment (Akinc et al., 2010). 
 
2.5.8.2. Cationic Lipids 
Novel cationic lipids were synthesized from N-cholesteryloxycarbonyl-3,7-diazanonane-1,9-
diamine (CDAN) that is conjugated to a dialkylglycylamide moiety to form N′,N′-dioctadecyl-N-
4,8-diaza-10-aminodecanoylglycine amide (DODAG). This was used to form lipoplex 
nanoparticles containing siRNA and these efficiently led to the in vivo delivery of siRNAs to the 
liver of transgenic mice mediating the suppression of HBV replication that showed a greater 
comparison to LMV with minimal observable liver toxicity (Mével et al., 2010). In other studies, a 
cationic lipid-DNA-complex (CLDC) was assessed for its capacity to aid HBsAg in extracting 
immune responses and to cause a decline in HBV DNA levels in transgenic mice. It was 
triumphant in accomplishing both of these functions (Morrey et al., 2011). Researchers 
evaluated the use of a synthetic HBV preS-derived lipopeptide, HBVpreS/2-48(myr) (HBVP), 
known to be equipped with a coercive ability for liver tropism, in site specificity for liver cell 
delivery. The lipopeptide was conjugated to PEGylated liposomes (HBVP-Lip). Data pointed out 
the capability of HBVP-Lip to deliver cargo to hepatocytes with definitive target specificity both in 
vitro and in vivo (Zhang et al., 2014). 
 
2.5.8.3. Liposomes 
Cationic liposomes have been considered as novel adjuvant systems because they themselves 
are not adequate enough as immunostimulating agents. Therefore ligands that do acquire this 
function are coalesced with the liposomes acknowledging them as adjuvants to the functional 
division of the complex and thus bringing about potential application for enhanced HBV vaccine 
delivery (Christensen et al., 2011). In one study, asialofetuin was affixed to cationic liposomes 
for hepatocyte selectivity and conjoined to it were diverse cyclodextrins and plasmid DNA for 
gene transfer. From the cyclodextrins, γ-cyclodextrin complexed with the DNA-asialofetuin 
liposome showed the most dominant transfection efficiency with zero cytotoxicity, highest 
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entrapment ratio of the DNA and the ability to stabilize the membrane of the asialofetuin-
liposome. γ-cyclodextrin was noted as an amplifier of gene transfer efficiency in liposomes 
appended with asialofetuin (Motoyama et al., 2011). 
  
2.5.8.4. Lipoplexes 
Authors evaluated the practicality of hindering HBV replication in vivo utilizing the recently 
reported altitrol-containing class of synthetic siRNAs. They were executed as lipoplexes and 
assessed in vivo using an HBV transgenic mouse model. Observations and findings revealed 
success in the silencing of HBV replication with no toxicity. Results correlated with conceding 
future application of altitrol-containing siRNA therapeutic lipoplexes (Hean et al., 2010). 
 
2.5.8.5. High Density Lipoprotein 
A study illustrating HDL's capability of transporting microRNAs (miRNA) was performed. 
miRNAs being a novel group of ailing biomarkers, warranted an efficient targeting potential, 
therefore its export to HDL was achieved by sphingomyelinase. Additional findings revealed that 
the delivery by means of HDL was reliant on scavenger receptor class B type I. Healthy patients 
and patients with high cholesterol levels exhibited dissimilar HDL-miRNA effects and this 
inspection specified HDL's means of cell-cell intercommunication allowing for miRNA transfer 
(Vickers et al., 2011). In other studies, contrast agents for MR imaging in the liver were 
developed using reconstituted HDL enclosing gadolinium-labeled-cholesterol as nanoparticles. 
This would be advantageous to determine anatomical variations in the liver. The contrast agent 
nanoparticles bound to HDL receptors on the HepG2 cells consenting uptake. Researchers also 
investigated whether the popular drug doxorubicin hydrochloride could be efficiently 
encompassed into reconstituted HDL for liver targeting. A doxorubicin-HDL compound was 
formed and assessments showed that the compound was successfully taken up into liver cells 
laden with the HDL-specific scavenger receptor class B type 1, had heightened and effective 
cytotoxicity results against many cell lines and has the ability to lessen cancer progression to a 
greater degree than the drug in liposomes. In this case the reconstituted HDL was fecund yet 
again in drug deliverance targeting the diseased liver [Rui et al., 2012; Yuan et al., 2013). 
 
2.5.8.6. Solid Lipid Nanoparticles 
Cationic and mannosylated solid lipid nanoparticles (SLNs) were prepared to show potential as 
a vehicle for HBV vaccine delivery via the subcutaneous route. The mannosylated SLNs 
displayed superior cellular internalization, a reduced amount of cytotoxicity as well as causing a 
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larger TH1 immune response type (Mishra et al., 2010). Cationic SLNs were also reconstructed 
from native low density lipoproteins and were formed to have application as specific target 
systemic delivery of connective tissue growth factor siRNA (siCTGF). The system was 
developed for the liver fibrosis treatment in HBV. Fluorescence imaging and single-photon 
emission computed tomography (SPECT) allowed for biodistribution studies which rooted the 
specific targeting, delivery and build-up of cationic solid lipid nanoparticles/siCTGF 
nanocomplexes in the liver (Kong et al., 2013). 
 
2.5.9. Cell Penetrating Peptides 
 
Mentioned earlier, a study took advantage of the complimentary execution of cytoplasmic 
transduction peptide (CTP) in delivering its payloads to hepatocytes. This was carried out by 
researchers purifying an anti-HBV core single-chain variable fragment welded to CTP and 
followed by assessment of its potential in HBV inhibition. It markedly reduced HBV DNA levels 
(Xun et al., 2013). Authors developed a series of artificial recombinant peptides along with cell 
penetrating sequence R7 and various nucleocapsid binding subunits. Conclusive data showed 
that the synthetic recombinant CPPs holding nucleocapsid binding subunits can enter into cells 
readily, cause the obstruction of nucleocapsid assembly and arrest HBV release (Pan et al., 
2011). A most recent novel drug delivery platform with its groundwork on a CPP motif called X-
Pep, derived from the extreme N-terminal region of the X-protein of HBV, is being said to retain 
application in having drugs delivered straight to cells specifically (Montrose et al., 2014). 
Researchers in another study also co-injected an N-acetylgalactosamine-melittin-like peptide 
with a siRNA compounded to cholesterol that is directed to coagulation factor 7 and validated 
the oppression of HBV's RNA, DNA and proteins with a lengthy effective continuity. Data 
proposed this system of RNAi-based therapeutics as procuring strong potential as a novel 
therapeutic for chronic HBV infections (Wooddell., 2013). 
 
2.6. Concluding Remarks 
 
Much needs to be done in the development of novel liver-specific drug delivery strategies to do 
away with the high morbidity and mortality that is related to diseases caused by the HBV 
infection. There should be a demand for carriers that reach the height of optimization with 
intracellular targeting, protection of its contents and efficient delivery thereof. Adequate 
information has been sought out with respect to receptors that dwell on the specific liver cell 
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types, therefore, with this knowledge and more, receptor-specific ligands can be embodied in 
the design of nanocarrier systems to achieve heightened efficiency of therapy. A desired 
characteristic of nanocarriers and an added advantage to anti-HBV therapy is the capacity to 
incorporate agents together with the required drug for liver imaging. The discovery of novel drug 
candidates together with relevant carriers should also prove to be promising in HBV eradication, 
or at least significant reduction. However, the objective of these drug candidates for treatments 
of a diseased liver owing to HBV is to attain clinical recovery and reparation in the least amount 
of time achievable to be devoid of the virus generating a resistant strain. It should be expected 
for future anti-HBV therapies to embrace a medley of agents such as the nucelot(s)ide analogs 
together with immunostimulants and curative vaccines. Once these ideal goals have been 
reached and achieved, quality of life will be greatly improved for patients suffering from this 
debilitating disease. 
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CHAPTER 3 
SYNTHESIS AND CHARACTERIZATION OF A NOVEL AMPHIPHILIC HYALURONIC 
ACID-GRAFT-EPSILON CAPROLACTAM COPOLYMER 
3.1. Introduction 
 
Hyaluronic Acid (HA), allied to a category of substances referred to as glycosaminoglycans, 
is a naturally occurring linear polysaccharide that comprises of interchanging links of D-
glucuronic and N-acetyl-D-glucosamine residues (Oh et al., 2010; Kogan et al., 2007; Kuo et 
al., 1991) [Figure 3.1.a]. The reason for its natural biocompatibility arises from the fact that 
HA is sourced from various origins such as those of animal tissue as well as microbial 
fermentations (Oh et al., 2010). HA is employed as a scaffold constituent in tissue 
engineering and has many uses in the preparation of polymeric drug delivery systems 
(Palumbo et al., 2006). Synthetic functionalization of HA through grafting has been reviewed 
in a favorable light and derived sizeable deliberation in biomedical relevance (Radhakumary 
et al., 2011). Polymer grafting encompasses surface modification of polymers, to enhance 
the performance of these polymeric materials (Kato et al., 2003). Block and graft copolymers 
and polysaccharides of a lipophilic nature are amphiphilic macromolecules that have been 
vastly examined for utilization as a targeted drug delivery system (Jeong et al., 2012). In the 
case of poly(vinyl) alcohol, the graft copolymerization method has been reported to generate 
a higher graft yield compared to other methods of chemical modification (Zheng et al., 2005). 
Conjugation and crosslinking allows for chemical modification of HA by an amalgam grafted 
onto the backbone of HA via a single bond and assorted HA chains are affiliated by two or 
more links, respectively (Schanté et al., 2011). These chemical modifications cause the HA's 
remedial properties to be adjusted via targeting its many sites and applying these 
functionalizations in diverse solvents to attain an effect that preferably correspond to the 
product traits being sought (Schanté et al., 2011). In one study, preparation of graft 
copolymers were accomplished by the linking of mono amine-terminated poloxamer with HA 
employing 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide and N-hydroxylsuccinimide to 
conjugate the two polymers (Cho et al., 2003). HA was also modified to determine its 
stability and thus resistance to enzymatic degradation by grafting numerous amino acids 
onto the carboxylic functional group of HA. The results proved successful with achievement 
of degradation resistance likened to native HA (Schanté et al., 2012).  
A hydrophobic polymer, epsilon-Caprolactam (ECL) [Figure 3.1.b)], bears favorable 
properties for structural integrity and stability in a solvent. These comprise durability, 
hardness and an ability to extend (Grahowski and Borg, 1964). The synthetic fiber NYLON-6 
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is a constitution of ECL monomers. A graft copolymerization process was carried out 
between ECL and a Kevlar-49 fiber (Kim et al., 1997). The resultant copolymer achieved 
enhanced thermal and mechanical properties in comparison to the original Kevlar-49 fiber 
alone. ECL is also a salient precursor to the malleable material, plastic (Maheswari et al., 
2003; Vilas and Tojo, 2010; Witjkamp et al., 1999). Anionic polymerization is the approach 
applied to elicit the linkage of polyesteramides from the cyclic monomers ECL and e-
caprolactone and these have been characterized (Chromcová et al., 2008).  
 
 
 
Figure 3.1: Chemical structure of a) HA and b) ECL. 
 
Thus anionic polymerization is a preferred method of choice to graft the ECL onto HA. But 
HA is unsatisfactorily soluble in essential organic solvents and this limitation restricts its 
operation in drug delivery systems when there is need for its chemical constitution with 
hydrophobic polymers for an effective specific outcome (Lee et al., 2009b). Poly (ethylene 
glycol) (PEG) is most frequently employed in polymer drug delivery and is covalently affixed 
by means of one or more of its chains to a peptide/non-peptide or protein molecule. This 
polymer is widely used because of its robust characteristics of nontoxicity, increasing of half-
life, being well soluble in water and having no antigenic or immunogenic response (Knop et 
al., 2010; Veronese and Pasut, 2005). PEGylation also allows for tumor targeting by way of 
an improved permeability and retention effect. The most attractive function of PEG is its 
ability to augment the solubility of hydrophobic compounds in an aqueous or organic 
environment (Banerjee et al., 2012; Roberts et al., 2002). Comparable to HA, many 
carbohydrates, proteins and DNA need to be dissolved in a separate organic phase to reach 
a steady state release of the drug delivery formulation. PEG may form complexes with these 
biomacromolecules to assist in solubilization of these compounds (Mok et al., 2008). 
 
Therefore the aim of this chapter is to synthesize a novel copolymer by an anionic graft 
copolymerization process for linking hydrophobic ECL chains onto the backbone of 
hydrophilic HA for use in drug delivery. To attain this, the hydrophilic HA requires 
modification for anhydrous dimethylsulfoxide (DMSO) solubilization by the additive 
Fitt
ed 
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methoxyPEG. The PEG nanocomplex formed with HA (HAmPEG) will enable graft 
copolymerization of the polymer with ECL. Overall characterization tests and investigations 
into micellar formation ability of the amphiphilic copolymer will determine whether there may 
be potential for application in targeted drug delivery and more specifically, against HBV, in 
this study. 
 
3.2. Materials and Methods 
 
3.2.1. Materials 
 
Hyaluronic acid sodium salt from Streptococcus equi, epsilon-Caprolactam (>=99 %), 
Poly(ethylene glycol) methyl ether (mPEG) (average Mw~2000 Da), Dialysis tubing cellulose 
membrane (Mw 12044 Da), N-acetylcaprolactam (99 %) (N-ACL), Sodium hydride (NaH) 
(powder moistened with oil, 55-65 % gas volumetric), Fluoroscein isothiocyanate (FITC) 
were all purchased from Sigma-Aldrich (St. Louis, MO, USA). Dimethyl sulphoxide (DMSO) 
and Dichloromethane (DCM) were purchased from Merck Chemicals (Pty) Ltd. (Germiston, 
Gauteng, South Africa). All other chemicals and reagents were of analytical grade. 
 
3.2.2. Desalting process of hyaluronic acid 
 
HA was converted to its acidic form by removal of its salt (Lee et al., 2008). Dry HA (1 g) was 
added to 100 mL of deionized water and left to stir until all HA was dissolved forming a 
viscous solution. This was dialyzed (Mw 12044 Da) for 24 hours against 3-5 L of deionized 
water to convert the sodium salt to the acid form (Figure 3.2.). The process can be hastened 
by having the beaker on a magnetic stirrer, disrupting the equilibrium between the 2 
compartments continuously. The acid form of HA was recovered by lyophilization with a 
freeze-dryer (Labconco Freeze-Dry Systems, Labconco Corp., Kansas City, MO, USA). 
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Figure 3.2: Illustration of HA desalting using dialysis tubing (Mw 12044 Da). 
 
3.2.3. PEG-assisted solubilization of HA in DMSO 
 
Desalted HA and methoxyPEG (mPEG) at an mPEG/HA weight ratio of 5:1 was added in 25 
mL deionized water to form a mixture. The solution was well-stirred for 3 days and 
lyophilized to obtain dry HAmPEG complex powder. A total of 100 mg of lyophilized 
HAmPEG complexes was added in 1 mL of anhydrous DMSO under dry N2, vigorously 
stirred at 80 °C for 2 hours to solubilize the mPEG-attached HA (Lee et al., 2008). 
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3.2.4. Anionic graft (co)polymerization of HA and ECL (HA-g-ECL) 
 
A set of five batches in alternating quantities of HA to ECL was prepared (Refer to Table 
3.1.). The polymers were added together and plugs and stoppers ensured a sealed system 
that was purged with N2 gas for 30 minutes. N-acetylcaprolactam (1mL) was added to the 
system through a syringe after which the tube was placed into an oil bath at a temperature of 
140 °C. After 15 minutes of stirring at this temperature, 0.153 g of NaH was carefully added 
to the flask. The polymerization was allowed to proceed for 3 hours under N2 gas (Tarkin-
Tas and Mathias, 2010) (Refer to Figure 3.3). After cooling down to room temperature, the 
mixture was dialyzed (Mw 12044 Da) against deionized water for 48 hours and put to freeze 
for 24 hours at -70 °C. The proposed graft copolymer was lyophilized. An illustration of the 
graft copolymerization of HA and ECL is depicted in Figure 3.4. 
 
Table 3.1: Quantities of hydrophilic to hydrophobic polymer used for optimal grafting 
efficacy. 
Batch 
No. 
 HA*1 
(mg/mL) 
ECL*2 
(mg) 
1  100 900 
2  300 700 
3  500 500 
4  700 300 
5  900 100 
*Volume and weight of N-ACL and NaH kept constant 
1HA- Hyaluronic acid 
2ECL- epsilon Caprolactam 
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Figure 3.3: Digital images displaying the set-up for anionic graft copolymerization; a – N2 
line, b – plugs and stoppers, c – polymers in DMSO, d – pot of heated oil, e – heated 
temperature-controlled magnetic stirrer, f – 3-necked round bottom flask, g – magnet, h – 
chemicals for copolymer synthesis, i – N2 tank pressure gauge/dial, j – N2 tank. 
 
a 
a 
a 
b 
c 
d 
e 
f 
g 
h 
i 
j 
47 
 
 
 
Figure 3.4: Synthetic graft (co)polymerization of HA-g-ECL. 
 
3.2.5. Graft copolymer batches and parameters 
 
Anionic graft copolymerization was performed on 5 batches consisting of varying mass ratios 
of HA:ECL (1:9 – 9:1). Percentage of grafting efficiency (GE) and percentage graft ratio (GR) 
were calculated according to Equation 1 & 2, respectively (Kumar et al., 2012): 
 
GE (%) =
Mass of graft copolymer (g) – Mass of HAmPEG (g)
Mass of graft copolymer (g)
 ×  100                                     Equation 3.1. 
 
GR (%) = 
Mass of graft copolymer (g)- Mass of HAmPEG (g)
Mass of HAmPEG (g)
× 100                                                 Equation 3.2. 
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3.2.6. Fourier Transform Infrared Spectroscopy analysis of copolymer synthesis 
 
Fourier transform infrared (FTIR) spectroscopy analysis was performed to ascertain the 
copolymerization between HA and ECL and the non covalent interaction between HA and 
mPEG. FTIR allow for structural changes and variations to be assessed between 
compounds as a result of molecular fingerprint spectra that are derived for each. Spectra 
were obtained utilizing a Perkin Elmer Spectrum 2000 FTIR spectrometer with a MIRTGS 
detector (PerkinElmer Spectrum 100, Llantrisant, Wales, UK). 
 
3.2.7. Differential Scanning Calorimetry 
 
Differential scanning calorimetry (DSC) thermal analysis was carried out on mPEG, HA, 
HAmPEG, ECL and HA-g-ECL samples to characterize their structural states and 
thermophysical properties, utilizing a DSC 1 with updated STARe Thermal Analysis software 
(Mettler Toledo, Switzerland). Accurately weighed samples of dry formulations were put into 
aluminium crucibles, sealed, and heated in the temperature range 25 ºC – 300 ºC at a 
heating rate of 10 ºC/min under constant purging of nitrogen. The reference standard used 
was an empty aluminium crucible. 
 
3.2.8. Thermogravimetric Analysis 
 
Thermal decomposition characteristics of HA-g-ECL copolymer and its constituents were 
carried out on a Themogravimetric Analyzer TGA 4000 (PerkinElmer Life And Analytical 
Sciences Inc., Shelton, CT USA). Weighed out samples within a range of 8-20 mg were 
placed in specialized crucibles. TGA analysis was conducted over a heating range of 30 ºC 
– 900 ºC at a rate of 10 ºC/min under a nitrogen stream. 
 
3.2.9. Approximate Molecular Weight measurement of HA-g-ECL 
 
Viscosity (η) of different concentrations of solutions of HA-g-ECL dissolved in 0.2 M NaCl 
was measured using a modular advanced rheometer (HAAKE MARS Modular Advanced 
Rheometer, Thermo electron Corporation, Karlsruhe, Germany) with a C35/1° Ti sensor. 
This was used to determine molecular weight of the graft copolymer using the Mark-Houwink 
equation (Equation 3.3.) as described by Lapčík, Jr. L and authors (1998): 
 
[η]=K.Mα                                                                                                              Equation 3.3. 
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where [η] is the intrinsic viscosity, K and α are constant parameters specific to a polymer and 
solvent system and M is the molecular weight. K and α constants specific for HA were 
0.0339 mL/g and 0.778, respectively (Caspersen et al., 2014). 
 
3.2.10. Visualization of HA-g-ECL using Scanning Electron Microscopy 
 
The surface morphology of HAmPEG, ECL and HA-g-ECL samples were observed by use of 
scanning electron microscopy (FEI Phenom™, Hillsboro, Oregon, USA). Powders were 
mounted on stubs and gold coated by use of a sputter-coater (SPI Supplies, STRUCTURE 
PROBE INC, West Chester, Pennsylvania, USA). Comparisons in surface structural 
variations were then evaluated at a ≈ 5000X magnification.  
 
3.2.11. Micelle characterization 
 
3.2.11.1. Determination of the Critical Micelle Concentration of HA-g-ECL 
 
A test to quantitatively elucidate the amphiphilic character of HA-g-ECL in its ability to form 
micelles was carried out. The critical micelle concentration (CMC) of HA-g-ECL copolymers 
was measured by a FITC UV measurement method, as described by Lin et al (2013). 
Micelles were prepared at a concentration of 1mg/mL by sonicating it in deionized water for 
3 minutes (Ultrasonic processor VCX 130 Watt (Sonics & Materials Inc., Newtown, CT, 
USA). A volume of 50 μL FITC solution at a concentration of 5 x 10-4 M was added into HA-
g-ECL solutions ranging in concentration from 10 – 1 x 10-7 mg/mL. The relative ratio of 
absorbance between the wavelength of 455 and 475 nm (A455nm/A475nm) was determined 
using a nanophotometer (NanoPhotometerTM, Implen GmbH, Munchen, Germany) by 
obtaining UV absorbance values at each concentration. A graph of absorption ratio 455 
nm/475 nm against HA-g-ECL micellar log concentrations were plotted to determine the 
CMC value. 
 
3.2.11.2. Micelle formation from Amphiphilic HA-g-ECL 
 
An emulsion solvent evaporation method was used to prepare micelles. A copolymer 
concentration of 10 mg/mL was dissolved in dichloromethane. This was added dropwise into 
10 mL deionized water with ultrasonication for 5 minutes [power on/off (10s/2s)], without any 
added surfactants in an attempt to investigate their ability of solely forming copolymeric 
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micelles. DCM was removed under vacuum in an oven (Vacuum Drying Oven “VACUTERM” 
EV-50, Raypa, Barcelona, Spain). 
 
3.2.11.3. Morphology and size determination of HA-g-ECL micelles utilizing 
Transmission Electron Microscopy 
 
The surface characteristics and shape of micelles formed were investigated with 
transmission electron microscopy (TEM) (JEOL 1200 EX, Tokyo, Japan, 120 keV). A drop 
from a micelle aqueous dispersion of 10mg/mL was placed on a copper grid composing 
perforated carbon film for viewing. The sizes of micelles were clearly visualized from the 
scale bar.  
 
3.3. Results and Discussion 
 
3.3.1. Grafting Efficiencies and Graft Ratios of novel copolymer 
 
Figure 3.5 show the physical appearance of synthesized HAmPEG and HA-g-ECL. Table 3.2 
reflects the impact that alternating quantities of the hydrophilic and hydrophobic polymers 
have on the efficiency of grafting and its ratio. The optimal values obtained for GE and GR is 
achieved with a 1:9 ratio of HA to ECL (100 mg/mL HA and 900 mg ECL). It was noted that 
an increase in the HA:ECL ratio causes a decrease in both GE and GR. The larger quantity 
of HA over ECL suggests that steric hindrance is most likely the reason for poor GE and GR. 
Molecules as large as HA wields considerable steric hindrance. Their molecular domains are 
bulky especially in the case of HA holding the ability of hydration and extension (Forrester 
and Lackie, 1981).  Thus it can be deemed that steric hindrance hinders graft 
copolymerization at greater HA:ECL ratios accordingly reflecting the supreme GE and GR of 
117.8 % and 54.1 %, respectively, at the lowest 1:9 ratio of HA:ECL. The 1:9 ratio of 
HA:ECL was therefore used in subsequent experiments and chapters. 
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Figure 3.5: Digital images of physical appearances of lyophilized A) HAmPEG complex and 
B) HA-g-ECL copolymer. 
 
 
 
 
 
A 
B 
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Table 3.2: Grafting parameters of the various copolymeric formulations synthesized. 
Sample Batch HA/ECL1 ratio Yield (%) GE2 (%) GR3 (%) 
1 1:9 4.59 117.80 54.10 
2 3:7 15.29 96.20 49.00 
3 5:5 26.94 85.60 46.12 
4 7:3 39.86 75.61 43.05 
5 9:1 52.78 70.52 41.36 
1HA/ECL- Hyaluronic acid to epsilon Caprolactam 
2GE- Grafting efficiency 
3GR- Graft ratio 
 
3.3.2. Evidence of grafting occurrence through infrared spectra observations 
 
FTIR spectra were observed and analyzed to compare individual constituents to the 
synthesized graft copolymer in an attempt to visualize the occurrence of actual graft 
copolymerization. Figure 3.6 illustrates the comparison of individual polymers participating in 
the graft copolymerization process and the final polymer HA-g-ECL. As evidenced in Figure 
3.6, HAmPEG exhibited its strong broad band at 3399 cm-1 which is characteristic of O-H 
and N-H stretching vibrations. The band at 2880 cm-1 is characteristic of C-H stretching 
vibrations. The 1614 cm-1 and 1412 cm-1 bands can be assigned to the asymmetric (C=O) 
and symmetric (C-O) stretching modes of the HA carboxyl groups. The bands that extend 
from 1500 cm-1 to 1700 cm-1 are characteristic of amide I and II bands (Yue, 2012). An 
intense band ranging from 945 cm-1 to 1203 cm-1 is consistent with COO- stretching in 
alcohols. The ECL spectrum demonstrates its characteristic peaks. The two bands 3199 cm-
1 and 3292 cm-1 represent the N-H stretching vibration and the bands of 2856 cm-1 and 2927 
cm-1 show the C-H stretches from its alkyl part. The strong 1654 cm-1 band can be attributed 
to C=O stretching (Rusu et al., 2009). In HA-g-ECL infrared spectra, bands show a new 
peak at 1735 cm-1 which is indicative of an ester formation unseen in the parent compounds 
and accompanying characteristic C-O stretches at 1240 and 1104 cm-1. 
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Figure 3.6: Comparative FTIR spectra of HAmPEG, ECL and HA-g-ECL. 
 
The analysis of FTIR spectra revealed that the essential chemical structure of native 
compounds is retained in the prepared copolymer. The new peak that arises at 1735 cm-1 in 
HA-g-ECL is the point of conjugation due to a covalent chemical bond formation. As a result 
of the ring-opening of ECL, an acyl group is left exposed (Havlice et al., 1999; Sepe, 2008) 
(Figure 3.7). Esterification of HA occurs at the hydroxyl group via the acyl group giving rise 
to the new ester peak. The peaks at 1204 and 1104 cm-1 are indicative of C-O stretches due 
to the ester formation (Zhang and James, 2004). The increase in intensity of band around 
3405 cm-1 is due to additional N-H stretching on the copolymer as a whole as a result of 
conjugation with the ECL derivative. 
 
3405 
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Figure 3.7: Ring opening polymerization of ECL (Adapted from Sepe, 2008).  
 
3.3.3. Differential Scanning Calorimetry thermal profiles 
 
Figure 3.8 exhibits the DSC curves of native polymers HA sodium salt, mPEG and ECL with 
their derivatives HAmPEG and HA-g-ECL in contrast. In Figure 3.8a HA sodium salt displays 
its characteristic broad endothermic transition at 113.21 °C which correlates with moisture 
loss from the HA molecule (Collins and Birkinshaw, 2008). The endotherm resembles a 
dehydration process as a result of evaporation. Its exothermic degradation peak is also seen 
at 238.18 °C. The ordered mPEG shows its maximum melting peak at 55.72 °C and 
thermostability as far as 300 °C can be seen. Figure 3.8c shows the HAmPEG complex 
attaining a lowered decomposition temperature (218.95°C) compared to HA sodium salt. 
This could be due to the less ordered state of HA in view of mPEG’s attachment to the 
molecule. The peak melting point of ECL can be seen at 75.78 °C from Figure 3.8d as the 
first endothermic transition. The second endothermic transition could be attributed to the 
degradation point of ECL at a temperature of 258.72 °C. Figure 3.8e presents the thermal 
profile of the copolymer. Only one endothermic transition is seen at 52.69 °C followed by 
remarkable thermostability greater than either of its parent polymers alone. The shift to a 
lower temperature in the melting endotherm from 56.30 °C to 52.69 °C indicates that the 
graft copolymerization of ECL monomers onto the backbone of HAmPEG changed the order, 
arrangement and thus the crystal structure of the molecule chain. There was destabilization 
of the molecules structure with the formation of new bonds to give a less ordered structure 
(Gill et al., 2010). An additional observation is the disappearance of the endothermal peak 
corresponding to the degradation of ECL. This indicates grafting onto HA.  
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Figure  3.8: Comparative differential scanning calorimetry thermograms of a) HA sodium 
salt, b) mPEG, c) HAmPEG, d) ECL and e) HA-g-ECL. 
 
 
 
 
 
 
 
 
 
258.72°C 
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3.3.4. Thermogravimetric Analysis thermal profiles 
 
Figure 3.9 depicts the thermograms of degradation obtained together with their first 
derivative curves for HAmPEG (A), ECL (B) and HA-g-ECL (C). The solid curves denote 
thermogravimetric analysis curves and the dash-dot curves denote the derivative 
thermogravimetric analysis curves for each sample. ECL, HA-g-ECL and HAmPEG proceed 
with 1, 2 and 3 degradation steps, respectively. The onset temperature of degradation (Tonset) 
for ECL is shown to occur at 143.56 °C and its complete degradation is attained at 252.77 
°C. These results correlate well with that of the DSC thermal profile of ECL depicted in 
Figure 3.8 d). The peak of greatest rate of weight loss change i.e. the point of inflection 
(Tpeak) at 218.84 °C for HAmPEG correlates well with the DSC thermal profile for HAmPEG 
[Figure 3.8 c)] which has been established as the degradation of HA. The initial 4.52 % 
weight loss observed in HAmPEG can be attributed to the loss of water molecules at this 
stage. It was noted that the Tonset for HA-g-ECL copolymer occurred at 211.63 °C and that for 
the native polymer constituents were 143.56 °C and 191.85 °C for ECL and HAmPEG, 
respectively. This demonstrated the thermal stability of the newly synthesized HA-g-ECL 
over its parent polymers alone. 
 
 
 
 
 
 
A 
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Figure 3.9: Thermogravimetric analytical and derivative thermogravimetry curves of A) 
HAmPEG, B) ECL and C) HA-g-ECL. 
B 
C 
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3.3.5. Approximate Molecular Weight determination of HA-g-ECL 
 
The average molecular weight of the novel copolymer was determined adopting intrinsic 
viscosity testing and measurements made on variable concentrations of HA-g-ECL in 
deionized water (0.01-0.0001 %). Figure 3.10 presents the graphs of viscosity against time 
for each HA-g-ECL concentration. Table 3.3 shows the last 6 runs of viscosity estimations 
for each copolymer solution. 
 
 
Figure 3.10: Graphs of viscosity for copolymer concentrations of a) 0.01 %, b) 0.001 % and 
c) 0.0001 % w/v. 
 
Determining the average intrinsic viscosity value of the last 4 runs at each concentration 
allowed its substitution into the Mark-Houwink formula (Equation 3.3) with the already 
determined K and α parameters which are known constants that are dependant on a 
particular polymer, its solvent used and the temperature at which the measurement is 
performed. Some of the determinants affecting the value obtained for molecular weight 
comprise polydispersity, temperature, chain stiffness, topology and type of solvent 
59 
 
(Bhattarai, 2012). The specified HA K and α constants were 0.0339 mL/g and 0.778 in a 0.2 
M NaCl solvent system at temperature 25 °C. These were inserted into the equation together 
with the obtained average intrinsic viscosity value of 864.55 mPas. The approximate 
molecular weight calculated for the synthesized HA-g-ECL copolymer was 3.398 X 107 Da. 
The molecular weight of the starting Hyaluronic Acid Sodium Salt from Streptococcus Equi 
was a high range of 1.5 – 1.8 X 106 Da. Yet again, this demonstrates that the anionic graft 
copolymerization procedure for covalently attaching ECL to the backbone of HA was 
successful causing an increase in the molecular weight of the compound as a result of its 
linkage. ECL bestowed a lipophilic attribute onto the water soluble polymer conferring an 
amphiphilic derivative that could have potential in a variety of biomedical applications 
 
Table 3.3: Depiction of last 5 runs of HA-g-ECL concentrations to determine viscosity 
average value. 
Run t [s] t seq [s] η [mPas] T [°C] 
0.01%
w
/v     
95 344.0 341.8 826.7 24.01 
96 347.7 345.5 803.5 23.98 
97 351.3 349.1 779.8 23.98 
98 354.9 352.7 759.7 23.99 
99 358.6 356.4 766.7 23.99 
100 362.2 360.0 767.1 23.99 
     
0.001%
w
/v     
95 344.8 341.8 871.2 24.01 
96 348.4 345.5 900.9 24.01 
97 352.0 349.1 875.7 24.00 
98 355.7 352.7 853.4 24.01 
99 359.3 356.4 846.9 23.97 
100 363.0 360.0 843.4 23.99 
     
0.0001%
w
/v     
95 344.8 341.8 900.0 23.99 
96 348.5 345.5 886.5 23.99 
97 352.1 349.1 883.4 24.02 
98 355.7 352.7 862.4 24.01 
99 359.4 356.4 853.0 24.01 
100 363.0 360.0 898.4 23.99 
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3.3.6. Visualization of HA-g-ECL via Scanning Electron Microscopy 
 
Figure 3.11 are scanning electron micrographs that display the external surface and 
morphologies of freeze-dried novel synthesized copolymer against its source homopolymers 
at a 5000 – 5250 X magnification. Forms of HA with its attached sodium salt as well as the 
free acid with attached mPEG are visulaized (Figure 3.11b & c). The porous nature of the 
hydrophilic polymer is evident in the micrographs and this is undeniably expected being the 
most hygroscopic molecule naturally present and having a significant characteristic of water 
retention (Wang et al., 2013a). Figure 3.11a shows the micrograph of ECL with its crystal-
like appearance and having a smooth surface. HA-g-ECL in Figure 3.11d demonstrates 
areas of smoothness as well as a somewhat rough surface. This could be understood as a 
consequence of bringing together two polymers that are not physically similar in their 
outward features. The portions of irregular surface on the copolymer is plausible by way of 
the vast porosity of HA. Embedded particles are visible on the surface of HA-g-ECL 
copolymer in Figure 3.11d. 
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Figure 3.11: Scanning electron micrographs of a) ECL at 5000X magnification, b) HA 
sodium salt at 5250X magnification, c) HAmPEG at 5150X magnification and d) HA-g-ECL at 
5050X magnification. 
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3.3.7. HA-g-ECL micellization ability 
 
It is conventional for amphiphilic copolymers possessing a satisfactory 
hydrophilic/hydrophobic balance to produce micellar networks when added to distinct 
solvents (Wu et al., 2005). Thus, the CMC of HA-g-ECL was determined by the use of FITC 
as a fluorescent probe. UV absorbance measurements as a ratio were made and tested on a 
10 – 1 x 10-7 mg/mL HA-g-ECL concentration range. A plot of the absorbance ratio 
455nm/475nm against the log concentrations of HA-g-ECL was made to determine the point 
at which the copolymer formed micelles (Figure 3.12). The point of intersection of the two 
tangent lines drawn is the point at which to calculate the CMC value on the graph (Lin et al., 
2013). At the lower concentrations of HA-g-ECL, there is only a small difference in the 
absorbance ratio. A sudden increase in the absorption ratio is noted as the copolymer 
concentration heightened. This signifies the partitioning of the fluorophore into the 
hydrophobic core of the micelles (Shen et al., 2009). The point at which this occurs, 0.0063 
mg/mL, is depicted on the graph, this being the CMC. Length ratio of polymers, total 
molecular weight and the chain architecture of the copolymer are factors that affect 
micellization. Depending on an aqueous or non-aqueous solvent, CMC decreases with 
increasing length ratio which favors the insoluble polymer and CMC increases with 
increasing length of the soluble polymer (Alexandridis and Lindman, 2000). 
 
 
 
Figure 3.12: The determination of the CMC value for HA-g-ECL micelles. 
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To investigate the capability of HA-g-ECL to efficiently form copolymeric micelles in aqueous 
solution without the aid of a surfactant, a solvent evaporation method was utilized. 
Investigations into their morphology and size was carried out with TEM. Figure  3.13 reveals 
the images obtained at a magnification of 50000X of HA-g-ECL micelles formed. It can be 
seen that the morphology of formed micelles were that of an intact structure and well-defined 
shape. Micelles were spherically discernible and it is known that due to the amphiphilicity of 
HA-g-ECL copolymer forming micelles in an aqueous solution; the hydrophobic ECL portions 
form the core of the micelle and the hydrophilic HA chains establishes the micelle corona. 
 
 
 
Figure 3.13: Transmission electron micrographs of formed HA-g-ECL micelles. 
 
The size of HA-g-ECL micelles can easily be clarified from the TEM images. Sizes of about 
25-30 nm could be calculated from the scale bar of images (Figure 3.13). 
 
3.4. Concluding Remarks 
 
Chapter 2 described several drug delivery polymer-based strategies formulated to make an 
impact on HBV. In this chapter, a novel copolymer was described and synthesized for its use 
as the foundation to a drug targeting HBV system in following chapters. This chapter put 
forth an anionic ring opening graft copolymerization mechanism that successfully allowed the 
grafting of ECL monomeric branches onto HA chains forming a novel amphiphilic HA-g-ECL 
copolymer that acquired the ability to form copolymeric micelles. An optimal ratio of 
hydrophile to hydophobe was selected for efficient grafting followed by a full characterization 
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of the novel graft copolymer. Micelles prepared were of a consistent size range and shape 
which can be exploited as potential candidates for important applications in nanoscale drug 
delivery. The core of the micelle is lipophilic and can be loaded with hydrophobic drugs 
acting as an assuring carrier to impart sustained drug release. However, the aim of this 
study is to encapsulate a model drug that is hydrophilic into this novel copolymeric system 
utilizing a method that is construed in the ensuing chapter. Because of this counter 
orientation of hydrophilic and hydrophobic polymers, the ACNS particles are in actual fact 
‘reverse micelles’ (Trivedi and Kompella, 2010). 
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CHAPTER 4 
TREND REFLECTION IN THE DESIGN AND IN VITRO CHARACTERIZATION OF HA-G-
ECL FORMING LAMIVUDINE-LOADED NANOPARTICLES 
4.1. Introduction 
 
The 21st century has welcomed nanotechnology as a looming and empowering technology 
due to the merging of science in various fields occurring at the nanoscale. The production of 
nanoparticles is a significant part of nanotechnology as definitive characteristics are 
recognized with nanoscale particles, crystals and layers. These nanoelements capitalize on 
the following outcomes: 
 Advanced biological, chemical and physical features as a consequence of size scaling, 
 The development of new phenomena as a result of the reduced size, 
 Utilizing various routes engendering different atomic and molecular material networks, 
 A pronounced hike in particle system processing speeds and magnitude of complexity 
(Roco, 1999). 
The attractiveness of biodegradable polymeric nanoparticles is derived by the polymers 
ability of acting as drug delivery agents achieving controlled release of drugs, target organ 
specificity, serving as gene therapy carriers as well as delivering therapeutics via a peroral 
administration route (Soppimath et al., 2001). 
 
HA has been employed as a coat or usually via conjugation with another chemical entity to 
be utilized in target specific intracellular delivery of anticancer therapeutics or genes. This 
polymer is known to be receptor-mediated endocytosed by way of CD44 and RHAMM 
receptors found on cells (Jin et al., 2010). The preference for HA in nanoparticle anticancer 
drug delivery is derived from the fact that it is biodegraded by hyaluronidase which is found 
to be abundant in malignancies and cancers. Many researchers exploit this reality to attain 
rapid drug release at the tumour site (Yeo, 2013). The diversity in chemical modification 
approaches with HA, via cross-linking or conjugation, gives way for many choices in 
synthesizing new HA derivatives possessing diversified characteristics (Schantè et al., 
2011). Copolymers synthesized from grafting HA with PEG have been investigated for their 
various characteristics that were additionally developed (Moriyama et al., 1999). PLGA 
chains were grafted onto the backbone of HA forming targeting micelles carrying doxorubicin 
(Lee et al., 2009b). Copolymerizing polylactic acid onto HA backbone produced a 
hydrophobic compound that had the ability to assemble in aqueous media (Palumbo et al., 
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2006). HA and poly(ε-caprolactone) (PCL) were graft copolymerized to produce micelles in 
aqueous media that entrapped fibroblast growth factor 1 (Lin et al., 2013). Another study 
reported preparation of a hydrogel by grafting of poloxamer and HA. The hydrogel 
successfully entrapped ciprofloxacin which could be released in a sustained manner (Cho et 
al., 2003). Oxaliplatin was also attached to a chemically modified HA-chitosan entity and this 
entire compound was contained in Eudragit S100 coated pellets for efficient targeting 
specifically to colon tumours (Jain et al., 2010). HA was used to coat paclitaxel containing 
poly(butyl cyanoacrylate) nanoparticles by a radical polymerization method (He et al., 2009). 
Wu and coworkers (2012) reported on conjugates of histidine and HA forming nanoparticles 
contaning doxorubicin.  
 
The cytosine analogue LMV has proved to be quite effective in treating human HBV by 
inhibiting HBV reverse transcriptase terminating DNA synthesis (Cuestas et al., 2010). Due 
to its unfavorable and serious side effects such as that of lactic acidosis, and the 
inconvenience of daily dosing, the drug should ideally be released in a controlled manner 
from a biodegradable and biocompatible system avoiding undesired effects. In one study, 
LMV was loaded into PLGA nanoparticles that were coated with bovine serum albumin for 
intracellular HBV delivery in one study (Wang et al., 2012). The PLGA particles were 
successfully internalized and showed sustained release of the drug. In another study, 
polymethacrylic acid nanoparticles encapsulated LMV and the release mechanism was that 
of zero order and was sustained over a duration of 24 hours (Tamizhrasi et al., 2009). LMV 
was also encapsulated in nanoparticles synthesized from glycyrrhizin linked to chitosan for 
liver specificity. An initial burst release of the drug was noted followed by a sustained release 
(Mishra et al., 2014). 
 
Design of experiments (DOE) is an approach that is selected to achieve the most data and 
information from an experimental model by fabricating additional experiments that will 
produce maximum informational results statistically. This can then be utilized in limit 
evaluations and validating the experimental model. Prior to data retrieval, the experiment is 
designed by addressing factors such as conditions under which experiments are performed, 
the choice of input variables and their modifications and determinants addressed by 
experimenter upon which they will observe phenomena being examined (Franceschini and 
Macchietto, 2008). The three-factor three-level Box Behnken design (Figure 4.1.) was 
chosen for this study to optimize the conditions for formulating the nanostructured system. 
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Figure 4.1: Graphic representation of a three-factor Box-Behnken design (Adapted from 
Lawson, 2010). 
 
The advantages of Box-Behnken designs over Central Composite designs are that a varying 
of factors over three levels is merely necessary possibly leading to less cost on 
experimenting and they usually need less total runs except for cases in five-factors (Lawson, 
2010). A study aimed to optimize PLGA nanoparticles loaded with lorazepam by assessing 
the effects of processing variables of polymer, surfactant, drug and aqueous/organic ratio on 
the desired responses of Z-average and drug entrapment efficiency utilizing the Box-
Behnken design. All data collected led to the successful estimation of optimized 
nanoparticles safety in Sprague-Dawley rats in the establishment of a nose-to-brain pathway 
(Sharma et al., 2014). One other study using the Box-Behnken design unfolded and 
optimized a method for obtaining PCL nanoparticles laden with Uncaria tomentosa extract.  
PCL concentration, polyvinyl alcohol concentration and aqueous/organic volume ratio were 
the processing variables studied with drug entrapment efficiency, particle mean diameter, 
polydispersity, and zeta potential as the desired responses. Conclusive results suggested a 
successful Box-Behnken design approach by the development of an optimized nanoparticle 
formulation with desired features (Ribeiro et al., 2013). 
 
In the following study, formulation variables- copolymer, surfactant and solvent quantities, 
were selected to be optimized to elicit the desired responses- maximum drug entrapment 
efficiency, minimized particle size and minimized mean dissolution time. Trends in the 
consequences of variable quantity combinations are examined and discussed in this chapter 
to begin developing a physicochemical understanding of the novel synthesized copolymer in 
terms of the chosen parameters. 
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4.2. Materials and Methods 
4.2.1. Materials 
Hyaluronic acid sodium salt from Streptococcus equi, epsilon-Caprolactam (>=99 %), 
Poly(ethylene glycol) methyl ether (mPEG) (average Mw~2000 Da), Dialysis tubing cellulose 
membrane (Mw 12044 Da), N-acetylcaprolactam (99 %), Sodium hydride (NaH) (powder 
moistened with oil, 55-65 % gas volumetric) and Pluronic F-127 were all purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Lamivudine (LMV) was received as an ex-gratia sample 
from Adcock Ingram Ltd. (Germiston, Gauteng, South Africa). Dimethyl sulphoxide (DMSO) 
and Dichloromethane (DCM) were purchased from Merck Chemicals (Pty) Ltd. (Germiston, 
Gauteng, South Africa). All other chemicals and reagents were of analytical grade. 
 
4.2.2. Synthesis of the amphiphilic graft copolymer 
 
The copolymerization process was carried out as outlined in Chapter 3, Sections 3.2.2. 
Desalting process of hyaluronic acid, 3.2.3. PEG-assisted solubilization of HA in DMSO and 
3.2.4. Anionic graft (co)polymerization of HA and ECL (HA-g-ECL). 
 
4.2.3. Construction of a Box-Behnken design for the preparation/formulation of 
copolymeric nanoparticles 
 
A 3-factor, 3-centre points Box-Behnken quadratic design was ascribed for statistical 
analysis carried out by use of a Minitab Statistical Software, Version 14 (Minitab Inc., State 
College, PA, USA) to optimize the formulation limitations and gauge their effects according 
to % DEE, size and mean dissolution time (MDT) from drug release curves. Experimental 
runs (15) are engineered and the nonlinear computer-generated quadratic model is 
expressed as Equation 4.1. 
 
Y= b0 + b1X1 +b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + b11X1
2 
+ b22X2
2 
+ b33X3
2        Equation 4.1. 
 
where, Y is the measured response associated with each factor level combination; b0 is an 
intercept; b1 to b33 are regression coefficients computed from the observed experimental 
values of Y; and X1, X2  and X3  are the coded levels of independent variables. The terms 
X1X2  and Xi
2 (i= 1, 2 or 3) represent the interaction and quadratic terms, respectively 
(Chopra et al., 2007; Motwani et al., 2008). The independent factors and dependent 
variables along with their limits are depicted in Table 4.1. These values were ordained 
proceeding from preformulation experimentation. The quantities of each chemical ingredient 
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employed in all 15 formulations received from the Box-Behnken quadratic design are listed 
in Table 4.2. 
 
Table 4.1: Variables for the Box-Behnken factorial design parameters. 
Independent Variables Limits   
 Lower Upper 
Amount of HA-g-ECL1 copolymer (mg) 150 350 
Amount of Pluronic F-127 surfactant (g) 1 2 
Volume of DCM2 solvent (mL) 
 
5 20 
Variable Response   
Particle size (nm) Minimize  
DEE3 (%) Maximize  
MDT4 (hrs) Minimize  
1HA-g-ECL- Hyaluronic acid-graft-epsilon Caprolactam 
2DCM- Dichloromethane 
3DEE- Drug Entrapment Efficiency 
4MDT- Mean Dissolution Time 
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Table 4.2: Formulation (F) compositions obtained from the Box-Behnken experimental 
design. 
Formulation Run Copolymer 
(HA-g-ECL) 
(mg) 
Surfactant 
(Pluronic F-127) 
(g) 
Solvent 
(DCM) 
(mL) 
F1 300 1 12.5 
F2 300 1.5 20 
F3 225 2 20 
F4 225 1.5 12.5 
F5 150 2 12.5 
F6 300 2 12.5 
F7 150 1.5 5 
F8 225 1.5 12.5 
F9 225 1 20 
F10 150 1.5 20 
F11 150 1 12.5 
F12 225 1.5 12.5 
F13 300 1.5 5 
F14 225 1 5 
F15 225 2 5 
 
4.2.4. Preparation of LMV-loaded HA-g-ECL copolymeric nanoparticles 
 
The copolymeric nanoparticles were prepared by a double emulsion (w/o/w) solvent-
evaporation method. Drug (60 mg/mL) was dissolved in deionized water. Varying amounts of 
copolymer (150 mg, 225 mg & 300 mg) were dissolved in varying amounts of DCM (5 mL, 
12.5 ml & 20 mL). The primary emulsion was prepared by adding the aqueous drug solution 
to the organic copolymeric solution with sonication [pulse on(10 s)/off(2 s)] for 20 minutes 
using an ultrasonic processor VCX 130 Watt (Sonics & Materials Inc., Newtown, CT, USA). 
Variable amounts of Pluronic F-127 surfactant (1 g, 1.5 g & 2 g) were dissolved in 100 mL of 
distilled water and the external aqueous phase solution was placed under a propeller stirrer 
and the primary emulsion added into this with a needle and syringe in a dropwise manner to 
form nanoparticles. The resultant secondary emulsion was put in a vacuum oven to remove 
the organic solvent (Trade Raypa® Digital drying oven, Barcelona, Spain maintained at 40 
˚C, -0.6 bar). 
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4.2.5. Transmission Electron Microscopy of the formed HA-g-ECL copolymeric 
nanoparticles 
 
The surface morphological and structural transitions of HA-g-ECL nanoparticles were 
determined by TEM (JEOL 1200EX, Tokyo, Japan) at a 50000X magnification. A 
concentrated drop of the nanoparticle suspension was placed on the TEM copper grid ahead 
of ultrasonication of the suspension. Staining of the grid was not a necessary requirement as 
the nanoparticles were clearly visible to the eye under microscope view. The copper grid 
was dried at room temperature for approximately 2 hours before analysis with the 
microscope. 
 
4.2.6. Size and Zeta Potential determination via Dynamic Light Scattering (DLS) 
The size and zeta potential of prepared nanoparticles was estimated by a Zetasizer NanoZS 
(Malvern Instruments Ltd., Malvern, Worcestershire, UK). The nanoparticle formulation 
suspension (1 mL) was diluted to 10 mL with deionized water and filtered through a 0.22 μm 
filter (Millipore Co., Massachusetts, USA). The filtrate in the sterilized cuvette (Malvern 
Instruments Ltd., Malvern, Worcestershire, UK) was made to reach the mark of maximum 
limit for dynamic light scattering testing. A particle’s Brownian motion in a suspended liquid 
form impels laser light to be scattered at varying intensities. Essentially, Brownian motion 
velocity and thus the particle sizes can be measured when these intensity variations are 
analyzed. Tests were performed in triplicate. 
 
4.2.7. Thermal analysis of HA-g-ECL copolymeric nanoparticles 
 
4.2.7.1. Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) thermal analysis was carried out on design 
nanoparticle samples utilizing a DSC 1 with updated STARe Thermal Analysis software 
(Mettler Toledo, Switzerland). Accurately weighed 2 mg samples (Murnane et al., 2008) of 
dry formulations were put into aluminium crucibles, sealed, and heated in the temperature 
range 25 ºC – 200 ºC at a heating rate of 10 ºC/min under constant purging of nitrogen. The 
reference standard used was an empty aluminium crucible. 
 
4.2.7.2. Thermogravimetric Analysis 
Thermal decomposition characteristics of design nanoparticle samples were carried out on a 
Themogravimetric Analyzer TGA 4000 (PerkinElmer Life And Analytical Sciences Inc., 
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Shelton, CT USA). TGA analysis was conducted over a heating range of 30 ºC – 900 ºC at a 
rate of 10 ºC/min under a nitrogen stream. 
 
4.2.8. Construction of a calibration curve to quantify LMV by its ultraviolet 
spectrophotometric absorptivity 
 
A calibration curve was constructed by preparing a stock solution of LMV in phosphate 
buffered saline (PBS) (0.1 M, pH 7.4) at a concentration of 0.3 mg/mL. Dilutions from stock 
were prepared at a range of concentrations (0.003-0.015 mg/mL). UV absorbance values at 
the various concentrations were recorded on a nanophotometer (NanoPhotometer™ 
IMPLEN, Munich, Germany) at a wavelength of 277 nm. A linear curve was plotted and its 
R2 value calculated with the assays being evaluated in triplicate for reproducibility. 
 
4.2.9. Drug encapsulation efficiency of HA-g-ECL copolymeric nanoparticles 
 
Lyophilized LMV-loaded HA-g-ECL nanoparticles were left to stir vigorously for 96 hours in 
PBS (0.1 M, pH 7.4) to attain complete drug leaching from the nanoparticles. The 
formulation was centrifuged at 20000 rpm for 10 minutes to separate free drug from the HA-
g-ECL copolymer. A volume of 4 μL supernatant was used to determine the amount of free 
drug therein employing ultraviolet spectroscopy (NanoPhotometer™ IMPLEN, Munich, 
Germany) at λmax 277 nm. The amount of drug in the nanoparticles was determined by 
Equation 4.2. 
 
Drug Encapsulation Efficiency (%) = 
Actual drug amount in nanoparticles
Theoretical drug amount of nanoparticles
 × 100       Equation 4.2. 
 
4.2.10. In vitro dissolution studies of LMV-loaded HA-g-ECL copolymeric 
nanoparticles 
In vitro LMV release studies were carried out by placing HA-g-ECL nanoparticles in dialysis 
tubing (Mw 12044 Da) with 2 mL of normal saline. The membrane bag was inserted into a jar 
with a tightly sealed lid containing 50 mL PBS buffer (0.1 M, pH 7.4). The complete system 
was placed in an orbital shaker bath (Labex, Stuart SBS40®, Gauteng, South Africa) kept 
constant at 37 ºC and shaking at 25 rpm. At predetermined time intervals, 100 μL of the 
release medium was sampled and replaced by 100 μL of PBS buffer. The amount of LMV 
released was detected and calculated using UV spectroscopy at λmax 277 nm and 
enumerated from a construction of a standard curve of linearity, respectively. Values of the 
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mean dissolution time (MDT) were estimated for each formulation with exertion of Equation 
4.3. where Mt  is the fraction of dose released in time 𝑡𝑖 = (𝑡𝑖 + 𝑡𝑖 − 1)/2 and M∞ corresponds 
to the loading dose (Mufamadi et al., 2013). Each test was carried out in triplicate.  
 
MDT = ∑ ti(
Mt
M∞
)𝑛𝑖=1                                                                                                 Equation 4.3. 
 
4.3. Results and Discussion 
4.3.1. Morphological characterization of HA-g-ECL copolymeric nanoparticles 
 
Transmission electron microscopy (TEM) was used to study the size and structure of the 
prepared copolymeric nanoparticles. TEM imaging reflected HA-g-ECL drug loaded 
nanoparticles in the nanometer range of consistent near-spherical morphology following 
preparation procedures. The surfactant served to reduce the surface tension contributing to 
the particles spherical shape and low aggregation tendencies. Figure 4.2 shows 
nanoparticles prepared with 1 g of Pluronic F-127, 225 mg HA-g-ECL and 5 mL DCM (F14); 
1.5 g of Pluronic F-127, 150 mg HA-g-ECL and 20 mL DCM (F10) and 1 g of Pluronic F-127, 
300 mg HA-g-ECL and 12.5 mL DCM (F1). Most nanoparticles were of an unvarying 
spherical shape with minimal aggregation. The slight aggregation of copolymeric 
nanoparticles seen in Figure 4.2b for F10 is due to the formation of smaller sized particles 
(discussed in Chapter 4, Section 4.3. Results and Discussion, Subsection 4.3.2. Size and 
Zeta Potential determination of HA-g-ECL nanoparticles by DLS). The smaller the size of 
particles, the more susceptible they are to agglomeration (Elzey and Grassian, 2010). The 
formation of spheres, in terms of structural integrity of particles, can be attributed to the 
curing conditions in formulating (Ruiz-Pèrez et al., 2010). From the TEM image it will be 
seen that the average diameter of nanoparticles corresponds to the measurements made by 
DLS later (Figure 4.3A and 4.3C). 
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Figure 4.2: Transmission electron micrograph of HA-g-ECL LMV-loaded nanoparticles at 
50000X magnification. a) F14, b) F10, c) F1. 
 
4.3.2. Size and Zeta Potential determination of HA-g-ECL copolymeric nanoparticles 
by Dynamic Light Scattering 
 
Particle size is significant as its measurement begets a direct pertinence to formulation 
aspects such as durability, drug entrapment, release, intracellular delivery and biodistribution 
(Sahana et al., 2008). The trends in terms of size comparisons of nanoparticles show that 
higher amount of copolymer used in formulation results in larger particle sizes (Figure 4.3). 
An increase in mean particle diameter can be seen from F11 to F1, F5 to F6 and F7 to F13 
when the HA-g-ECL copolymer amount is increased from 150 mg to 300 mg whilst the other 
variables are kept constant. F10 comprised of copolymeric nanoparticles of the smallest size 
of 32.03 nm with 150 mg copolymer used in its formulation. It may be presupposed that the 
higher amount of HA-g-ECL conduced an elevation in the frequency of the collisions 
between the molecules which led to the union of particles in the formulation process thus 
raising their mean diameter. An increase in sizes was also brought about by the raise in 
viscosity of the organic phase which affected the interplay between the internal and external 
phases of the formulation. Elevating copolymer amounts or concentration increases the 
viscosity of the two phases causing an increase in the particle size diameter on account of 
 Aggregation of 
nanoparticles 
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the unequal distribution of shear energy (Chakravarthi, 2008). The size of nanoparticles 
depends on the stability of the emulsion when it is dropped into the dispersion medium with 
the occurrence of collision and coalescence developing and following. 
 
Smaller amounts of Pluronic F-127 produced nanoparticles of larger sizes. Results reflected 
a modest decrease in nanoparticle size when the surfactant amount increased. Comparisons 
between F1 and F6, F9 and F3 and F14 and F15 demonstrate this. The Pluronic F-127 is an 
amphiphilic non-ionic surfactant with ethylene oxide as the hydrophilic block and a central 
propylene oxide as the hydrophobic block (Yapar and İnal, 2012). The surfactants 
amphiphilic character allows it to adsorb onto the hydrophobic portion of the copolymer 
(ECL) while its hydrophilic property dispenses steric stabilization as a result of it possibly 
being solvated by the water (Sarkari et al., 2002). 
 
The change in the volume of the solvent, DCM, used in design formulations had an inverse 
effect on the prepared HA-g-ECL nanoparticles, with lower volume giving larger size 
particles and vice versa. There showed considerable size increases of 37.92 nm, 55.56 nm, 
56.46 nm and 67.37 nm between F13 & F2, F15 & F3, F7 & F10 and F14 & F9, respectively, 
when HA-g-ECL and Pluronic F-127 amounts were held constant. The formulation 
containing a small amount of DCM, being the dispersed phase, has a high viscosity and is 
added dropwise into the continuous phase. A higher energy magnitude is presumably 
necessary to partition the droplets in the emulsion into smaller ones. Thus due to the higher 
internal phase viscosity, mean nanosizes were increased. Formation of the smaller 
nanosizes with a higher DCM volume occurs because droplet coalescence is not permitted 
due to the spacious solvent volume readily available for diffusion into the external aqueous 
phase. 
 
In summary, the size of the nanoparticles were directly proportional to HA-g-ECL copolymer 
and inversely proportional to both surfactant and solvent. Distribution profiles of Formulation 
6 from the experimental design is shown in Figure 4.4. Zeta potential measurements of all 
formulations in the design displayed a negative surface charge in the range of -11.7 to -24.8 
mv. 
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Figure 4.3: Comparison of the effect of variables on nanoparticle sizes. A) Copolymer 
amount, B) Surfactant amount, C) Solvent volume. 
 
 
 
Figure 4.4: Zeta size and potential distribution profiles of Formulation 6 from the Box-
Behnken design showing a) size of 74.60±6.76 nm and b) zeta potential of -16.8±6.55 mv. 
a) 
b) 
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4.3.3. Thermal characterization of HA-g-ECL copolymeric nanoparticles 
 
4.3.3.1. Differential Scanning Calorimetry 
 
DSC thermograms revealed slight yet fairly noticeable differences comparing maximum and 
minimum limits of process variables for particle design formulations. HA-g-ECL copolymer 
amount of 150 mg and 300 mg has been compared in F5 and F6 respectively (Figure 4.5A); 
surfactant amount of 1 g and 2 g has been compared in F1 and F6 respectively (Figure 
4.5B) and solvent volume of 5 mL and 20 mL has been compared in F13 and F2 respectively 
(Figure 4.5C). These were evaluated in terms of phase transitions on each thermal curve as 
shown in Figure 4.5. Melting point peaks were noted to be similar at ~54.50 °C for all 
formulations. Differences were seen with the glass transition thermal event. Glass transition 
temperature (Tg) is strongly dependent on water moisture content. With increasing water 
content, the Tg decreases to a certain extent (Lapčík Jr. et al., 2010). Therefore an increased 
copolymer amount would equal an added amount of water molecules and thus increased 
moisture content in the HA structure causing the Tg to decrease from around 41.48 ºC (F5) 
to 31.57 ºC (F6) (Figure 4.5A & Table 4.3). It is also known that Tg is reduced when 
dispersants such as plasticizers or surfactants are added as a result of improved flow of 
particles (Jadhav et al., 2009). This can be seen with F6 containing the higher surfactant 
amount of 2 g showing a Tg of 31.57 ºC as opposed to 39.21 ºC with the lower 1 g surfactant 
in F1 (Figure 4.5B & Table 4.3). Formulations comparing the effects of solvent volume reveal 
Tg values larger for F2 than for F13 as depicted in Figure 4.5C and Table 4.3. In essence, a 
greater solvent volume would cause greater particle dispersion in the aqueous phase as it is 
being dropped through the needle and syringe and thus leading to a higher diffusion rate. A 
smaller solvent volume in the internal phase would yield a higher copolymer concentration 
and thus increased viscosity resulting in greater tendency of the copolymeric particles to 
coalesce and agglomerate. The latter would eventually result in larger particles. 
Consequently, the rationale links to that for greater copolymer amounts compared to smaller 
amounts as discussed above. Larger particles would indicate greater copolymer content and 
thus a smaller Tg for F13 with the larger solvent volume compared to F2 (Table 4.3). 
 
 
 
 
79 
 
 
 
Figure 4.5: Comparison of the effect of variables on DSC. A) Copolymer amount, B) 
Surfactant amount, C) Solvent volume. 
 
4.3.3.2. Thermogravimetric Analysis 
 
Thermal decomposition curves are depicted in Figure 4.6. In all of the TGA curves it can be 
noted that an initial increase in weight occurs before melting and decomposition processes 
commence. The initial weight increase that occurs could possibly be a result of carbon 
impurities in the formulations undergoing chemical reactions causing the formation of non-
volatile or volatile products (Gabbott, 2008). Thermal stability of formulation variables are 
revealed- an increase in the amount of copolymer does not significantly improve its thermal 
stability. A slight change of about 2.7 ºC is observed for one fold increase in copolymer 
content (Figure 4.6A). However the onset of melting occurs first with F6.  A lower surfactant 
amount also increases thermal stability by just approximately 2 ºC (Figure 4.6B). Although 
there is no considerable difference noted in each design formulation due to variable 
parameters, all formulations did display a 3-step degradation procession. Table 4.3. 
summarizes the temperature ranges of each degradation step for design formulations 
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representing upper and lower limits of the design variables. The first gradual step of each 
degradation (the initial mass change) can be attributed to the evaporation of water i.e. the 
moisture loss on melting because HA has a high water-sorption and water retention 
magnitude and low molecular weight products. The main thermal event with maximum loss 
of sample weight occurs at the second stage. This is the apt chemical breakdown of the 
copolymer. The final degradation moment corresponded to the decomposing of sample 
material. However, a greater residual mass is seen with F1 and F6. The melting that begins 
with F6 compared to F5 can be attributed to the increased amount of moisture due to the 
higher copolymeric content of F6 and thus more H2O molecules. This allows for evaporation 
first. Carbon black pigment is unable to decompose in nitrogen and is left behind. This is the 
residual mass. F6 has a higher copolymeric content compared to F5 resulting in greater 
carbon pigment and thus greater residual mass. F1 produces larger sized particles 
compared to F6 therefore it would also generate more residual mass. A slight poor thermal 
stability is seen with a formulation utilizing a greater solvent volume with polymer 
degradation occurring approximately 2 ºC earlier compared with a smaller volume of solvent 
(Figure 4.6C). The reason lies in the already established explanation of the inverse 
relationship between particle size and solvent volume. Due to the expansive surface area of 
smaller compared to larger sized particles, consequently, thermal degradation would occur 
at a faster rate. The residual mass of either formulation were almost the same. 
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Figure 4.6: Comparison of the effect of variables on thermal degradation. A) Copolymer 
amount, B) Surfactant amount, C) Solvent volume. 
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Table 4.3: Comparative thermal events: Three step thermal degradation and glass transition 
temperatures of copolymeric nanoparticles. 
  Degradation 
temperature 
range (°C) 
 1Tg (°C) 
 
 1st 2nd 3rd  
F1 30-220 270-480 490-600 39.21 
F2 30-360 380-495 495-605 34.10 
F3 30-350 360-490 495-600 35.15 
F4 30-340 360-480 490-600 38.38 
F5 30-340 370-460 490-550 41.48 
F6 30-355 370-480 490-610 31.57 
F7 30-330 340-460 480-600 42.07 
F8 30-340 360-480 490-600 38.57 
F9 30-340 350-480 490-600 36.92 
F10 30-350 370-460 490-600 37.22 
F11 30-340 370-480 495-605 37.98 
F12 30-340 360-480 490-600 38.21 
F13 30-385 390-490 495-600 32.56 
F14 30-340 350-480 490-610 34.03 
F15 30-340 350-480 495-600 33.73 
1Tg - Glass transition temperature 
 
4.3.4. A calibration curve for LMV for evaluation of its entrapment and release 
 
A calibration curve was plotted as depicted in Figure 4.7. This was used to ascertain the 
amount of LMV entrapped in HA-g-ECL nanoparticles. Concentrations of drug solution in 
PBS (0.1 M, pH 7.4) ranged from 0.003 – 0.015 μg/mL and was measured at a wavelength 
of 277 nm.  
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Figure 4.7: Calibration curve of LMV in PBS (0.1 M, pH 7.4) at 277 nm. 
 
4.3.5. Drug Entrapment Efficiencies of HA-g-ECL copolymeric nanoparticles 
 
Before trend analysis, it is evident that drug entrapment efficiency results reveal that LMV 
was successfully incorporated in the HA-g-ECL nanoparticles. The efficiency of entrapment 
of LMV varied from 18.52±1.23 % to 47.77±0.10 % reflected in Table 4.4. F2, 6 & 13 
comprising of 300 mg of copolymer depicted highest percentage of drug entrapment 
(44.93±1.07 %, 46.96±0.94 % and 47.77±0.10 %, respectively). It is evident that entrapment 
efficiency somewhat decreases when the amount of surfactant Pluronic F-127 is increased 
from 1 g to 2 g (Refer to Figure 4.10 DEE response surface plots) while other variables are 
fixed. When the volume of DCM increases from 5 mL to 20 mL (with additional variables 
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sustained) drug entrapment efficiency is virtually the same with only a very weak decrease in 
its percentage (Figure 4.10).  
 
Table 4.4: Drug entrapment efficiency and particle sizes of formulations. 
Formulation Code Entrapment efficiency 
(%) ± SD 
Particle size (nm) PDI 
F1 27.17 ± 0.55 82.13 0.260 
F2 44.93 ± 1.07 56.03 0.330 
F3 
F4 
F5 
F6 
F7 
F8 
F9 
F10 
F11 
F12 
F13 
F14 
F15 
23.52 ± 0.72 
38.19 ± 0.34 
18.52 ± 1.23 
46.96 ± 0.94 
27.25 ± 0.67 
37.58 ± 0.88 
35.10 ± 0.14 
26.47 ± 0.11 
20.26 ± 0.59 
38.15 ± 0.32 
47.77 ± 0.10 
31.57 ± 0.42 
30.35 ± 0.91 
42.28 
68.46 
61.07 
74.60 
88.49 
67.43 
65.58 
32.03 
60.59 
64.44 
93.95 
132.95 
97.85 
0.381 
0.278 
0.463 
0.364 
0.261 
0.296 
0.436 
0.234 
0.431 
0.300 
0.234 
0.359 
0.356 
 
Drug entrapment efficiency results showed that elevated copolymer amounts in the emulsion 
formulation led to a heightening of the effectiveness in LMV encapsulation. It is plausible that 
the steepened viscosity level of the dispersed organic phase led to LMV being contained 
from leaching to the external water phase and this led to the improvement of drug 
entrapment efficiency (Jadhav et al., 2009). The chemical interaction between LMV and the 
copolymer may also have contributed to the raised entrapment efficiency percentage. If a 
drug has more solubility for the continuous phase it will be more inclined to this phase and 
migrate leading to more of the drug leaching through diffusion (Dhakar et al., 2012). The 
enlarged copolymer load could also grant more room to entrap LMV. Smaller particles carry 
a greater surface area-to-volume ratio which would increase drug adsorption on the particles 
surface precipitating lowered encapsulation ability and loading efficiency (Jana et al., 2014) 
and consequently a faster release rate, interpreted in a later discussion. Affinity of the 
hydrophilic drug to the large external aqueous phase is great and the shorter distance that a 
smaller particle provides from its center to its surface allows for rapid escape and thus low 
encapsulation efficiency. An elevated surfactant concentration beyond its critical micellar 
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concentration will diminish its effective lowering of the surface tension as well as particle size 
(this would therefore lower the entrapment efficiency) hence the reason for the inverse 
relationship of entrapment efficiency to surfactant (Ekambaram and Sathali, 2011; Sathali 
and Rajalakshmi, 2010). The almost constant entrapment efficiency with an increased 
solvent volume may correspond with the small amount of LMV (drug dose/amount is 
constant) in a greater unmatched volume of DCM solvent. The combined effects of variables 
on DEE display regions of response surface maxima in all plots and demonstrate that low to 
intermediate amounts of surfactant, higher amounts of copolymer and a moderate volume of 
solvent lead to greatest entrapment efficiency. 
 
4.3.6. In vitro drug release profile of HA-g-ECL copolymeric nanoparticle design 
formulations 
 
The cumulative release of LMV drug from all the 15 HA-g-ECL nanoparticles is shown as a 
percentage in Figure 4.8. The release of LMV eventuated in two phases: a stage of initial 
burst release ensued by a stage of slow and steady release. The HA-g-ECL copolymer 
nanoparticles manifested an initial drug release in PBS solution with a full release of drug 
from 6 out of the 15 design formulations (F4, 7, 8, 10, 12 and 15) occurring over a period of 
4 days (96 hours). The burst effects were noted to a lesser degree (inaugural bursts of 20-30 
%) in formulations 1, 2, 6 and 13 accommodating a higher amount of copolymer in 
correlation with formulations 5, 7, 10 and 11 (inaugural bursts of 50-65 %) harbouring the 
least amount of copolymer.  Drug release from smallest size nanoparticle formulation F10 
(32.03 nm) was observed to occur considerably rapidly in comparison to the larger sized F14 
(132.95 nm) which released only 76.90 % of drug over 96 hours. The in vitro drug release 
profiles show a lagging sustained release of LMV especially with F2. The possible drug 
release mechanism as described by Sinha and Trehan (2003) include i) desorption either 
from the surface or through pores on the particle; ii) depending on the characteristics of the 
polymer concerned, via diffusion either by way of the unscathed polymer wall or a water-
surged wall; iii) bulk degradation and the rate of polymer eroding depending on polymer 
properties. The prompt initial release of drug is ascribed to drug that is adsorbed to the 
surface of the nanoparticles. Subsequently, a diffusion-controlled delayed release phase 
proceeds. It is understood that the increased amount of HA-g-ECL preceded a compact and 
compressed polymeric state and thus burdened the ease of drug diffusion constraining the 
burst effect. A relatively dense structure would also prompt reduced release of the surface 
bound drug. A smaller amount of copolymer produces a less compact polymer phase which 
prompts drug migration towards the surface of the nanoparticles during the drying phase 
where large pores would have formed and diffusion would be independent of copolymer 
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control (Huang and Brazel, 2007). An accelerated release of drug was obtained with the 
smaller particles as these would possess a larger surface area for advanced drug migration. 
This lagged drug release at physiological pH 7.4 may be salutary because a prolonged 
release of LMV will diminish the side effects that are related to a copious uptake of LMV drug 
in an unspecified manner. Table 4.5 reveals the MDT values for Box-Behnken design 
formulations. The range spans from 14.01 – 34.28 hours with these extremes being those of 
Formulation 7 and Formulation 5, respectively. Formulation 7 produced particles of a larger 
size (88.49 nm) compared to Formulation 5 producing particles of size 61.07 nm. This falls in 
line with the explanation that smaller sized particles would lead to a faster release of LMV 
and hence a greater MDT value due to enhanced drug migration as a result of the larger 
surface area. The larger particles of Formulation 7 prolonged LMV release (smaller MDT 
value) because of the compact copolymeric structure retarding LMV release in comparison. 
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Figure 4.8: In vitro LMV release profiles from HA-g-ECL copolymeric nanoparticles. a) 
Formulations 1-5, b) Formulations 6-10 and c) Formulations 11-15, (SD≤2.5 in all cases, 
n=3). 
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Table 4.5: MDT values obtained for formulations generated from the Box-Behnken design. 
Formulation No. MDT value (hrs) 
1 30.22 
2 28.61 
3 26.08 
4 22.69 
5 34.28 
6 24.05 
7 14.01 
8 23.34 
9 12.53 
10 17.94 
11 18.20 
12 23.04 
13 15.66 
14 14.44 
15 17.60 
 
4.3.7. Analysis of the Box-Behnken Design 
 
Linear regression was employed to optimize the ACNS by incorporating the responses from 
each of the given variables into an experimental design utilizing the MINITAB® software to 
yield a possible optimized formulation. A prediction of variable confidence intervals were 
determined and their effects with the estimated p-values are reflected in Table 4.6. A p-value 
of a variable ≤0.05 is treated as significant and the response is to be noted. 
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Table 4.6: Variable effects with estimated p-values on outcomes. 
  p-value  
Term DEE Size MDT 
HA-g-ECL 0.836 0.206 0.961 
Plu F-127 0.087 0.105 0.381 
DCM 0.602 0.032 0.217 
HA-g-ECL2 0.550 0.207 0.118 
Plu F-1272 0.025 0.099 0.435 
DCM2 0.920 0.166 0.005 
HA-g-ECL*Plu F-127 0.080 0.689 0.008 
HA-g-ECL*DCM 0.842 0.371 0.141 
Plu F-127*DCM 0.340 0.559 0.100 
 
The full linear polynomial regression equations that were generated by the MINITAB® 
software for drug entrapment efficiency, size and mean dissolution time are as described by 
Equation 4.4, 4.5 and 4.5: 
 
Drug Entrapment Efficiency = -44.4737 + 0.0511[HA-g-ECL] + 74.9458[Plu F-127] + 
1.0069[DCM] - 0.0003[HA-g-ECL2] - 32.4317[Plu F-1272] + 0.0048[DCM2] + 0.1435[HA-g-
ECL*Plu F-127] - 0.0009[HA-g-ECL*DCM] - 0.6907[Plu F-127*DCM]                 Equation 4.4 
Size = 179.972 + 0.653[HA-g-ECL] - 133.346[Plu F-127] - 10.193[DCM] - 0.001[HA-g-ECL2] 
+ 39.722[Plu F-1272] + 0.141[DCM2] - 0.053[HA-g-ECL*Plu F-127] + 0.008[HA-g-ECL*DCM] 
+ 0.787[Plu F-127*DCM]                                                                                      Equation 4.5 
Mean Dissolution Time = -8.0034 - 0.0063[HA-g-ECL] + 17.7193[Plu F-127] + 1.3384[DCM] 
+ 0.0004[HA-g-ECL2] + 4.5483[Plu F-1272] - 0.1155[DCM2] - 0.1483[HA-g-ECL*Plu F-127] + 
0.0040[HA-g-ECL*DCM] + 0.6927[Plu F-127*DCM]                                            Equation 4.6 
 
Additionally, Analysis of Variance on the regression and residual error from each response 
was carried out and is emulated in Table 4.7. The adjusted sum of squares for regression 
over that for residual error was large in each case of response. This implies that regression 
justifies the data generated. The p-values in all cases of responses were shown to be 
significant (≤0.05) with size and MDT displaying the most significance. 
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Table 4.7: Regression and residual errors ANOVA. 
 DF Adj SS Adj MS F P 
DEE      
Regression 9 1093.857 121.5396 5.03 0.045 
Residual Error 5 120.858 24.1716   
Total 14     
Size      
Regression 9 7915.23 879.470 9.90 0.011 
Residual Error 5 444.22 88.843   
Total 14     
MDT      
Regression 9 550.629 61.1810 9.22 0.012 
Residual Error 5 33.173 6.6347   
Total 14     
DF- Degrees of freedom 
Adj SS- Adjusted sum of squares 
Adj MS- Adjusted mean squares 
 
4.3.7.1. Residual error plot analysis for Drug Entrapment Efficiency, Size and Mean 
Dissolution Time 
 
The residual plots for DEE, size and MDT design responses are shown in Figure 4.9 and 
evaluates the residual error of the design. The normal probability plots for all three 
responses displayed the scatter points all along and around the straight line which indicated 
that there was satisfactory distribution of residual data. The residual versus the fitted values 
showed random scatter around the line of 0 which meant that the error variances were 
uniform. Ideally, the histogram plots should be bell-shaped graph layouts and because this 
was not observed in all responses suggested the presence of large residual data points. The 
residual versus the order of the data plots reflect a non-random error and shows serial 
correlation that is positive for all responses.  
 
4.3.7.2. Response surface and contour plot analysis for Drug Entrapment Efficiency, 
Size and Mean Dissolution Time 
 
Figure 4.10 and 4.11 showcase the surface and contour plots for respective responses and 
their synergy with variables established by the Box-Behnken experimental design. From the 
plots for DEE, a significant p-value of 0.025 (Table 4.6) was obtained for the effect of 
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surfactant quantity on DEE (Refer to Chapter 4, Section 4.3. Results and Discussion, 
Subsection 4.3.5. Drug entrapment efficiencies of HA-g-ECL nanoparticles for discussion). A 
significant p-value of 0.032 was generated for the outcome that volume of solvent had on the 
size response and this is evident by the response and contour plots for depicted for size. A 
trend is noted were the volume of solvent on increasing causes a reduction in the size value 
and vice versa. As mentioned earlier in Chapter 4, Section 4.3. Results and Discussion, 
Subsection 4.3.2. Size and Zeta Potential determination of HA-g-ECL nanoparticles by DLS, 
a larger solvent volume adds space for droplets of the emulsion to be readily dispersed while 
dropped into the external aqueous phase, not being forced to conjoin, where larger sizes 
would result. The model also computed considerably significant p-values of 0.005 and 0.008 
for effects on MDT by solvent volume and copolymer/surfactant quantities, respectively. 
Figure 4.10 and 4.11 plots clearly show a lowering of the MDT value as DCM levels lower. 
The link between these two lie in the explanation that lower DCM volumes cause larger 
particle sizes to be produced as discussed above. Larger particle sizes would lead to a more 
controlled release of drug and thus a smaller MDT value because of the packed and 
condensed copolymeric make-up of the larger particle. Similarly attested on the plots for 
copolymer quantity effects on MDT response, the substantiation abides. 
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Figure 4.9: Residual plots for the design responses of size, DEE and MDT. 
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Figure 4.10: Response surface plots showcasing the effects of HA-g-ECL, Pluronic F-127 and DCM on DEE (%), Size (nm) and MDT (hrs).  
DEE SIZE MDT 
 
9
3
 
94 
 
 
Figure 4.11: Response contour plots showcasing the effects of HA-g-ECL, Pluronic F-127 and DCM on DEE (%), Size (nm) and MDT (hrs).
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4.4. Concluding Remarks 
The information procured from this chapter indicated trends seen when two polymers were 
grafted together configuring an amphiphilic copolymer. A Box-Behnken experimental design 
strategy was used to generate formulations to assess these trends in terms of copolymer, 
surfactant and solvent quantity (variables) effects on nanoparticle size, drug entrapment 
efficiency and mean dissolution time (responses). The prepared nanoparticles displayed definite 
characteristics as a result of its constituents that were utilized in the formulation procedure. 
When intensifying the concentration of the element making up a particle, the average diameter 
of the particle will also be increased and this may be due to the rise in viscosity of the internal 
phase. An increase in viscosity will naturally create a retardation of movement of any substance. 
This would therefore affect drug entrapment and release. Pluronic F-127 enabled non-
agglomeration of particles observed on TEM as well as acceptable nanometer size ranges 
reflected by DLS that would be ideal for intracellular delivery of the system. DCM, furthermore, 
accorded viscosity changes to the internal phase having a conclusive effect on nanoparticle 
sizes, drug entrapment and release. Surfactant and solvent quantities are crucial in the 
development of a drug delivery system as these impart and mend to different degrees, 
depending on the substances concerned in formulation: stability, solubility and consequently 
bioavailability of the actives. Thus, it is indeed possible to utilize the novel HA-g-ECL 
copolymeric nanoparticles for encapsulation and sustained release delivery of therapeutic 
molecules. The copolymer may have potential for various other drug delivery vehicle forms with 
restriction not being limited to a nanoparticle form. Surface modifiers may also allow for site-
specific targeting of the HA-g-ECL based drug delivery system for directed effects. The following 
chapter unveils the optimal conditions for ACNS production that were determined by the Box-
Behnken design.  
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CHAPTER 5 
STATISTICAL OPTIMIZATION, IN VITRO CHARACTERIZATION AND ELUCIDATION OF A 
CHITOSAN-GRAFT-LINOLEIC ACID COATED HA-G-ECL LAMIVUDINE-LOADED 
COPOLYMERIC ACNS FOR TARGETED HEPATO DELIVERY 
5.1. Introduction 
 
Globally, liver contagion caused by HBV is colossal. Approximately two billion people are 
affected and infected by the virus with 350 million people categorized as chronic carriers. A 
supposed number of 1.2 million people die annually from disease caused by HBV (Lavanchy, 
2004; van Tong et al., 2014). Furthermore, co-infection with HIV-1 and the hepatitis viruses has 
the tendency to lead to more severe consequences of chronic liver disease. The human HIV 
retroviruses utilize the same infection route employed by the hepatitis viruses and thus co-
infection by these viruses is a frequent occurrence (Moreira et al., 2013). Currently, antiviral 
treatment is insufficient due to poor effectiveness of therapy and the major problem of drug 
resistance. In addition, when antiviral treatment is interrupted, viral cccDNA is still prevalent in 
hepatocytes thus viral rebound is often noticed (Cuestas et al., 2010). Therefore, there remains 
a need for drug delivery systems to efficiently target infected liver parenchyma. 
 
Chitosan - a derivative of chitin, is an α (1→4)-linked 2-amino-2-deoxy-β-D-glucopyranose that 
has undergone N-deacetylation. The degree to which it undergoes deacetylation is varied and 
as a result is ultimately a copolymer product of N-acetylglucosamine and glucosamine. Both 
chitin and chitosan are polymers found in copious amounts naturally and they possess attractive 
properties such as those of biocompatibility, biodegradability, non-toxicity and have the capacity 
to adsorb onto cells in a combative manner (Dutta et al., 2004). 
  
Essential fatty acids fall into the category of polyunsaturated fatty acids which are strictly 
obtained from diet. Polyunsaturated fatty acids are 18, 20 and 22 carbon chain lengths. One 
type of polyunsaturated fatty acid, linoleic acid (LA), contains an 18 carbon chain with 9 and 12 
positioned double bonds in cis arrangement along its length (Du et al., 2009). These 
polyunsaturated fatty acids have approvingly presented anticarcinogen effects and repressed 
effects on atherosclerotic contusions as a result of heightened immunity effects, reduced body 
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fat and increase in lean body mass observed in many animal models (Aydin, 2005; Du et al., 
2009). 
 
Liver plays a central role in body metabolism. LA in the body first concentrates in the cells of the 
liver and thus plays a pivotal role in the hepatic environment (Thomas et al., 1988). Accordingly, 
LA is sought as a trigger ligand to arbitrate internalization into hepatic cells (Cheong et al., 
2009). The manner in which this occurs is via recognition pathways utilizing the ASGP-R found 
on hepatocytes and a biochemical lipid metabolism pathway involving cholesterol and 
triglyceride synthesis once LA is concentrated in hepatocytes (Cheong et al., 2009; Lee et al., 
2009a). LA has also been shown to increase transfection efficiency of lipid nanoparticles when 
incorporated into the system for hepatic delivery (Yu et al., 2012).  
 
Chitosan and LA have been paired in numerous studies as a result of communal positive 
properties in diverse areas of biomedical applications. A study demonstrated the effect of LA 
grafted to chitosan oligosaccharide prepared as micelles for delivery of doxorubicin into tumor 
cells. Favorable results were obtained with doxorubicin contained in these micelles compared to 
a solution of doxorubicin hydrochloride alone (Du et al., 2009; Du et al., 2011). Another study 
needed an efficient topical delivery system for dermal regeneration and repair of tissue.  
Chitosan was hydrophobically altered with LA and oleic linkage to demonstrate a positive tissue 
repairing capability (Bonferoni et al., 2014). Hydrogel nanoparticles can also be made up by LA 
chemically modified with chitosan for reliable encapsulation of trypsin (Liu et al., 2005). 
Principally and with relevance to this study, the polymer pair have been implicated conjointly for 
a hepato-targeting ability. A study that has utilized these polymers in similar manner is one that 
developed a hepatocyte targeting magnetic resonance imaging contrast agent utilizing water 
soluble chitosan conjugated to LA that was developed into superparamagnetic iron oxide 
nanocrystals and nanoparticles (Cheong et al., 2009; Lee et al., 2009a). 
 
A scaling down of the vast experiment numbers as a result of vast variable parameters is 
resolved by the DOE approach. Thus, implementing DOE is advantageous in refining 
experiments for designing an optimal formulation especially due to complicated glitches that 
occur as well as the costly procedures that are necessary for experimenting (Kincl et al., 2005). 
In this chapter chitosan and LA will be graft polymerized and utilized as a chemically adsorbed 
coating on an optimized ACNS, to capitilize on the physicochemical properties of these 
compounds in favor of liver and thus HBV targeting. 
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5.2. Materials and Methods 
 
5.2.1. Materials 
Hyaluronic acid sodium salt from Streptococcus equi, epsilon-Caprolactam (>=99 %), 
Poly(ethylene glycol) methyl ether (mPEG) (average Mw~2000 Da), Dialysis tubing cellulose 
membrane (Mw 12044 Da), N-acetylcaprolactam (99 %), Sodium hydride (NaH) (powder 
moistened with oil, 55-65 % gas volumetric), Pluronic F-127, Chitosan low molecular weight (75-
85 % deacetylated), Linoleic acid (≥99 %), Acetic acid (glacial, ≥99.85 %), N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, crystalline (EDC) were all purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Lamivudine (LMV) was received as an ex-gratia 
sample from Adcock Ingram Ltd. (Germiston, Gauteng, South Africa). Dimethyl sulphoxide 
(DMSO), D-Mannitol (≥99 %) (Mw 182.17 g/mol) and Dichloromethane (DCM) were purchased 
from Merck Chemicals (Pty) Ltd. (Germiston, Gauteng, South Africa). All other chemicals and 
reagents were of analytical grade. 
 
5.2.2. Preparation of an optimized LMV-loaded ACNS by the Box-Behnken design 
strategy 
 
5.2.2.1. Response Optimization 
 
An optimized formulation encompassing constraints that ensured the smallest nanometer sized 
particles (≤100 nm), the greatest drug entrapment efficiency and a sustained LMV release was 
acquired by use of statistical software (Minitab®, V14, Minitab Inc®, PA, USA). These constraint 
settings are displayed in Table 5.1. Figure 5.1 portrays desirability plots of the single optimal 
formulation generated as a result of constraint optimization. The optimal desirability value was 
shown to be 0.959. 
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Table 5.1: Constraints employed for optimized formulation. 
Variable Response Level 
Size (nm) Minimize 
DEE (%) Maximize 
MDT (hrs) Minimize 
 
 
 
Figure 5.1: Desirability plots demonstrating variable values required for optimized formulation 
preparation and desirability values expected for responses. 
 
5.2.2.2. Generation of the optimum ACNS 
A representation of the quantities derived from response prediction for the optimal copolymeric 
nanoparticle formulation is shown in Table 5.2. 
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Table 5.2: Optimized LMV-loaded HA-g-ECL copolymeric nanoparticle formulation developed 
by the response surface technique. 
Formulation Components Optimized formulation 
HA-g-ECL copolymer (mg) 195.11 
Pluronic F-127 surfactant (g) 1.35 
DCM solvent (mL) 16.38 
 
5.2.3. HA-g-ECL amphiphilic graft copolymer synthesis 
 
The copolymerization process was carried out as outlined in Chapter 3, Sections 3.2.2. 
Desalting process of hyaluronic acid, 3.2.3. PEG-assisted solubilization of HA in DMSO and 
3.2.4. Anionic graft (co)polymerization of HA and ECL (HA-g-ECL). 
 
5.2.4. Drug-loaded HA-g-ECL copolymeric nanoparticle preparation 
 
The preparation of nanoparticles was carried out as described in Chapter 4, Section 4.2.4. 
Preparation of LMV-loaded HA-g-ECL copolymeric nanoparticles, utilizing the optimized variable 
quantities according to Table 5.2. 
 
5.2.5. Chemical modification of chitosan through graft synthesis with linoleic acid 
producing Chitosan-Linolate 
 
The grafting of linoleic acid to the polymer, chitosan was carried out according to the method by 
Kim and co-workers (2011) with slight modification. Low molecular weight chitosan (1 %w/v) was 
dissolved in 1 %v/v dilute aqueous acetic acid. A volume of 20mL chitosan solution was used 
with 0.77 mL linoleic acid for the graft procedure. The linoleic acid was dissolved in 36.80 mL 
DMSO. The chemical link, EDC, was added into the chitosan solution at a weight of 0.394 g and 
was made to dissolve. The two solutions were added together and grafting of linoleic acid to 
chitosan was performed through EDC chemistry at pH 4.75 through vigorous stirring for 24 
hours. C-LA was received after its precipitation in 200 mL organic solvent (32 % Ammonia 
solution). The product was centrifuged at 5000 rpm (Table Top High Speed Centrifuge (TG16-
WS), Hunan Xiangyi Laboratory Instrument Development Co., Ltd, Hunan, China) for 10 
minutes three times washing with deionized water at each interval to remove any trace of 
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organic solvent. C-LA was then lyophilized to obtain a semi-stiff cotton wool-like textured 
product (Figure 5.2). An illustration of the grafting synthesis of C-LA is depicted in Figure 5.3. 
 
 
Figure 5.2: Digital image of A) synthesized lyophilized C-LA in physical form. 
 
A) 
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Figure 5.3: Schematic of the synthesis of C-LA (Adapted from Kim et al., 2011). 
 
5.2.6. Selection process for a suitable cryoprotectant in favor of HA-g-ECL nanoparticles 
size maintenance 
 
A range of cryoprotectants at a range of different concentrations were tried and tested to 
maintain the size of formed HA-g-ECL nanoparticles as this is one of the significant variable 
responses of the three that must be kept constant for targeted hepatic cell delivery. Table 5.3 
shows various cryoprotectants at their respective concentrations that were added to Formulation 
7 of the Box-Behnken design acquiring a size of 88.49 nm. These were added into the 
formulation before freezing at -80 °C for 24 hours and lyophilizing. Thereafter, powdered 
cryoprotected HA-g-ECL nanoparticles were redispersed in the same volume of liquid initially 
 
 
 Chitosan Linoleic Acid 
Chitosan-linolate 
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held in before freezing. Cryoprotectants were evaluated by their effect on nanoparticles in terms 
of their flowability, redispersibility and size maintenance. 
 
Table 5.3: Cryoprotectants used for HA-g-ECL nanoparticle size maintenance assessment. 
Cryoprotectant Concentration (%w/v) 
Sucrose 3 
 16 
 30 
Glucose 3 
 16 
 30 
Lactose 1 
 3 
 8 
Mannitol 3 
 10 
 20 
Pluronic F-127 1 
 
5.2.7. Preparation of C-LA coating and coated optimized HA-g-ECL ACNS 
 
Lyophilized 2 %w/v C-LA was made to dissolve in 1 %
v/v dilute acetic acid with magnetic stirring 
for 3 hours. Powdered HA-g-ECL nanoparticles (10.5 mg) with cryoprotectant was added to and 
redispersed in the C-LA coating solution. The solution was taken off the magnetic stirrer and left 
in a dark cupboard for 24 hours to allow for chemical adsorption of C-LA onto HA-g-ECL 
nanoparticles to occur. The coating-nanoparticle solution was then centrifuged on high (15000 
rpm, 99 minutes) (Universal 320R, Hettich Zentrifugen, Germany) to remove excess coating 
from the nanoparticles. 
 
5.2.8. Determination of molecular vibrational bands utilizing Fourier Transform Infrared 
spectroscopy 
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Fourier Transform Infrared Spectroscopy (FTIR) analysis was employed to obtain infrared 
spectra of native chitosan, native linoleic acid and synthesized C-LA as well as the optimized 
ACNS, coated optimized ACNS, LMV and non LMV-loaded optimized ACNS. The vibrational 
characteristics of the samples were detected in response to infrared radiation allowing for 
interpretation of the quality and consistency of the sample compounds. Infrared spectra were 
created on a Spectrum 100 FTIR Spectrometer (PerkinElmer Life And Analytical Sciences Inc., 
Shelton, CT USA). 
 
5.2.9. Transmission Electron Microscopy imaging of the optimized C-LA coated ACNS 
 
TEM imaging of the coated optimized ACNS was carried out as outlined in Chapter 4, Section 
4.2.5. Transmission Electron Microscopy (TEM) of the formed copolymeric nanoparticles. 
 
5.2.10. Thermal analysis employing Differential Scanning Calorimetry 
 
Optimized samples were thermally analyzed according to the method described in Chapter 4, 
Section 4.2.7, Subsection 4.2.7.1. Differential Scanning Calorimetry. 
 
5.2.11. Thermal analysis employing Thermogravimetric Analysis 
 
Optimized samples together with their individual constituents were thermogravimetrically 
analyzed as described in the method under Chapter 3, Section 3.2.8 Thermogravimetric 
analysis. 
 
5.2.12. Dynamic Light Scattering size and zeta potential determination of the optimized 
ACNS 
 
DLS measurements of optimized samples before and after coating were performed as 
described in Chapter 4, Section 4.2.6. Size and Zeta Potential determination via Dynamic Light 
Scattering (DLS). 
 
5.2.13. Drug Entrapment Efficiency of the optimized ACNS 
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According to the method outlined in Chapter 4, Section 4.2.9. Drug encapsulation efficiency 
(DEE) of HA-g-ECL nanoparticles, the optimized coated and uncoated ACNS formulations were 
tested for their DEE. 
 
5.2.14. In vitro drug release profile of the optimized ACNS  
 
Optimized coated and uncoated ACNS formulations were subjected to drug release profiling 
according to the process described in Chapter 4, Section 4.2.10. In vitro dissolution studies of 
LMV-loaded HA-g-ECL nanoparticles. 
 
5.3. Results and Discussion 
 
5.3.1. Predicted and Observed values for the optimized ACNS 
 
An ACNS formulation was optimized by way of variable response optimization utilizing the 
Minitab® statistical software (Minitab®, V14, Minitab Inc®, PA, USA). The optimal formulation 
computed from the programme constituted quantity use of 195.1102 mg HA-g-ECL, 1.3476 g 
Pluronic F-127 and 16.3837 mL DCM. Table 5.4 portrays the predicted and observed 
measurements achieved with their corresponding desirability value. All of the results were good 
with the best desirability of 100 % achieved for size response and the least desirable (yet 
acceptable) of 93.21 % obtained for DEE. 
 
Table 5.4: Predicted experimental and desirability measurements of the optimized HA-g-ECL 
based nanoparticle formulation. 
Measured Variable 
Response 
Predicted 
Measurement 
Observed 
Measurement 
Desirability (%) 
Size (nm) 52.25 51.19±4.37 100 
DEE (%) 33.85 31.55±3.10 93.21 
MDT (hrs) 20.04 19.45±1.59 97.01 
 
Bearing in mind that the targeting for the drug to the liver for HBV eradication involves the 
coating of the ACNS which occurs after optimization of the plain uncoated ACNS, a comparison 
of the C-LA coated ACNS was made to the optimized plain ACNS which is shown in Figure 5.4. 
Variations in results were noted with an expected increase in size of approximately 25 nm to the 
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ACNS due to the addition of diameter to the structure as a result of the chemical adsorption of 
the C-LA coat. This was still acceptable being below 100 nm for hepatocyte internalization. DEE 
reflected an approximate 1.5 % reduction which could be overlooked and MDT showed a 
considerable increase in hours of approximately 9.5 which was most desired as the response 
optimization goal for the ACNS initially was a maximized MDT value. This was also expected 
due to the coat serving as a barricade to LMV and sustaining its release from the ACNS 
structure. 
 
1O C-ACNS- Optimized coated architecturally configured nanoparticulate system 
2O UC-ACNS- Optimized uncoated architecturally configured nanoparticulate system 
 
Figure 5.4: Bar graph illustrating the comparitive assessment of observed measurement 
responses between optimized coated and uncoated ACNS. 
 
5.3.2. Selection of a suitable cryoprotectant to limit the increase of ACNS size 
 
A variety of cryoprotectants were evaluated for their ability to sustain the size of formed ACNS 
nanoparticles due to freeze-drying processes that alter its properties causing agglomeration in 
aqueous redispersion and thus a defective size increase. Sucrose, glucose, lactose and 
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mannitol sugars as well as 1 % Pluronic F-127 solution, were prepared in concentrations 
depicted in Table 5.5. The cryoprotectants were assessed on their capacity to efficiently cause 
the freeze-dried ACNS to flow, redisperse and maintain its initial size (Formulation 7 of 88.49 
nm from  the experimental design) before freezing at -80 °C and freeze-drying. Results indicate 
the optimal cryoprotectant to be 20 % mannitol which caused only a slight increase in size of the 
ACNS by 0.97 nm in addition to the ACNS demonstrating good flowability and redispersibility. 
Mannitol at this concentration was thus employed in preparation of the ACNS for the 
subsequent stage of formulation with C-LA coating. 
 
Table 5.5: Estimation of cryoprotectants flowability, redispersiblity and size maintenance 
functional ability for optimized ACNS. 
Cryoprotectant %w/v Flowability Redispersibility Size (nm) PDI 
Sucrose 3 ++ + 97.24 0.322 
 16 + -/+ 106.5 0.247 
 30 -/+ -/+ 117.56 0.235 
Glucose 3 - ++ 99.58 0.610 
 16 -/+ + 122.6 0.286 
 30 -/+ + 118.3 0.236 
Lactose 1 -/+ + 95.19 0.410 
 3 + ++ 164.83 0.257 
 8 ++ ++ 173.06 0.263 
Mannitol 3 -/+ + 108.40 0.288 
 10 + + 99.15 0.352 
 20 + + 89.46 0.257 
Pluronic F-127 1 - -/+ 143.1 0.781 
 ---Lump formation; --Very poor; -Poor; -/+Moderately good; +Good; ++Very good 
 
5.3.3. Structural variation investigations via Fourier Transform Infrared spectroscopy 
analysis 
 
The synthesized C-LA was analyzed with FTIR to ascertain the graft polymerization occurrence 
between chitosan and LA. Figure 5.5 depicts the spectra obtained for plain chitosan (a), plain 
LA (b) and the formed C-LA (c). Figure 5.5a demonstrated the characteristic chitosan spectrum 
displaying the OH vibration at 3286 cm-1, CH stretching vibration at 2868 cm-1, C=O stretching 
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vibration at 1624 cm-1 and the NH of amide stretching vibration at 1558 cm-1 (Kim et al., 2011). 
Figure 5.5b also shows that LA displayed characteristic peaks at 1708 cm-1 which resembled 
the carboxylic acid group, 2854 cm-1 and 2923 cm-1 frequencies which correlated with the CH 
stretching vibration and 3008 cm-1 which was the alkene peak on the molecule (Kim et al., 
2011). Proof that LA grafted onto the structural backbone of chitosan was sought by the 
disappearance of the carboxylic acid peak at 1708 cm-1 suggesting the attachment of the 
molecule at this point on the chitosan chain. There was also evidence of an increased peak 
intensity at 1648 cm-1 which corresponded to a stronger carbonyl peak as a result of the 
interaction of chitosan and LA as well as the appearance of an acrylate double bond at 900 cm-
1. These FTIR findings indicated successful graft copolymerization between chitosan and LA to 
form C-LA. Figure 5.6 displays the FTIR spectra of optimized coated and uncoated formulations 
comparatively with C-LA and LMV. The difference in spectra between the coated and uncoated 
drug loaded formulations (Figure 5.6a & d) is the intensity of the peak in a) at 1637 cm-1 that is 
larger than the same peak seen in d). This peak in either formulation corresponds to the drug 
peak at 1631 cm-1 which is rightly so as both uncoated and coated ACNS were LMV-loaded. 
However, the intensity variation occurs because of the C-LA peak at 1648 cm-1 which is being 
detected by infrared radiation at the same point on the coated ACNS resulting in the heightened 
intensity. Moreover, the broad OH vibration of C-LA is also seen at the same frequency range in 
the coated ACNS formulation suggesting again that C-LA did indeed exist on the ACNS 
structure. These raised intensities are unseen on the spectra of the non coated LMV-loaded 
ACNS. 
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Figure 5.5: FTIR spectra of a) native chitosan, b) native linoleic acid and c) C-LA. 
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Figure 5.6: FTIR spectra of a) C-LA coated LMV-loaded ACNS, b) C-LA, c) LMV and d) 
uncoated LMV-loaded ACNS. 
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5.3.4. Morphological investigations of optimized C-LA coated ACNS utilizing 
Transmission Electron Microscopy 
 
The TEM image depicted in Figure 5.7 revealed mostly spherically-shaped C-LA coated ACNS 
particles which were favorably non-agglomerated and properly individualized relaying clarity of 
ACNS morphology. The C-LA coat can be clearly seen as it imparts the darkened color onto 
nanoparticles implying and confirming its chemical adsorption onto plain HA-g-ECL ACNS. 
Figure 5.7 also discloses the size of the C-LA coated ACNS later seen to correlate with DLS 
measurements of size distribution and zeta potential profiling. The transmission electron 
micrograph was taken at 42000X magnification and it can be estimated by the scale bar that 
sizes of C-LA coated ACNS particles were in the range of 70-80 nm. 
 
Figure 5.7: Transmission electron micrograph of optimized C-LA coated ACNS. 
 
5.3.5. Differential Scanning Calorimetry thermogram analysis of C-LA and the optimized 
ACNS 
 
The thermal profiling from DSC is disclosed in Figure 5.8 and Figure 5.9. By comparison, they 
depict the curves of indigenous polymers to their derivative graft products as well as the LMV-
loaded optimized ACNS in its C-LA coated and uncoated form. Figure 5.8 distinguishes 
between the low molecular weight chitosan and the amorphous LA from its graft product C-LA. 
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Figure 5.8a displays the broad endotherm of chitosan at 103.76 °C that would correspond to the 
dehydration of the water molecules on the compound. Its exotherm at the onset temperature of 
283.78 °C conforms to decomposition of the molecule. Linoleic acid in Figure 5.8b shows no 
thermal event until around 260 °C which may correlate to the boiling of LA and/or a fraction of 
thermal decomposition of the fatty acid followed by a broad exothermic transition at around 280 
°C which may correspond to the decomposition products (Kapusniak and Siemion, 2007). The 
graft copolymerization of LA onto chitosan can be deduced from the new endothermic transition 
that occurs at a peak maxima of 167.80 °C. This is most probably representative of a melting 
endotherm as the first broad endothermic transition observed at a ~100 °C can be labelled the 
Tg as a result of LA’s amorphous nature contributing to it. The melting endothermic peak occurs 
because of the solid nature imparted on the C-LA product and thus an existing but very low 
extent of crystallinity. 
 
Figure 5.8: Differential scanning calorimetry curves; a. Native low molecular weight chitosan, b. 
Native LA and c. C-LA. 
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The drug LMV in its pure form is shown in Figure 5.9a. The sharp endothermic peak at 182.91 
°C is representative of its melting thermal transition (Singh and Nath, 2012). The fact that this 
significant endotherm disappears in the curves of the LMV-loaded optimized formulations 
(Figure 5.9c & e) implies that the drug has been successfully encapsulated into the copolymeric 
ACNS structure (Park et al., 2014) within the hydrophilic part of amphiphilicity. The exothermic 
transition identified at around 270 °C is most probably associated with the degradation of the 
drug at this point. Figure 5.9b demonstrates the melting endotherm of mannitol at its peak 
temperature 162.16 °C. Being in its physical form and basically blended in optimized 
formulations merely to manifest its cryoprotectant effect, its endothermic peak can be seen in 
both coated and uncoated optimized formulations at 163.05 °C and 162.44 °C respectively with 
the enthalpy value being greater for the uncoated optimized formulation. In Figure 5.9c the first 
endothermic peak of 53.08 °C resembles the melting endotherm transition of HA-g-ECL (Figure 
5.9d). Yet, this endothermic transition is absent in the C-LA coated optimized formulation, 
providing evidence that the coating indeed exists as it acts as a barrier restricting HA-g-ECL 
from melting at the temperature that it does. In addition, C-LA illustrates its broad endothermic 
peak at 167.80 °C in Figure 5.9f and the optimized C-LA coated ACNS shows an analogous 
peak at a slightly lower 162.36 °C (possibly due to disruption from attachment) implying the 
existence of the coat. 
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Figure 5.9: Differential scanning calorimetry curves; a. Pure LMV, b. Mannitol, c. Optimized 
non-coated LMV-loaded ACNS, d. HA-g-ECL, e. Optimized C-LA coated LMV-loaded ACNS 
and f. C-LA. 
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5.3.6. Thermogram analysis of C-LA and the optimized ACNS thermal degradation 
 
TGA analysis was carried out to observe the degradation mechanism for samples revealed in 
Figures 5.10 & 5.11. The thermogravimetric curves (solid) are depicted with their respective first 
derivative curves (dash-dot). Both polymer and copolymer samples in Figure 5.10 displayed 3 
steps of degradation. In the first steps for chitosan (A) and C-LA (C), the Tpeaks are 81.61 °C and 
58.43 °C, respectively. These can be attributed to the loss of water molecules taking place. The 
following two decomposition steps occurring for C-LA at 277.65 °C and 522.47 °C are as a 
result of the breakdown of chitosan backbone and the linoleic acid graft, respectively (Hülya et 
al., 2006). However, due to the graft procedure that caused disruption of the bonds on the 
chitosan backbone, a decrease in thermal stability was observed with C-LA with Tonset occurring 
at 207.40 °C when compared to the later occurrences of degradation in chitosan and LA alone 
at 291.32 °C and 265.62 °C, respectively, suggesting greater stability in parent compounds. 
 
Figure 5.11 reveals the thermal degradation profiles for the optimized drug-loaded C-LA coated 
(C) and non-coated ACNS (D) in addition to LMV pure drug (A) and the cryoprotectant used in 
formulation, mannitol (B). A prominent thermal stability difference can be noted between the 
drug-loaded optimized C-LA coated and uncoated ACNS. A Tonset difference of 5.73 °C is 
obtained between the two suggesting that C-LA coat confers greater degradation stability in an 
optimized ACNS (Tonset = 280.81 °C) compared to the poor uncoated optimized ACNS (Tonset = 
275.08 °C). Another notable feature calculated from the degradation thermograms of the 
comparative optimized formulations were the residual mass percentages. The uncoated ACNS 
had a residual mass of 1.748 % and the coated ACNS had a residual mass of 4.325 %. This 
confirmed evidence of successful C-LA chemically adsorbed coating onto plain HA-g-ECL 
ACNS by indicating that the extra mass was due to extra components on the chemical structure 
of plain HA-g-ECL ACNS. The degradation thermogram of the pure drug proceeded in two 
stages (Figure 5.11 A). The major weight loss that is noted is at Tpeak = 295.73 °C and this is 
attributed to the evolving water molecules that are present in the chemical structure of LMV. The 
second decomposition occurs at Tpeak = 599.73 °C and this is attributed to the breakage of the 
N6-C12 bond in the drug molecule (Ramkumaar et al., 2012). Mannitol has the ability to contain 
thermal energy avoiding weight loss stably below a Tpeak = 300.15 °C (Kumaresan et al., 2011). 
The Tonset of Mannitol was extrapolated to be 315.35 °C from Figure 5.11 B and the complete 
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weight loss of the sample was completed in one step with the major portion of thermal 
degradation occurring at Tpeak = 381.83 °C. 
 
 
 
 
Figure 5.10: Thermogravimetric analytical and derivative thermogravimetry curves of A) 
Chitosan, B) LA and C) C-LA. 
A 
B 
C 
117 
 
 
 
 
  
 
Figure 5.11: Thermogravimetric analytical and derivative thermogravimetry curves of A) Pure 
LMV, B) Mannitol, C) Optimized C-LA coated LMV-loaded ACNS and D) Optimized uncoated 
LMV-loaded ACNS. 
 
5.3.7. Size and zeta potential evaluations exploiting Dynamic Light Scattering 
 
Dynamic light scattering was employed to assess the size and surface charge distribution of the 
optimized ACNS formulation before and after it was subjected to C-LA coating. Figure 5.12 
displays the DLS size and zeta potential graphs obtained for the optimized ACNS before C-LA 
A B 
C D 
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was chemically adsorbed onto it. The size distribution by intensity displayed a peak well below 
100 nm. This corresponded to the measurement of 51.19±4.37 nm that was recorded. Zeta 
potential distribution displayed a negative charge of -19.6±3.19 mV on the surface of the ACNS 
copolymeric structure. Figure 5.13 depicts the DLS distributions of size and zeta potential of the 
optimized ACNS following C-LA chemical adsorption. The DLS graph of size reveals proof of 
successful coating of the targeting ligand by the observed shift in peak size closer to the 100 nm 
mark corresponding to 76.00±14.98 nm. Furthermore, the zeta potential distribution showed a 
complete opposite positive surface charge of +25.7±2.87 mV on the ACNS structure which 
evidently reflects the charge of chitosan on the nanosystems surface. 
 
 
 
Figure 5.12: DLS profiles of the optimized ACNS before C-LA coating; a) size and b) zeta 
potential. 
a) 
b) 
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Figure 5.13: DLS profiles of the optimized ACNS after C-LA coating; a) size and b) zeta 
potential. 
 
5.3.8. In vitro drug release profiles of the C-LA coated and uncoated ACNS 
 
In vitro drug release profiles of optimized C-LA coated and uncoated LMV-loaded ACNS 
formulations are illustrated in Figure 5.14. Both formulations displayed sustained release 
profiles however the ACNS lacking coating showed an initial burst release of 40.78 % within 8 
hours compared to the C-LA coated ACNS which was efficiently sustained due to a layer 
surrounding the nanosystem that drug must pass through and ultimately constraining the burst 
effect. The copolymer of the ACNS uncoated nanosystem holds drug that is adsorbed on its 
surface which is exposed to the diffusion medium resulting in prompt initial burst release 
thereof. The size difference between the coated and uncoated ACNS is also vast which leads to 
the much smaller sized uncoated ACNS of approximately 50nm dispelling drug rapidly due to 
the relatively shorter distance to the nanoparticle surface for migration. The coated C-LA ACNS 
a) 
b) 
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showed a lagged release of drug with merely 41.89 % released after 4 days. Comparatively, 
66.93 % was released after 4 days in uncoated ACNS. A further consequence to exposed 
copolymeric ACNS is the open pores readily in contact with diffusion media that provides a 
direct channel for the hydrophilic LMV to move through. Coating adsorbed to the surface would 
act as a sealant preventing this passage of drug. LA comprises a lipid property. Lipids are 
infamous for demonstrating difficulty in being passively impermeable providing a relatively 
condensed blockade for the hydrophilic LMV. MDT values of 28.96±2.20 and 19.45±1.59 hours 
was achieved with C-LA coated ACNS and uncoated ACNS, respectively. Thus, the chitosan-
linolate adsorbed onto the outer make-up of ACNS displayed the more favorable near zero-
order drug release of LMV. 
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Figure 5.14: Fractional drug release profiles of the uncoated and C-LA coated optimized ACNS 
formulations. 
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5.4. Concluding Remarks 
 
The present chapters objective was to elucidate and characterize the processed parameters 
previously statistically determined using the Box-Behnken model, to have a considerable effect 
on the three responses (DEE, size and MDT) to obtain their optimized values. The optimization 
process was carried out by use of polynomial mathematical equations and response surface 
plots which allowed for the determination of the compound independent variables with 
predictable profile of experimental responses. An optimized ACNS was developed and fully 
characterized to evaluate its physicochemical characteristics as well as compare predicted and 
observed response measurements attained by the model. Responses measurements showed 
good correlation. In addition, a graft copolymerization between chitosan and LA occurred 
successfully synthesizing C-LA. Preparation of a C-LA coating into a chemically adsorbed 
copolymeric liver targeting ligand also developed successfully as discerned by DLS size and 
surface charge characterization tests as well as an enhanced sustained drug release 
observation. The in vitro characterization and elucidation of the optimized C-LA coated ACNS 
was most rewarding, however the most critical investigation lay in the actual performance of the 
nanosystem as a hepatocyte targeting therapeutic complex which is divulged in the following 
chapter as cellular internalization of the ACNS is explored. 
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CHAPTER 6 
EX VIVO INVESTIGATIONS:  VISUALIZATION OF CELLULAR INTERNALIZATION OF C-LA 
COATED ACNS INTO A HEPATIC CELL LINE 
6.1. Introduction 
 
Nanoparticulate carrier systems have attained significance in nanomedicine through conferring 
appealing pharmacokinetic feats for various drug treatments. Apt drug delivery is achieved by 
augmented solubility and stability of drug provided by these nanoparticulate carrier systems 
including a lagged systemic circulation and target specificity leading to accumulation of 
therapeutic at the target area. Moreover, proper efficacious cellular passage is achievable by 
these delivery systems (Song et al., 2013). Nanoparticulate carrier systems display physical and 
chemical traits that determine its fate at the level of biological system such as its transit across 
the cell surface. Some of these traits constitute the makeup of the nanoparticulate system, its 
surface chemistry, charge and size (Bannunah et al., 2014). From the time inorganic 
nanoparticles have been successfully internalized into cells, they have become a long-
established means of fluorescent imaging in live cells (Serdiuk et al., 2014). Nanomachinery are 
readily taken up into a cell and localized herein at varying intensities significantly dependent on 
the chemical makeup of the surface of the nanomaterial along with their shape and size which 
notably impacts cellular internalization. A particular cell will internalize a nanoparticle size suited 
to the distinctiveness of the cell. In terms of shape, it was found that spherically shaped 
nanostructures have been taken up more readily than rod-shaped nanostructures. In terms of 
surface charge, positively charged nanostructures have been most competent in passing over a 
cells membrane and reaching internal locations (Verma and Stellacci, 2010). 
 
Phagocytotic and non-phagocytotic processes such as that of clathrin- and caveolin-mediated 
endocytosis and macropinocytosis, are mechanisms by which nanoparticles are cellularly 
internalized. Phagocytosis is an inadmissible mechanism because of macrophages identifying 
the nanostructures as foreign bodies and thus eliminating them resulting in failed therapy. 
Phagocytosis should be avoided by surface modification of nanostructures with ligands, 
exposing a hydrophilic surface and preparing extremely nanosized particles. Target site delivery 
necessitates efficiency in decisiveness about a nanoparticle’s surface modification and ligand 
attachments. Receptor-mediated endocytosis occurs through the high-affinity receptors found 
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on the surface of most cells that seize nanoparticles. Surface caveolin is a dimeric protein that is 
triggered by the nanostructures that facilitates their internalization. Surface clathrin coated pits 
cause the transit of nanoparticles into cells leading to the formation of endosomes once inside. 
Macropinocytosis is an internalization route that is limited to larger particles (Gad, 2008; 
Plajnšek et al., 2012). 
 
Fluorescent chemical substances that are within the scope of re-emitting light are termed 
fluorophores. They emit fluorescence by way of the electron excitation and its subsequent falling 
back into the orbit of an electron. These chemical compounds have the ability to perform 
sensitive detection simultaneously evading concerns with safety and special execution of the 
experiment. They have long been implemented in ligand assays for their function (Renberg, 
2006). Figure 6.1 show some of the frequently ordained fluorophores being fluorescein, 
tetramethylrhodamine and the organic Cy3 and Cy5 dyes used in DNA and protein microarrays. 
 
 
Figure 6.1: Fluorophore chemical structures. A) Cy3, B) Cy5, C) Fluorescein and D) 
Tetramethylrhodamine (Adapted from Renberg, 2006). 
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The mechanism by which fluorescent dyes impart their reactivity is through direct labeling of 
proteins and their blends. Reactive derivatives that are prominent are those of isothiocyanates 
and N-hydroxysuccinimide esters that are readily clasped covalently to lysine side chain amino 
groups and amine terminal groups (Renberg, 2006). Fluorescence microscopy is routinely 
availed to detect cellular uptake of a compound upon ligand binding and supplementing the 
chemical entity that is of interest with the fluorescent dye. After the attachment process, 
polymers in particular command a legion of fluorescent dye washing cycles because of the extra 
background fluorescence that is imperative to be removed. Thereupon, polymeric 
macromolecules holding a fluorescent label can illuminate the pathway upon cellular 
endocytosis tracking the movement of the entire nanostructure (Mangold et al., 2008). 
 
Many cell lines of liver source are utilized extensively in biomedical research. The organotypic 
HepG2 cell line was chosen for the ex vivo component of this study as it is usually utilized as an 
in vitro surrogate for the specified organ of importance – the human liver; as is the case for 
Caco-2 and Caki-1 for human intestine and human kidney resembling, respectively (Hilgendorf 
et al., 2007). This most resourceful HepG2 cell line was formerly sequestered by Aden et al. in 
the year 1972 from an 11 year old Argentine male with a primary hepatoblastoma. HepG2 cells 
are able to preserve particular actions lacking in most cultured primary hepatocytes such as the 
extrusion of major plasma proteins. Accordingly, HepG2 cells are sought when it comes to liver 
disease research, therapeutic actions and mechanisms as well as gene transcription and gene 
expression (Mersch-Sundermann et al., 2004). Studies that employed fluorescein 
isothiocyanate (FITC) as a fluorophore together with use of the HepG2 cell line reported 
valuable and favorable data.  A study that simultaneously used rhodamine B isothiocyanate with 
FITC on silica nanoparticles demonstrated in flow cytometry that the cellular internalization of 
the particles was reliant on size, concentration and culturing time. Results reflected 
nanoparticles to be concentrated in cytoplasm, endosomes and HepG2 cell surfaces (Hu et al., 
2011). Jiang et al (2013) reported on HepG2 cells subjected to cholesterol-modified pullulan 
nanoparticles that were covalently appended with FITC. Fluorometry showed nanoparticle 
uptake reliance on concentration and temperature. Results also implicated clathrin-mediated 
endocytosis and macropinocytosis in the cellular internalization. One more study illustrated 
fluorescence on a novel chitosan derivative that was linked with many galactose residues in an 
antennary manner. Additionally, a galactosylated chitosan derivative was also prepared. Data 
displayed poor fluorescence with plain FITC conjugated chitosan nanoparticles, greater 
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fluorescence with FITC conjugated galactosylated chitosan nanoparticles and the best 
fluorescence with FITC conjugated multiple galactose-chitosan nanoparticles in HepG2 cells (Mi 
et al., 2007). 
 
The objective of the following ex vivo study is to visibly ascertain the HepG2 internalization of 
the C-LA coated verse the uncoated ACNS formulations by way of fluorescence labeling, also 
applying FITC as the fluorophore. Fluorescent microscopy was used to establish the extent of 
internalization of each. 
 
6.2. Materials and Methods 
6.2.1. Materials 
HepG2 cells were obtained from ATCC (American Type Culture Collection, Manassas, USA). 
Flourescein 5(6)-isothiocyanate (FITC) (Bioreagent, mixture of 2 components, ≥90 % (HPLC)), 
0.25 % Trypsin-EDTA Solution (2.5 g porcine trypsin and 0.2 g EDTA, 4 Na/L HBSS), Fetal 
Bovine Serum (FBS) (cell-culture tested, USA origin, sterile-filtered, hybridoma tested), 
Penicillin-Streptomycin Solution (Pen-Strep) (stabilized with 10 000 units penicillin and 10 mg 
streptomycin/mL, sterile-filtered) and Trypan Blue Solution (0.4 %) were all purchased from 
Sigma Aldrich (St. Louise, MO, USA). RPMI 1640 w: L-Glutamine, w: 2.0 g/L NaHCO3, sterile 
filtered, was purchased from Pan Biotech (PAN-Biotech GmbH, Aidenbach, Germany). A Bright-
Line Hemacytometer (supplied with two cover slips) was purchased from Sigma Aldrich (St. 
Louise, MO, USA). Tubes used for centrifuging were purchased from The Scientific Group, 
Randburg, South Africa. Tissue cell flasks and other cell culture equipment was purchased from 
Lasec (South Africa). The coated and uncoated optimized formulations were prepared as 
discussed in Chapters 3, 4 and 5. All other chemicals used were of analytical grade and 
employed as purchased. 
 
6.2.2. Employment of Aseptic technique for cell procedures 
 
Sterility and avoidance of cell contamination was ensured by aseptic method procedures put 
into place. Aseptic techniques provide a barrier against viruses, fungi and bacteria laden 
naturally in the air from reaching cell culture. The designated laboratory used for cell culturing 
and procedures is a sterile environment exposed to UV radiation when not in use. Before the 
commencement of any procedures as well as entering the sterile work area, good and proper 
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personal hygiene was made certain of and hands were washed. Gloves were worn to cover up 
skin, a sterile laboratory coat was used to cover up clothes that held dust and dirt and a mask 
was used to cordon off contamination from breathing or talking. The sterile work area was a 
laminar flow unit (Labotec, Midrand, South Africa) and its surface was wiped with 70% ethanol 
solution before placing in it cell culture and/or media and reagents that were used in cell 
culturing. All bottles, flasks and pipettes were sprayed with the alcohol before taking into the 
unit. Gloved hands were periodically rubbed with alcohol before and after leaving the laminar 
flow unit. A lit bunsen burner was used in the laminar flow unit with handling and work 
performed around the flame. All container mouths and closures were flamed upon opening and 
closing. Media and reagents for reuse were film sealed at their capped lids. All cell culture 
procedures were performed as rapidly as possible to minimize contamination.    
 
6.2.3. HepG2 cell culturing and cell maintenance protocols 
 
The HepG2 cell line used for the uptake study was cultured according to a standard protocol 
utilizing the RPMI 1640 media (with L-Glutamine and 2.0g/L NaHCO3). Media was 
supplemented with 10 %v/v FBS and 1 %
v/v Pen-Strep. Media and supplements were warmed to 
37 °C at each preparation time before adding to cell culture flasks. Frozen solutions were placed 
in warm water to thaw 45 minutes before preparation.  
 
6.2.3.1. Cell revival 
 
The first step in the culturing process was the revival of the cell line from frozen in storage. 
During preparation of media, cell revival required a doubling in the quantities of FBS and Pen-
Strep (20 %v/v and 2 %
v/v, respectively) due to the compromised state of the cells as a result of 
the environment it had been subjected to. It was crucial that this step be carried out swiftly to 
prevent death of cells. The frozen cells were left to thaw around the bunsen burner flame. The 
cells were immediately transferred to a sterile centrifuge tube and dispersed in a matched 
volume of media. They were then transferred to a T-25 cm3 cell culture flask containing 6-10mL 
media. The flask was gently tilted back and forth to swirl the contents and ensure uniform 
dispersion of the cells when undergoing cell attachment. The flask with cell culture was 
incubated at 37 °C in humidified air with 5 % CO2. The media was changed 24 hours later with 
standard undoubled quantities of media.  
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6.2.3.2. Cell subculturing 
 
Cell culture was viewed daily for their attachment and normal growth. A yellow-orange like 
discolouration of the media observed in the flask was a sign for a media change. When cells 
reached confluency, subculturing was necessary. HepG2 cells were allowed to grow to 75 % 
confluency. Thereafter, the removal of media from the flask was followed by rinsing of the cells 
using sterile PBS (0.1 M, pH7.4, 37 °C). Trypsin-EDTA (0.25 %) was added to the flask, swirled 
and left in for a few minutes for cells to change shape and complete the trypsinization process. 
The duration of this process varies among different cell lines. Trypsinization of HepG2 was 
relatively quick (±5 minutes). A confirmation of detachment was obtained through light 
microscope (Olympus CKS microscope, Olympus, Japan) viewing to observe cells floating 
completely. The culturing flask may also be tapped thrice gently on the side of cell attachment to 
dislodge cells, if necessary. A matched volume of media was added to the flask to dilute the 
Trypsin-EDTA as cell culture should not be exposed to pure Trypsin-EDTA longer than 
necessary. The Trypsin-EDTA-media contents were then transferred to a sterile tube and 
centrifuged at 5000 rpm for 3 minutes. A pellet of cells was noted at the bottom of the tube. The 
Trypsin-EDTA-media was discarded and 1 mL fresh media was added to the pellet with 
redispersion. Cells were then passaged to two T-75 cm3 holding 20 mL fresh media. Cells were 
viewed under the microscope for proper dispersion in each flask. 
 
6.2.3.3. Cell counting 
 
Cell counting was carried out on the day cell splitting/ passaging was required. A sterile 
hemacytometer was the instrument used for counting and this was done using the trypan blue 
exclusion assay. Trypan blue is a dye that stains the nuclei of non-viable or dead cells isolating 
them from live viable ones and allowing this distinction to be observed under the light 
microscope. A 0.4 %w/v trypan blue solution in sterile PBS (0.1 M, pH 7.4) was prepared for cell 
counting. A cell volume of 20 μL and a trypan blue volume of 60 μL were mixed together. This 
was a 1:3 ratio which produced a dilution factor of 4. Figure 6.2 depicts a hemacytometer with 
grid on which stained and unstained cells were displayed and visualized under the light 
microscope. The four quadrants of the hemacytometer grid (numbers depicted in Figure 6.2) 
that held cells not stained were counted and inserted into Equation 6.1 to obtain the total 
number of HepG2 cells. 
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Figure 6.2: Illustration of the Improved Neubauer Hemacytometer scrutinizing the grid layout, 
adapted from http://homepages.gac.edu/~cellab/chpts/chpt1/figure8.html, [Accessed August 5th, 
2014]. 
 
Number of cells counted
Number of quadrants counted
 ×  DF × 104 cells/mL                                                             Equation 6.1. 
 
where DF is the dilution factor used and 104 is a constant. Cells of 95 % viability were employed 
in ensuing uptake image tests. 
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6.2.3.4. Cell freezing 
 
Freezing of HepG2 cells was necessary for preserving them in storage encountering probable 
use in later stages of experimentation. The media in which they were frozen was constituted 
with a solution of 0.5 %v/v DMSO in FBS. Cells were counted before placing in the freezer and a 
number of 105 – 2X105 cells were allocated to 1 mL of freezing solution. However, cells had to 
be passaged at least twice before they could be used further for experimentation purposes to be 
sure of an optimal state. 
 
6.2.5. Preparation of the optimized ACNS samples and controls 
 
Internalization uptake studies necessitated at least 4 samples per measurement to ensure a 
thorough understanding of observations on microscopy images. This constituted: 
1. HepG2 cells; 
2. Optimized non-/ coated ACNS 
3. Optimized C-LA coated ACNS with HepG2 cells and 
4. Optimized non-coated ACNS with HepG2 cells. 
Sample numbers 1 and 2 served as the controls. FITC was used as the fluorophore on ACNS to 
detect their movement and receipt by cells in the subsequent fluorescent imaging evaluations. 
Coated and uncoated samples (2 mg/mL) were combined with FITC (1 mg/mL) in sterile PBS 
(0.1 M, pH 7.4). For conjugation to occur, this solution was stirred for 40 minutes at 37 °C whilst 
protecting the light-sensitive FITC from light. These samples containing both FITC conjugated to 
ACNS (FITC-ACNS) and free FITC were then dialyzed against 3 L deionized water for 24 hours 
to remove the free FITC. The dialyzing beaker was covered with foil to protect the FITC-ACNS 
from light. 
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6.2.6. Visualization of intracellular uptake of the fluorescent ACNS 
6.2.6.1. Confocal fluorescence microscopy imaging 
 
Confocal microscopy was utilized as the first method to visualize possible uptake of the ACNS 
systems through fluorescence detection. A quantity of 200 μL HepG2 cells (2 X 10
5 cells/mL) 
were dropped on cover slips that were placed in disposble petri dishes (BRAND®, 55 mm x 16 
mm) and carefully spread out to completely fill the cover slip. This was incubated at 37 °C and 5 
% CO2 to allow for the cells to attach to the slips and grow overnight. Care was taken by 
periodically monitoring the slips every hour to ensure the media had not fully dried out due to 
the warm temperature of the incubator. Media was carefully replenished if this was the case. 
FITC-ACNS coated and uncoated formulations were then added with 0.20 μm filter-sterilization 
(Millipore Co., Massachusetts, USA) together with media to cover slips in a ratio of 1:4. Controls 
received complete plain media (cells) and complete formulation. These were left for another 24 
hours to allow internalization to occur. Thereafter, FITC-ACNS-media were removed and the 
cover slips were washed thrice with sterile PBS (0.1 M, pH 7.4). A thin layer of PBS was left on 
and the slips were taken to a fume hood outside the sterile laboratory to fix the cells with 3 % 
paraformaldehyde. Paraformaldehyde is highly toxic and required the use of protective wear at 
the fumehood. Fixative solution was added to each cover slip at a volume of 2 mL. Fixing 
occurred for 15-30 minutes after which it was removed and each slip was washed with PBS (0.1 
M, pH 7.4) three to four times. They were left for 24 hours at 4 °C. Finally, the cover slips were 
mounted on slides with a drop of glycerol. They were left to dry for 3 hours before viewing for 
fluorescent uptake via microscopy (Zeiss LSM 780, Carl Zeiss Microscopy GmbH, Goettingen, 
Germany). 
 
6.2.6.2. High speed fiber-optic fluorescence microscopy live imaging 
 
The second method to detect fluorescent uptake of nanosystems was via a high speed fiber-
optic fluorescence microscope (Cellvizio® LAB, coupled with Microprobes and ImageCell™ 
Software; Visualsonics and Mauna Kea Technologies, USA). The cells with FITC-ACNS were 
visualized as floating entities on images thereby eliminating the step for cell attachment and 
growth. Media and FITC-formulations were mixed in a ratio of 1:4 and added with 0.20 μm filter-
sterilization to 2 mL eppendorf tubes containing 500 μL HepG2 cell culture (5 X 105 cells/mL). 
Tubes were incubated at 37 °C and 5 % CO2 for internalization to occur and images were taken 
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at 30 minutes and 24 hour post incubation time points to evaluate the rate of internalization into 
HepG2 cells. 
 
6.3. Results and Discussion 
 
6.3.1. HepG2 cell culturing 
 
HepG2 cells are human liver carcinoma cells which were cultured according to a standard 
protocol with Figure 6.2.1A, B and C depicting the morphology of the cells at different 
magnifications under Brightfield light. HepG2 are epithelial cells and cell growth of this particular 
cell line was relatively rapid, occurred in a monolayer format and required passaging every 2-3 
days. They also displayed a trend of aggregate growth in the flask. Cell death would occur if 
confluency approached 100 %. The changing of media was essential as media discolouration 
was a resultant feature of cells depleting the nutrients obtained from the supplements (FBS, L-
Glutamine and NaHCO3) for their growth found therein. The colour change to yellow was due to 
the acid production during cellular metabolism. 
 
6.3.2. Visualization of intracellular uptake of fluorescent ACNS by means of confocal 
fluorescence microscopy imaging and high speed fiber-optic fluorescence microscopy 
live imaging 
 
The investigations made on cellular uptake called for samples of plain cells and plain 
nanosystems together with the custom test nanosystems as this allowed for a resolute 
comparison of the efficacy of ACNS coated with C-LA against that lacking coating on the uptake 
by HepG2 cells. Visualization of the ACNS inside a cell is made possible through fluorescence 
emanating off FITC. FITC bears the highly amine reactive isothiocyanate entity that is the main 
conjugator to amine functional groups on molecules (Schmitt et al., 2007). Free FITC removal 
was a prerequisite to prevent erroneous misleading fluorescent images. 
 
ACNS internalization observations through confocal fluorescent imaging are demonstrated in 
Figure 6.3 2A i) & ii) and 2B i) & ii) and 3A i) & ii) and 3B i) & ii) 24 hours after incubation, for the 
uncoated optimized FITC-ACNS and C-LA coated optimized FITC-ACNS, respectively. The 
snapshots are taken in Brightfield light initially followed by a comparison against their respective 
fluorescent images in the unchanged position and magnification (40X) observed. It is quite clear 
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that a distinct enhanced fluorescence is found in cells incubated with the FITC-ACNS system 
that was coated with C-LA [Figure 6.3 3A i) & ii) and 3B i) & ii)] while a dimmer fluorescence is 
noted within cells with the uncoated FITC-ACNS system [Figure 6.3  2A i) & ii) and 2B i) & ii)].  
 
 
1A B 
 C 
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Figure 6.3: Confocal microscopy images of 1. Plain HepG2 cells at magnifications of A - 10X, B 
- 20X and C - 40X; 2. Uncoated optimized ACNS uptake (40X magnification) under A i) & ii) – 
2Ai) 2Bi) 
2Aii) 2Bii) 
3Ai) 
3Aii) 
3Bi) 
3Bii) 
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Brightfield light and B i) & ii) - Fluorescent light and 3. C-LA Coated optimized ACNS uptake 
(40X magnification) under A i) & ii) - Brightfield light and B i) & ii) - Fluorescent light (Refer to 
attached CD for electronic image of Figure 6.3 depicting fluorescence clarity). 
 
Similarly, the live fluorescent images of fiber-optic imaging (Figure 6.4) display an augmented 
uptake of C-LA coated FITC-ACNS after both 30 minutes (d) and 24 hours (e) of incubation 
compared to uncoated FITC-ACNS at 30 minutes (b) and 24 hours (c) of incubation. An 
augmented uptake is designated by a brighter fluorescent cluster. These are the floating HepG2 
cells harvesting ACNS fluorescent particles. Figure 6.4a shows an image of the appearance of 
plain FITC-ACNS in solution. The yellow arrows indicate mild aggregation of FITC-ACNS to 
differentiate between HepG2 cell internalized ACNS shown as the larger clusters in Figure 6.4b, 
c, d & e. Also quite clear-cut is the observance that the longer the incubation time of the ACNS 
systems with cells, the greater the internalization into the cell (30 minutes  24 hours). 
 
The reason for both cases of imaging reflecting coated C-LA ACNS as hepato-preferrable lies 
with the prominent liver targeting ligand, linoleic acid, employed in the make-up of the system. 
Linoleic acid is one of the fundamental polyunsaturated fatty acids that exist and is often used 
as a hepatic trigger entity by virtue of its pivotal role occurring in the liver (Cheong et al., 2009), 
because the liver is an organ that performs a cardinal role in lipid metabolism and via the 
metabolic pathway- fatty acid oxidation, linoleic acid is markedly implicated (Macarulla et al., 
2005). The link resides here.  
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Figure 6.4: High speed fiber-optic fluorescent live images of a. fluorescent optimized ACNS, b. 
fluorescent uncoated optimized ACNS and HepG2 cells (>30 minutes incubation), c. fluorescent 
uncoated optimized ACNS and HepG2 cells (>24 hours incubation), d. fluorescent C-LA coated 
optimized ACNS and HepG2 cells (>30 minutes incubation), e. fluorescent C-LA coated 
optimized ACNS and HepG2 cells (>24 hours incubation). 
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6.4. Concluding Remarks 
 
Effectual binding of FITC molecule onto ACNS surface both coated and uncoated was 
accomplished. Two types of fluorescence microscopy techniques were employed to investigate 
the nanoparticle distribution within HepG2 cells. It was quite apparent to see that in large 
quantities, the rapid uptake of ACNS formulation by HepG2 cells was that which was coated 
with chitosan-linolate. This resembled active targeting. The content of ACNS surface therefore 
stipulated the kinetics of cellular internalization. The presence of chitosan relaying enhanced 
binding, a liver cells attraction toward linoleic acid as a consequence of lipid metabolism, and a 
favorable <100 nm particle size all owed to the enhanced preferential ACNS binding at the cell 
surface and subsequent internalization. 
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CHAPTER 7 
IN VIVO ASSESSMENT OF THE ACNS VIA INTRAPORTAL IV ADMINISTRATION IN THE 
RAT MODEL: A PILOT STUDY 
7.1. Introduction 
 
The information acquired thus far from previous chapters on in vitro work performed is 
beneficial only when the conclusive results are equated to in vivo data. The reason for this is 
because of the possible and real threat to mankind or even an environmental threat that 
could be perilous as a result of the compound being surveilled (Han et al., 2012).  
  
Animals are crucial to comprehending and exploring therapies that are essential for a variety 
of both human and animal ailments. As models, they are able to aid in deciding whether 
medicinal products and many other compounds are practical, adequate and safe (Stokes 
and Marsman, 2014). The introduction of a chemical substance into an animal will lead to 
interactions within its body at different sites where information on the unforeseen side effects 
or safety of the substance being studied can be acquired. The intricacy of pharmacokinetic 
and pharmacodynamic data cannot be replicated solely on cell cultures or laboratory 
procedures (in vitro testing) simulating a living physiological environment (Bertau et al., 
2008). However, animal welfare is equally pivotal and should not be neglected. When 
necessity calls for in vivo examinations, the 3Rs ideology for animal welfare should never be 
lost sight of: 
 Reduction entails using a minimal amount of animals concurrently achieving the pertinent 
information necessary to develop valuable conclusive data. 
 Refinement entails a change that is realized during the study that may possibly require a 
reduction in the harshness of the inhumane operations the animals are to be subjected 
to. 
 Replacement entails applying scientific methods that are feasible on non sentient matter 
instead of sentient animals (Madden et al., 2012). 
 
Chronic liver disease encompasses a liberal loss of liver function and transformation of the 
liver parenchyma into fibrotic and cirrhotic tissue. Pathogenesis of this disease normally 
engenders portal hypertension and ultimately complete hepatic failure. Causative agents of 
chronic liver disease are hepatitis B and C viral infections, both nonalcoholic and alcoholic 
fatty liver disease, schistosomiasis infections and biliary fibrosis. Again, complete and 
thorough comprehension of liver disease pathogenesis is necessary on a dependable 
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experimental animal model. Thus far, an appropriate animal model has not been identified 
as one suitable enough to emulate hepatic disease. Only certain attributes of the disease are 
currently possible to assume in an animal model. Rodents are noted by investigators as 
most relevant animal models due to their small size, are short-lived and as a result of these, 
are particularly easy maintenance. Moreover, they have a considerably noteworthy genetic 
resemblance to humans allowing them to be most suitable a choice of model for human liver 
disease studies (Liu et al., 2013). 
 
The liver acquires approximately 75 % of its blood supply from the portal vein therefore an 
additional and enhanced liver targeting approach would be administration of ACNS via an 
intraportal injection. In the study of portal haemodynamics for instance, a procedure allowing 
for an accessible reproducible administration of liquid solutions into the portal circulation of 
an animal model would be favored. This expedites inquiry into a drugs metabolism, possible 
toxicity of certain drugs on the liver, as well as examining and evaluating the functioning of a 
drug targeted in the treatment of hepatic diseases (Blumgart et al., 1971). There are a lot of 
complications related to injections into the hepatic circulatory system and as such, injections 
into the tail veins of rodents are merely implemented in in vivo studies. The problem with this 
is the small analogy with that of a clinical setting (Bagi and Andresen, 2010). Figure 7.1 
expresses the differences in accumulation of microbubbles in the liver that are seen when 
the injection administrations occur via A) tail vein, B) portal vein and C) hepatic artery. 
 
Figure 7.1: Ultrasound images of livers in the rodent animal model following injection 
administrations of microbubbles in A) tail vein, B) portal vein and C) hepatic artery. 
Enhanced microbubble contrast (green) is achieved with hepatic artery or portal vein with 
minimal contrast observed in tail vein (Adapted from Bagi and Andresen, 2010). 
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The in vivo determination of drug released within the liver and evaluating an efficient liver 
targeting ability of the novel drug delivery system compared to the conventional systems are 
one of the significant outcome measurements in this chapter. This was achieved through 
incorporation of a targeting appendage polymer design in the outer make-up of the drug 
delivery system for attachment, a liver targeting fatty acid incorporated in these appendages 
and an administration route (intraportal) that would reach the liver first. 
 
7.2. Materials and Methods 
7.2.1. Materials 
Sprague Dawley rats employed in this study were received as per the protocols of the 
Central Animal Services (CAS) of the University of the Witwatersrand. Lamivudine (LMV) 
was received as an ex-gratia sample from Adcock Ingram Ltd. (Germiston, Gauteng, South 
Africa). Zidovudine (AZT) was purchased from GlaxoSmithKline (Middlesex, UK). Double de-
ionized water was obtained from a Milli-Q system, (Milli-Q, Millipore, Johannesburg). All 
solvents utilized for UPLC-UV detection were of UPLC grade whereas all other reagents 
were analytical grade. 
 
7.2.2. Animal Ethics Clearance 
 
The Animal Ethics Screening Committee (AESC) of the University of the Witwatersrand 
provided an animal ethics clearance for this research study (No. 2014/01/C) (Appendix F). 
 
7.2.3. Animal Housing Conditions and Husbandry 
Housing conditions were maintained according to the CAS Standard Operating Procedures 
(guidelines set by the South African National Standard for the care and use of animals for 
scientific purposes). In both pilot and main study, the Sprague Dawley rats were housed in single 
in cages at the CAS which were monitored on a 12 hour light/ 12 hour dark cycle (Figure 7.2). 
They were provided with water and rat feed ad libitum. Rats were also observed daily for one hour 
periods to detect behaviour changes. They were weighed on a weekly basis and a complete fill-
out of a score sheet was made with observations as a result of the state of the animals noted.  
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Figure 7.2: Digital image showing Sprague Dawley rats housed in single in cages at the CAS 
animal experimental room. 
 
7.2.4. In vivo studies on the rat model 
7.2.4.1. Need for a Pilot Study 
7.2.4.1.1. Logistic time points 
A pilot study was conducted to evaluate a definite need for a 12 hour time point as it clashed with 
and disrupted CAS units operating times. Information acquired would evaluate a definite need for 
a 12 hour time point. CAS staff may not be available at this time point to conduct necessary 
surgical procedures and drug administrations in view of the CAS units operating times. Findings 
from blood samples with reference to fate of drug at 0, 3, 5, 8 and 24 hours may provide an insight 
into definite time points for use in main study that could allow for the exclusion of a 12 hour time 
point. 
 
7.2.4.1.2. Surgical approach 
The procedure described for the intraportal vein injection (Jacob et al., 2004) was one untried by 
the CAS veterinarians. A test of this method on a small number of animals would allow an 
141 
 
assessment of feasibility of the method by observing the animal and its state supposing death 
occurred due to possible excessive bleeding in the process and/or embolism in the liver and 
lungs. A main study could not commence if this had developed on all rats. 
 
7.2.4.2. Experimental Design 
Twenty rats with an initial weight of ~225 g were assigned to 4 groups (5 rats per group) for the 
pilot study. The main study comprised one hundred rats with an initial weight of ~225g which were 
assigned to 4 groups (25 rats per group) (Refer to Flow diagram, Figure 7.3). Group 1 was a 
placebo group of healthy rats which received an injection of the non-drug loaded C-LA coated 
ACNS. The group was administered with the nanosystem intravenously via the portal vein. The 
test group (Group 2) was administered with the LMV-loaded C-LA coated ACNS via intraportal 
injection. Group 3 and Group 4 were comparison groups. Group 3 involved the model drug, LMV 
being administered orally in healthy rats. Healthy rats of Group 4 received LMV administered 
through an intravenous bolus injection via the tail vein. The control non-drug loaded delivery 
system (placebo group) and the drug-loaded delivery system (test group) were the only groups 
that received an intraportal injection. All rats were caged singly post-surgery. For each group in 
the main study, a biodistribution imaging procedure was done 15 minutes before blood sampling 
analysis and livers were removed immediately after blood sampling and euthanasia. 
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120 RATS 
Test 
Pilot study 
 
Placebo Comparison 1 Comparison 2 
Group 1:  
5 rats: 500μL 
portal vein 
injection 
(25mg/kg) of the 
non-drug loaded 
C-LA coated 
ACNS 
Group 2:  
5 rats: 500μL 
portal vein 
injection (25mg/kg) 
of the LMV-loaded 
C-LA coated 
ACNS 
Group 3 
5 rats: 500μL 
oral (25mg/kg) 
administration 
of LMV 
Group 4 
5 rats: 500μL 
intravenous 
(25mg/kg) 
bolus injection 
of LMV 
Findings revealed by the pilot study in terms of feasibility, logistic time points and surgical 
procedure approaches allowed the following main study to commence 
At 0 hours, the anaesthetic standard protocol (left) was administered to 
all 20 rats after which they were surgically incised: Placebo and test 
groups were injected and treated with the non-drug loaded and drug-
loaded intraportally administered nanosystems, respectively, and were 
recovered; comparison groups were recovered and received the oral 
administration and intravenous bolus injection of lamivudine (Refer to 
groups above). 
Anaesthetization 
with 
intramuscular 
Anaket
®
 
(Ketamine, 
100mg/kg) and 
Chanazine
® 
(Xylazine, 
5mg/kg) 3-4 
minutes before 
surgical incision 
and blood 
sampling. 
Sampling was conducted at 
pre-determined time intervals: 
0, 3, 5, 8 and 24 hours post 
administration of all 
formulations. A group of 5 rats 
were assigned to these time 
points. 
Processes were undertaken to monitor the animals and ensure a general state of well-being in 
all rats by use of a score/evaluation sheet and periods of observation of animals to provide a 
progress report. 
Main study 
Animals were euthanized with 
sodium pentobarbital after blood 
sampling. 
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Figure 7.3: Schematic representation of in vivo animal studies to be conducted on the rat 
model with depiction of assigned experimental and control groups. 
Group 1 
25 rats: 500μL 
portal vein 
injection 
(25mg/kg) of the 
non-drug loaded 
C-LA coated 
ACNS 
Group 2 
25 rats: 500μL 
portal vein 
injection 
(25mg/kg) of the 
LMV-loaded C-LA 
coated ACNS 
Group 3 
25 rats: 500μL 
oral (25mg/kg) 
administration 
of LMV 
Group 4 
25 rats: 500μL 
intravenous 
(25mg/kg) 
bolus injection 
of LMV 
Processes were undertaken to ensure a general state of well-being in all rats 1 week prior to 
experimentation by use of a score/evaluation sheet and periods of observation of animals. 
Anaesthetization with 
intramuscular Anaket
®
 
(Ketamine, 100mg/kg) and 
Chanazine
® 
(Xylazine, 5mg/kg) 
3-4 minutes before blood 
sampling 
At 0 hours, the anaesthetic standard protocol was administered to all 100 rats after which they were 
surgically incised: Placebo and test groups were injected and treated with the non-drug loaded and 
drug-loaded intraportally administered nanosystems, respectively, and were recovered; comparison 
groups were recovered and received the oral administration and intravenous bolus injection of 
lamivudine (Refer to groups above). 
Sampling was conducted at 0, 3, 
5, 8, 24, 48, 72 and 96 hours 
post administration of all 
formulations. A group of 25 rats 
was assigned to each of these 
time points. 
All 100 rats undertook the biodistribution study via the Vevo 2100
® 
micro ultrasound imaging 
system. The biodistribution of the nanoparticles were observed in the rat via the Vevo 2100
® 
micro 
ultrasound imaging system at 15 minutes before respective sampling time point. Rats underwent 
gas anaesthesia (2% Isofluorane) for the duration (10-15 minutes) of imaging and analysis with the 
Vevo 2100
® 
micro ultrasound imaging system. 
Blood samples were collected from the rats and stored at -70°C until UPLC could be 
performed. 
Animals were euthanized with sodium 
pentobarbital after blood sampling. 
 
Placebo Comparison 1 Comparison 2 
Livers of all rats were surgically 
removed for drug detection analysis. 
Test 
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7.2.5. Intricate intraportal injection surgical procedure 
A surgical procedure was performed on all groups of rats initially, although not necessary for 
respective treatments and administrations, but to maintain animals in a standard state due to 
the surgery that is necessary for the intraportal injection in Groups 1 and 2. It took 10-15 
minutes to anaesthetize, open, inject, close and recover each rat.  In Groups 1 and 2 rats, a 
transverse incision was made directly beneath the xyphoid process towards the animals left 
side. The portal vein was located, isolated and an intraportal injection was performed slowly 
without excessive pressure to avoid complications and the death of the animals (Jacob et al., 
2004). A volume of 500 μL was injected into the portal vein. Rats of Groups 3 and 4 were 
anaesthetized and the same incision was performed after which they were closed and 
recovered. All of the above applied to the pilot and the main study. The registered 
veterinarians did not have experience with the technique of intraportal injection therefore the 
pilot study provided insight into the feasibility of the surgical approach. Figure 7.4 outlines 
the intricate intraportal injection surgical procedure. A description of the procedure is as 
follows: 
a) Anaesthetized rat shaven, prepared and ready for surgery. 
b.i – b.iii) Transverse incision being made above liver. 
c.i – c.vi) Locating the portal vein. 
d) Slow and controlled injection into the portal vein. 
e) Careful placement of organ back into abdominal cavity.  
f.i – f.iii) Suturing of incision. 
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Figure 7.4: Successive digital images depicting the entire portal vein injection surgical procedure. 
 
1
4
5
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7.2.6. Animal welfare and humane end-points 
The recovery period post intraportal surgery was a critical stage to ensure scrutinized observation 
and monitoring of animals. Figure 7.5 depicts the contribution to animal welfare in providing an 
environment most suitable to the specific needs of the animals by provision of heat to ease the 
discomfort experienced in recovery. Analgesia was employed when needed especially for rats of time 
points ≥24 hours, immediately, to relieve pain experienced by the rats as a result of the complex 
surgery. When any altered or disparate behaviour of the rats were recognized, they would have 
immediately been removed from the study. Use of score sheets and twice daily observation periods 
ensured the welfare of the animal and avoidance of any suffering. The following were clinical signs 
that would have required the rat to be euthanized: 
 Signs of internal bleeding through stitches; 
 Rats that lost 15 % of their body weight when compared to controls; 
 Rats that lost 10 % of their body weight in 24 hours; 
 Self-mutilation of the feet and 
 Rats that developed seizures or convulsions (Schoefield, 2012). 
Any of the above wayward findings would have allowed for pertinent data in evaluating the ACNSs 
biosafety. 
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Figure 7.5: Digital images of recovery stage post-surgery; a) Rat 1 from group A recovering from 
anaesthesia, b) A recovery room with blankets and heater. 
 
7.2.7. High-frequency ultrasound preclinical imaging 
 
Ultrasound imaging was used to observe the biodistribution of the ACNS within the rat using the Vevo 
2100® Micro Imaging Platform enhanced with the Cellvizio® Lab Module (VisualSonics (Pty) Ltd, 
Toronto, Ontario, Canada). This was readily observed due to the impedance mismatch between the 
polymeric nanoparticles and body tissues/fluids. Imaging was conducted on anaesthetized rats 
following drug and drug delivery system administrations to the relevant animal groups 15 minutes 
a) 
b) 
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before a sampling time point. The rat was anaesthetized with xylazine and ketamine (1:4 mixture, 0.1 
mL/100g) at CAS before being taken to the Dept. of Pharmacy and Pharmacology laboratory to 
perform the ultrasound imaging. The anaesthetized animal was placed on the stage fitted with a 
heated pad and its snout placed in the opening of the tube delivering 2 % Isofluorane gas 
anaesthesia and oxygen (Figure 7.6). A warmed gel specific to ultrasound imaging was gently 
smeared on the shaved area of the rat exposing the surgical stitches in the vicinity of the liver. The 
probe was placed on the area of interest and imaging was conducted. 
 
 
Figure 7.6: Digital image of anaesthetized Rat 3A undergoing an ultrasound imaging procedure. 
 
7.2.8. Blood and liver sampling 
 
Blood samples and liver tissue samples were obtained from rats for drug detection in Ultra 
Performance Liquid Chromatography (UPLC) analysis. These were terminal procedures for each 
individual rat to allow for sufficient blood collection and organ removal (Beeton et al., 2007). Blood 
sampling was carried out to determine that minimal to no drug was released from the delivery system 
in the circulatory system due to release in the liver (hepatic system). The sampling was taken via 
Scanning 
Gas 
Stitched-up 
surgical incision 
Stage 
Animal ID 
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intracardiac puncture in rats. Blood samples of 5 mL were acquired with a sterile syringe while the 
animals were under anaesthesia with IM Anaket® (Ketamine, 100 mg/kg) and Chanazine® (Xylazine, 
5 mg/kg). Sampling was conducted at fixed time intervals (Refer to Figure 7.2) and blood samples 
were collected in vacutainer tubes containing clotting factor to draw out serum. Animals were then 
euthanized with sodium pentobarbital. After euthanasia, the livers of the rats were extracted for UPLC 
analysis. The blood tubes were left to stand overnight at 4 °C for collection of plasma the next day. 
The supernatant, containing the plasma, was carefully aspirated and transferred into clean 2 mL 
eppendorf tubes and were put to freeze at -80 °C immediately till further UPLC analysis.  
 
7.2.9. Liver removal and treatment 
 
The livers of euthanized rats were surgically removed to be homogenized and evaluated 
through UPLC for any drug release in the liver. The liver removal surgery took 1-2 minutes for 
each rat. The rat was opened up with a medial incision and the liver was revealed. It was 
carefully cut, removed and transferred immediately to a beaker of 100mL ice-cold 0.9 % NaCl 
solution to reduce its temperature. It was further placed in 10 %v/v formalin solution and stored 
in liquid nitrogen until homogenization and analysis of the organ could commence. Figure 7.7 
shows a liver that was removed at the 8 hour time point of rat from Group C. 
 
 
 
Figure 7.7: Digital aerial view image of liver removed from Rat 1 Group C in 10 %v/v 
formaldehyde solution. 
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For the homogenization process, 100 mg/mL of liver tissue was ground to a pulp with sterile saline 
using a pestle and mortar in a fumehood. The liver pulp was then transferred to ice and underwent 
further homogenization by non-pulsed ultra-sonication for 10 minutes at an amplitude of 80 (Vibra-
Cell Ultrasonicator, Sonics, USA). The thoroughly homogenized liver was then transferred to clean 
eppendorf tubes to be centrifuged on high at 15000 rpm for 15 minutes (Universal 320R, Hettich 
Zentrifugen, Germany). Supernatant was aspirated with a pipette and transferred further to clean 
tubes for storage at -80 °C for UPLC analysis. 
 
7.2.10. Applying Ultra Performance Liquid Chromatography to ascertain LMV content in blood 
and tissue samples 
 
Sensitive analytical methods for quantification are required in order to improve the understanding 
toward the relationship between pharmacokinetics, pharmacology and the bioavailability of LMV 
within a system (Wang et al., 2009). UPLC is an analytical method used to quantify and improve the 
analysis of samples encountered during pharmaceutical development (Wren et al., 2006). The blood 
and liver samples were analyzed to gather information about the drug molecule through UPLC to 
determine drug concentration against time. The concentration of LMV from blood and livers sampled 
during the study was used to determine the ability of the drug delivery system to be superior than the 
comparators by achieving better drug release profiles. 
 
7.2.10.1. Ultra Performance Liquid Chromatography analysis conditions: Washes, mobile 
phases and separation parameters 
 
Chromatographic detection and quantification of LMV was performed making use of a Waters 
AcuityTM Ultra Performance Liquid Chromatographic (UPLC) system (Waters Corporation, Milford, 
Massachusetts, USA) which comprised a binary solvent manager, a sample manager and was fitted 
with a photodiode array detector (PDA). An Acuity UPLC® HSS T3 1.8 μm; 2.1x150 mm analytical 
column (Waters Corporation, Dublin, Ireland), fitted to a VanGuardTM Pre-column 3/Pk 2.1x5 mm 
column (Waters Corporation, Dublin, Ireland), was employed for drug detection at a temperature of 40 
°C. Before proceeding with runs, the machine had to be primed with a standard set of solvents that 
consisted of 100 % methanol, 100 % acetonitrile (ACN), a strong wash made up of 90/10 ACN/water 
and a weak wash made up of 10/90 ACN/water. Table 7.1 shows the gradient method that was 
employed for detection and quantification of LMV with Zidovudine (AZT) being employed as the 
internal standard, and mobile phases of 0.2 % Formic acid in water (A) and 100 % ACN utilized. 
151 
 
 
Table 7.1: UPLC gradient method for the elution of LMV and AZT (internal standard). 
Time (min) Flow Rate (mL/min) 0.2% Formic Acid % Acetonitrile 
0 0.5 90 10 
1.0 0.5 70 30 
1.5 0.5 90 10 
 
The photoiodide UV/vis detection occurred at 277 nm. The sample injection volume was 10 μL and 
the runtime spanned 3 minutes. All solvents and solutions were filtered with 0.22 μm membrane filters 
(GHP Acrodisc® 13 mm Syringe Filters, Pall Corporation, New York, USA). 
 
7.2.10.2. Preparation of stock and standard solutions 
 
A stock solution of LMV was prepared to be used for the working standard solutions in the 
concentration range 8-40 μg/mL (n=5). This was achieved by dissolving 10 mg of LMV in 100 mL 
ultra-pure double de-ionized water (Milli-Q Gradient, Millipore, MA, USA, electrical conductivity 18.2 
MΩ.cm at 25 ˚C) and serial dilutions made thereof. The internal standard, AZT, was prepared and 
used at an unvarying concentration of 500 μg/mL. 
 
7.2.10.3. Verifying of optimal solvent/s to be used for liquid-liquid drug extraction procedure 
 
A liquid-liquid extraction procedure was selected because of LMVs approving low protein binding feat. 
The chosen solvent/s were pipetted at a volume of 1500 uL into plasma and liver tissue homogenate 
aliquots of 100 uL in eppendorf microtubes (Eppendorf AG, Hamburg, Germany), followed by 
vortexing (Vortex-Genie 2, Scientific Industries Inc., Bohemia, NY, USA) for 1 minute to extract the 
proteins that would be found therein. The solvent-plasma/solvent-liver tissue homogenate samples 
were then centrifuged on high at a speed of 12000 rpm for 10 minutes at 4 °C (Universal 320R, 
Hettich Zentrifugen, Germany). The supernatant was decanted into clean eppendorf tubes and 
samples were dried completely directing a gentle stream of N2 into the tubes in a fumehood. The 
residue was reconstituted with 500 uL of mobile phase A and spiked with the uniform internal 
standard concentration, before being filtered into the UPLC Waters glass vials and placing in the 
sample compartment. 
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7.2.10.4. Precision and accuracy validation 
 
Inter- and intra- day accuracy and precision elucidation is a between-day and within-day 
reproducibility test of the assay and involved the preparation of three different spiked concentrations 
of plasma samples processed as three replicates and treated by the extraction procedure defined in 
Subsection 7.2.10.3 on three discontinuous days (Inter-day precision) as well as repeatability in one 
day (Intra-day). Drug concentrations were prepared in the range of 1, 2.5 and 5 µg/mL. The validation 
was computed by means of percentage relative standard deviation (%RSD) in Equation 7.1. 
 
%RSD = 
SD
Mean
 × 100                                                                                                           Equation 7.1 
 
where SD is standard deviation. 
  
7.2.10.5. Construction of a calibration curve to gauge drug quantities in blood plasma and liver 
treated samples 
 
A calibration curve was constructed to quantify the levels of LMV found in blood plasma compared to 
the liver of rats.  Frozen plasma and liver treated samples were thawed and 100 µL of sample were 
transferred to clean 2 mL eppendorf tubes. Added to this were the extraction solvents mentioned in 
Subsection 7.2.10.3 and profiled in imminent subsections. Tubes with sample were subjected to the 
extraction procedure portrayed in Subsection 7.2.10.3. Following spiking with the internal standard, 
samples were filtered and analyzed. 
 
7.3. Results and Discussion 
 
7.3.1. Conclusive findings from the Pilot study for the commencement of the Main study 
 
A pilot study (Figure 7.3) was conducted to: 
 Evaluate a definite need for a 12 hour time point as it clashes with and disrupts CAS 
units operating times; 
 Assess the feasibility of the surgical approach which involves an intraportal vein injection 
procedure previously untried by CAS veterinarians by observing the animal and its state 
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supposing death occurs due to possible excessive bleeding and/or embolism in the liver 
and lungs. 
 
7.3.1.1. Day 1 – Practice Surgery 
 
Three CAS unit rats were used to perform a mock surgical procedure of portal vein injection. A 
26 gauge needle was used for the intraportal vein injection of sterile water. Outcomes: The 
entire surgical procedure proved successful, in terms of the mid-line incision and location of the 
portal vein, up until the injection with the 26 gauge needle. It was found that the needle gauge 
was slightly large for the tiny vessel and caused the rat to bleed incessantly. It was gathered 
that a smaller gauge needle (27-30 gauge) was needed to cause minimal to no vein damage for 
intraportal administration. 
 
7.3.1.2. Day 2 - Intraportal vein injections on comparison groups C and D 
 
Five rats from group C and five rats from group D were treated with oral and IV LMV, 
respectively. Portal vein injections were not necessary for these groups; however a sham 
surgery was conducted on all experimental animals to ensure a standard state for accurate 
results. The blood sampling and euthanasia time points to be assessed for the pilot study were 
0, 3, 5, 8 and 24 hours. This occurred in a random, alternating fashion with rats assigned to the 
8 hour time point undergoing the experimental procedures first. Outcomes: A procedure was 
undertaken for accommodating the 8 hour time point to occur within CAS operating times 
(08:00-16:30). Therefore, rats for both groups belonging to the 8 hour time point were worked 
on first which brought the end of the day’s experimental procedure to 16:35 the latest. The 
preparations before the procedures commence needed to occur 15 minutes in advance (07:45) 
to save up on unnecessary lost time. 
 
7.3.1.3. Day 3 – Intraportal vein injections on placebo and test groups A and B 
 
Five rats from group A and five rats from group B were treated with the C-LA coated LMV-
loaded ACNS and C-LA coated non-drug loaded ACNS, respectively, via the intraportal injection 
administration route. The time points of 0, 3, 5, 8 and 24 hours were assessed in the same 
manner as demonstrated with groups C and D in Subsection 7.3.1.2. Outcomes: Day 3 involved 
the complicated intraportal injections which required thorough concentration and careful animal 
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handling. For this reason, the last sampling and intracardiac puncture 8 hour time point was 
expected to shift slightly later than anticipated. Therefore compensation for this would be an 
earlier start to the days procedures (>15 minutes in advance). Main study sampling points would 
proceed for more days after the 24 hour time point therefore a lack of a 12 hour time point would 
certainly not misconstrue drug level readings in the least bit. A thinner 27 gauge needle was 
used for intraportal injections of Day 3 to evaluate its efficacy. Amongst ten rats, two displayed 
problems. Rat 1 A had lost a considerable amount of blood during the procedure and had to be 
treated with Ringer’s Lactate solution to replace the lost volume. Rat 5 A had to be terminated 
as it showed continuous blood loss from the wound, whilst in its cage throughout the day. The 
27 gauge needle was clearly not thin enough. As a result, the main study had to make use of a 
much thinner 29 or 30 gauge needle to avoid damage to the vein and ensure bleeding did not 
occur at all at the site of injection. 
 
7.3.1.4. Summary and Resolutions 
 
The exclusion of a 12 hour time point was carried through and an intraportal vein injection on 
the rat model was feasible but with use of an extremely thin needle. Thirty gauge needles had 
been sought, ordered and received for its use in the main study. 
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7.3.2. High-frequency ultrasound preclinical imaging 
 
High-frequency ultrasound imaging is a non-invasive procedure that encompasses a process of 
sound wave generation from transducers that pass into a living entity. When this occurs, the 
waves are reflected back and the transducer then converts them into 2D and 3D images. 
Anaesthetized rats, 15 minutes before a sampling and termination point, were imaged in the 
supine position (Figure 7.6) with the transducer being positioned over the rats liver which is 
suspended just beneath the diaphragm anatomically. Images obtained were to show the 
presence of C-LA coated ACNS (as well as its movement through the vein through the 
instruments capability of 3D tracking) due to the acoustic mismatch between the materials of the 
ACNS from that of body tissue (Yang et al., 2008). Figure 7.8 is an ultrasound image acquired 
at the last time point of 96 hours displaying the median/cystic lobe of rat livers administered with 
the C-LA coated LMV-loaded ACNS (A), C-LA coated non drug-loaded ACNS (B), oral LMV (C) 
and IV LMV (D). The red circled parts denote the homogenous liver parenchyma. A healthy rat 
liver would show medium level echogenicity on an ultrasound image as normal distinguishing 
features together with a regular hepatic surface (Resende et al., 2011). This is also denoted by 
the red circles. However, an enhanced echogenic portion on the liver lobe is evident in Figure 
7.8 A & B of rats that were administered with the C-LA coated ACNS systems that is absent in 
Figure 7.8 C & D. The first reason for this lies in the high concentration of cryoprotectant, 
mannitol, which was used in the formulation of the C-LA ACNS in its initial stages of preparation 
for size maintenance. Mannitol is known to have an acoustic property that causes ultrasound 
reflectivity and produces echogenic systems in which it is incorporated greater than any other 
sugar (Huang et al., 2001). The other reason for the high contrast liver lies in the targeting 
ligand used in the make-up of the coating of the ACNS, linoleic acid. It is well-known that linoleic 
acid is a fatty acid that is classified as a lipid. Materials such as lipids are also highly echogenic 
because they acquire the potential of acoustic backscattering as a result of the gas/air bubble 
they are capable of capturing causing the echogenic effect (Son et al., 2014). This proves in 
Figure 7.8 A & B images that the C-LA coated ACNS is still present in the liver 4 days later 
compared to the conventionals (Figure 7.8 C & D) which show minimal to no echogenicity. 
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Figure 7.8: 96 hour time point ultrasound liver images of rat administered with A) Optimized C-LA 
coated LMV-loaded ACNS, B) Optimized C-LA coated non drug-loaded ACNS, C) Oral LMV and D) 
IV LMV. 
 
7.3.3. Elution times of LMV and the internal standard 
 
The chromatographic conditions employed for quantification and detection of LMV and its internal 
standard, AZT, proved to be successful as chromatographic data showed peaks that corresponded to 
their elution times. Figure 7.9 reflects the 2D chromatogram plot and its interrelated 3D PDA plot of 
LMV and internal standard spiked in ACN:double deionized water (1:1) (A) and LMV and internal 
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standard spiked in blank plasma (B). LMV was the first to elute at a retention time of 0.905 minutes 
and internal standard at 1.756 minutes in a 1:1 ratio of ACN and double deionized water. However, a 
slight difference in elution times was noted with both drug and internal standard when spiked in a 
blank plasma sample. A difference of 0.017 minutes was seen when LMV separated in the blank 
plasma sample with elution occurring earlier at 0.888 minutes. Likewise, with AZT a slightly higher 
difference of 0.024 minutes was eminent in its elution with the blank plasma sample occurring at 
1.732 minutes. 
 
 
 
 
Figure 7.9: Elution depictions on 2D and PDA 3D plot for A. Spiked LMV (Retention time = 
0.905 minutes) and AZT (Retention time = 1.756 minutes) in double deionized water and B. 
Spiked LMV (Retention time = 0.888 minutes) and AZT (Retention time = 1.732 minutes) in 
blank plasma sample. 
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7.3.4. Substantiation of most optimal solvent/s for liquid-liquid extraction in drug detection 
clarity and recovery 
 
The blood plasma samples and liver tissue treated samples from rats must be ‘clean’ before injection 
into the UPLC column as protein makes up the bulk of the constituents which produce interferences 
on a chromatogram leading to flawed data. It is therefore crucial to employ the most favourable 
solvent/s that manages to achieve almost total cleanliness of in vivo samples. A wide range of 
solvents were tested to achieve minimal interference through stray peaks originating from blank 
plasma samples. Solvents were utilized in solitary as well as ratios. Table 7.2 displays the solvents 
tried and tested with success or fail. 
 
Table 7.2: Solvent selection for liquid-liquid extraction procedure. 
Deproteinating agent Baseline Result 
Acetonitrile ↕↕ 
Ethyl Acetate ↕ 
Perchloric Acid (6 %) ↕↕ 
Trichloroacetic acid (10 %) ↕↕↕ 
Ethanol ↕↕ 
Methanol ↕↕ 
*Acetonitrile/Ethyl Acetate ↕↕ 
*Dichloromethane/Ethyl Acetate ↕ 
*Trichloroacetic Acid (10 %)/Ethanol ↕↕↕ 
*Formic Acid (1 %)/Acetonitrile ↕↕ 
#Acetonitrile/Dichloromethane/Ethyl Acetate ↕ 
#Ammonium Sulphate/Acetonitrile/Ethanol ↕↕ 
*Zinc Sulphate/Acetonitrile ↕↕ 
↕ - Closest to baseline; ↕↕- Further from baseline; ↕↕↕- Furthest from baseline 
*1:1 
#1:1:1 
 
The table shows solvents that resulted in a peak that was either small enough (closest to the 
baseline) that could be ignored for erroneous results and utilized for extraction, slightly heightened 
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which could interfere with drug detection elution (further from the baseline) or large enough to 
completely dispel any useful data (furthest from the baseline). Ideally, a solvent resulting in peaks 
formed closest to the baseline would be preferable. This was seen with Ethyl Acetate (EA), a 1:1 ratio 
of Dichloromethane/Ethyl Acetate (DCM/EA) and a 1:1:1 ratio of ACN/DCM/EA. The solvent and 
solvent combinations were further tested to evaluate which generated the best recovery of LMV. This 
is depicted in Table 7.3. 
 
Table 7.3: Recovery of LMV drug in spiked blank plasma from selected deproteinating agents 
(n=3). 
 1EA 2,*DCM/EA 3,#ACN/DCM/EA 
Recovery (%) 71.253 41.378 93.179 
4RSD (%) 2.586 19.221 5.422 
1Ethyl Acetate 
2,*Dichloromethane/Ethyl Acetate, 1:1 
3,#Acetonitrile/Dichloromethane/Ethyl Acetate, 1:1:1 
4Percent Relative Standard Deviation 
 
The solvent blend of ACN/DCM/EA showed the best drug recovery percentage of 93.179 % with an 
RSD percentage value of 5.422. These were acceptable results and the combinations of these 
solvents were thus chosen for liquid-liquid extraction in cleaning the blood plasma and hepatic tissue 
treated samples. However, paramount emphasis is on the actual recovery of LMV from the extraction 
procedure and consequently the solvent blend was tried and tested on spiked LMV blank plasma 
samples (10 µg/mL) at ratios of 3:2:1 and 5:1:2.5 to estimate the optimal recovery of LMV against the 
1:1:1 ratio already demonstrated. Table 7.4 reflects the data obtained with the varying ratios of the 
solvent blend. 
 
Table 7.4: Recovery of LMV drug in spiked blank plasma from variable selected deproteinating 
agent ratios (n=3). 
  1ACN/DCM/EA  
 1:1:1 3:2:1 5:1:2.5 
Recovery (%) 93.179 83.844 91.720 
2RSD (%) 5.422 3.875 0.893 
1Acetonitrile/Dichloromethane/Ethyl Acetate 
2Percent Relative Standard Deviation 
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A 1:1:1 ratio of ACN/DCM/EA yielded the highest amount of drug recovery with a 5:1:2.5 ratio coming 
in second with 91.720 % of recovered drug. A 3:2:1 ratio holding EA in the least amount proved to be 
unsatisfactory with the lowest recovery of 83.844 %. Accordingly, a 1:1:1 ratio of ACN/DCM/EA was 
used in the liquid-liquid drug extraction procedure for all blood plasma and hepatic tissue treated 
samples. 
 
7.3.5. Validation of precision and accuracy 
 
Assessments of inter- and intra- day variability were performed for precision and accuracy validation 
and results are reflected in Table 7.5. Concentrations of drug solutions used were 1, 2.5 and 5 µg/mL. 
The RSD value for intra- and inter- day variability with concentrations 1 (1 µg/mL), 2 (2.5 µg/mL) and 
3 (5 µg/mL) ranged from 1.023-3.834 %, 0.246-3.565 % and 1.095-3.085 %, respectively. These 
results were admissible (Karnes and March, 1993) and validated precision and accuracy of the 
sample treatment procedure as well as method. 
 
Table 7.5: Inter- and Intra- day variability testing precision and accuracy of assay. 
  Intra-day   Inter-day  
 1 2 3 1 2 3 
%RSD Concentration 1 3.620 2.048 1.023 3.834 1.405 2.836 
%RSD Concentration 2 1.275 1.604 1.152 3.565 1.076 0.246 
%RSD Concentration 3 1.570 3.085 1.915 2.627 2.290 1.095 
 
7.3.6. Construction of a calibration curve for LMV quantification in blood plasma 
 
A calibration curve was plotted to be able to quantify LMV in the biological fluid samples and this is 
depicted in Figure 7.10. A drug concentration range of 1-5 µg/mL (n=5) was used and the ratio of the 
area under the curve of LMV to that of AZT was calculated and plotted against concentration (µg/mL). 
The calibration curve showed good linearity with a correlation coefficient (R2) of 0.989. 
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Figure 7.10: Calibration curve of LMV in blank plasma at 277nm. 
 
7.3.7. Quantification of LMV concentrations in blood plasma and livers of rats 
 
An imperative final assessment to be made in this in vivo study was the actual quantification of 
LMV detected in the blood plasma of rats treated against their levels in the hepatic region. 
Figure 7.11 discloses contrasting LMV concentrations in plasma and liver of plain drug that was 
administered intravenously (a & b), orally (c & d) and via the optimized C-LA coated LMV-
loaded ACNS (e & f). With reference to Figure 7.11 a & b, following tail vein injection of LMV, 
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the drug reaches its peak concentration (Cmax) of 75.736 µg/mL in the first measured time point 
of 3 hours in plasma and that of the liver is Cmax = 70.983 µg/mL. These are, without 
reservation, high peak levels and understandably so as the drug possesses a low plasma 
protein binding ability (~<36 %). LMV levels achieved immediately after IV injection in both the 
plasma and liver were fairly high, but had dropped rapidly by the 5th sampling point. The slightly 
higher level of concentration in the plasma compared to the liver at this time can be attributed to 
the apparent fact that the drug was injected directly into the circulatory system leading to 
immediate soaring concentrations detected therein. The slightly lower LMV concentration in the 
liver is due to the fact that post administration of most drug compounds via a tail vein injection in 
the rat model distributes to the liver first (Meibohm, 2006). The lowest level of 0.0368 µg/mL and 
0.0582 µg/mL is detected after 12 hours in the blood and liver, respectively. The drug release 
profiles of the conventional orally administered LMV depicted in Figure 7.11 c & d demonstrate 
peak serum levels of drug reaching 52.675 µg/mL 3 hours post administration. LMV 
concentration levels decline rapidly over the next 9-10 hours. The levels of LMV in the liver 
show a slightly higher Cmax = 54.241 µg/mL 3 hours after administration of oral LMV. These 
results are fair because LMV has been known to have a satisfactory pharmacokinetic profile 
with bioavailability after oral administration being fairly high (~80 %). Despite this favorable 
reality of the oral conventional LMV, one should not lose sight of the undesirable side effects it 
avidly holds such as that of lactic acidosis and hepatotoxicity being the more serious forms. 
Figure 7.11 e & f presents LMV release profiles in the plasma and liver from rats administered 
with the C-LA coated ACNS. LMV Cmax in the liver tissue was achieved 8 hours after the 
intraportal injection of the C-LA coated ACNS at a remarkable concentration of 91.723 µg/mL 
compared to LMV Cmax of 8.947 µg/mL in plasma at the same time point suggesting desired and 
successful C-LA ACNS hepato-targeting ability. LMV, after 4 days, reflects a concentration of 
73.888µg/mL in the liver indicating that the drug is being released in a controlled manner 
overcoming peak-to-trough fluctuations. Fluctuations in LMV being released were not observed. 
The drug loaded C-LA coated system distinctly surpassed the IV and orally administered LMV. 
Minimal LMV is detected in the plasma, thus potentially minimizing the systemic side effects of 
LMV significantly i.e. the oral system does not differentiate between plasma vs. liver delivery 
and high levels of LMV are detected in the plasma that would lead to the undesirable systemic 
side effects. The levels of LMV attained in the liver are within therapeutic range as LMV is in fact 
not a narrow therapeutic range drug and spans across a wide window. Additionally, research 
studies that fixated on overdosing did not reveal any organ toxicity from the high levels of the 
drug (Strauch et al., 2011). However, one study did confirm the chromosome damaging effect of 
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LMV at a concentration dose of 125 µg/mL (48 hour time period) and 150 µg/mL (24 hour time 
period) in the blood (Bayram and Topaktaş, 2008). Figure 7.11 a) depicting Cmax = 75.736 
µg/mL with the pooling of LMV in blood plasma after intravenous administration is significantly 
the closest to this toxic concentration of the drug compared to an insignificant Cmax = 8.947 
µg/mL [Figure 7.11 e)] achieved with the ACNS. 
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Figure 7.11: In vivo LMV concentrations measured in, a) IV administration in plasma, b) IV 
administration in liver, c) Oral administration in plasma, d) Oral administration in liver, e) C-LA 
ACNS intraportal administration in plasma, f) C-LA ACNS intraportal administration in liver. 
 
7.4. Concluding Remarks 
 
This in vivo chapter demonstrated that the ACNS is a suitable carrier for a hydrophilic antiviral 
and further demonstrated an exceptional ability of targeting when coated or chemically modified 
on its surface.  The absent model disease, HBV, and drug, LMV, were applied for affirmation of 
the ACNS functionality. A coat consisting of chitosan linked LA on its surface was employed to 
target the hepatic environment wholly. Lucrative data were obtained with majority of LMV found 
pooled in ACNS and pseudo-released in the liver as compared to the circulatory system. A pilot 
study was carried out to assess the feasibility of an intraportal administration in the rodent 
model and this turned out successful as well as successful in providing the augmented hepato-
targeting. Biodistribution images proved coated ACNS targeting ability and positive lagged drug 
release in the liver for days with potential of sustenance for more hours to days. This study 
opened up areas for ACNS to reveal its potential in diverse applications as a drug/gene carrier 
and targeting system. 
 
 e) f) 
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CHAPTER 8 
CONCLUSIONS AND RECOMMENDATIONS 
8.1. Conclusion 
Numerous pathogenic viruses exist which cause infectious viral diseases in humans when 
specific cells are attacked and virus replication occurs due to immunity of the host failing. A 
renowned trait of these microorganisms is their rapid spreading ability. In consequence, viral 
pandemics are not unusual with pointed fingers at HIV/AIDS currently rife globally. The most 
alarming and recent outbreak occurrence is the Ebola Virus where numbers of Ebola cases and 
infected persons are soaring at present, with fear of this virus also spanning to a ‘pandemic’ 
proportion.  
 
Duly, there is dire concern and desperation to control and curb a viral infection because being 
tricky organisms, they maintain a capacity of adjusting, conforming to be resistant to antivirals 
as well as incorporating themselves into host DNA at which point tumors are then developed. 
For this reason, they reside in the nucleus and cytoplasm of cells which necessitates 
therapeutic action to be directed to these areas. With that said, a novel virus-resembling 
antiviral intracellular delivery system is put forward in this research study with Hepatitis B Virus 
(HBV) selected as the model viral disease and Lamivudine (LMV) as the antiviral therapeutic to 
be delivered into the cytosol of a targeted hepatic cell where HBV would ordinarily reside. 
 
A hydrophile - Hyaluronic acid (HA), and a hydrophobe - epsilon-Caprolactam (ECL), were 
successfully graft copolymerized in a novel fashion to synthesize an amphiphile (HA-g-ECL) 
capable of gaining intracellular entry when formulated into suitably sized nanoparticles. 
Intracellular entry was possible and distinct for cells within hepatic radius due to the surface 
chemical modification of the architecturally configured nanoparticulate system (ACNS) with a 
liver targeting ligand coat of Chitosan and the fatty acid, Linoleic acid (LA). The polymer and 
fatty acid were equally successful in being copolymerized, and in similar manner as HA-g-ECL, 
with synthesis of Chitosan-Linolate (C-LA). Affixing C-LA as a coat for ACNS was fruitful in 
conveying a liver targeting ability as evinced in in vivo investigations. Ex vivo investigations 
approvingly manifested HepG2 cellular internalization proficiency of C-LA ACNS particles due to 
a required and achieved nanoscale size. C-LA ACNS was able to deliver acceptably entrapped 
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LMV to hepatic cells aided by intraportal administration in the rat model. In vivo ultrasound 
imaging over the hepatic region confirmed this. The system provided sustained release of the 
antiviral over a measured period of 96 hours. Concurrently, results revealed favorably mediocre 
LMV levels in the blood circulatory system further demonstrating a positive hepato-targeting 
inclination of C-LA ACNS. 
 
Due to the novel HA-g-ECL displaying a valuable capacity that relays to micelle structuring, 
parallel to most amphiphiles, this proposed amphiphile can be extended to a vast array of 
therapeutic molecules, not limited to LMV, an antiviral or even a hydrophile. In any event, the 
basic intent purpose for a micelle is the encapsulation of hydrophobic drugs due to the 
unembellished primary oil in water emulsion preparatory method that leads to it. Therefore HA-
g-ECL poses as a platform for sustained hydrophilic or poorly soluble drug release promising a 
feasible therapeutic carrier. Moreover, HA-g-ECL is able to afford intracellular direction of these 
contained drugs due to its capability of forming extremely nanosized particles and being open to 
surface decorating with chemical compounds specialized for a targeting requirement. The aim 
and all of the objectives unfolded at the outset of this dissertation were achieved. This new type 
of amphiphilic copolymer exhibited worthy intracellular targeted drug delivery potentiality with 
multifunctional characteristics and therefore could be expanded to a multitude of applications in 
biomedical areas. 
 
8.2. Recommendations 
 
The rodent animal model employed in this study was not induced with the representative human 
disease being addressed. HBV was absent in the animal model. A more accurate data 
presentation is likely to be generated following induction of the actual disease being targeted. 
Such available animal models that have been studied are HBV-transfected mice and human 
liver chimeric mouse models for HBV (which consist of the Trimera mouse model and SCID Alb-
uPA mice for studying HBV) that could be utilized to determine precise C-LA ACNS therapeutic 
potential. 
 
An essential aspect of the in vivo study entailed immediate -80°C freezing of removed liver 
tissue following euthanazia of rats for homogenization to establish drug quantities therein. Due 
to this disparate manner of immediate liver treatment following removal that is not conducive to 
immunohistochemistry and pathology storage conditions for examination, these tests were 
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overlooked at this time. This, in addition to a cytocompatibility analysis, should be carried out to 
further confirm safety or toxicity of ACNS. 
 
Expansion to this study can accommodate another veracity measure optimizing the C-LA 
coating by using an experimental model mediating variable quantities of chitosan to LA. This 
should also be considered because LA in excess has been shown to promote prostate cancer 
risk by enhancing growth of prostate tumor cells in animals. 
 
A portal vein administration was sought and utilized to further enhance the hepatic targeting 
ability of C-LA ACNS. An alternative to this injectable route is an intrahepatic arterial injection 
being equally if not more beneficial as a liver targeting route (Illustrated in Chapter 7, Section 
7.1 Introduction, Figure 7.1). 
 
The HA-g-ECL amphiphile and formed ACNS can be indispensable to a wide range of infectious 
diseases and ailments. It can be exploited in applications of anticancer mitochondrial 
therapeutic delivery, targeted nuclear gene delivery, lysosomal targeting of a possible enzyme 
deficiency and cytoplasmic therapeutic delivery. Need for sophisticated HIV/AIDS treatment is 
currently paramount. Application of novel ACNS to various intracellular operations can be 
valuable to eliminate disease. Its performance may be scrutinized by selecting other model 
diseases (or possible inducing actual disease in animal models) and therapeutic treatments to 
determine the extent of ACNS as a functional intracellular drug delivery system. 
 
The ACNS resembles a virus with C-LA targeting nano-appendages representing viral 
glycoprotein spikes for entry into cells. Modification of the ‘glycoprotein spikes’ to better suit 
delivery of ACNS with encapsulated therapeutic across the Blood-Brain-Barrier (BBB) can be 
attained. This study adopted an uninvolved and uncomplicated method of chemical adsorption 
of targeting nano-appendages on ACNS surface, however, innovative methods and steps such 
as electrospinning may be undertaken for adsorbing target-specific ligand nano-appendages for 
slightly arduous biomedical applications such as the above mentioned drug delivery across 
BBB. 
 
Bearing in mind the points proffered, additional experimental design studies can be executed 
based on possible predictions able to be derived from this study. This research may be reflected 
on by scientists utilizing it as an information-rife foundation building on, integrating existing and 
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acquiring new knowledge for impending pharmaceutical based applications in advanced drug 
delivery. 
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